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ABSTRACT: Dopamine (DA) has become a sort of buzzword as the ‘pleasure’ neurotransmitter 
that signals for natural rewards, but is ‘hijacked’ by drugs of abuse and the instant gratification we 
derive from our phones, Facebook, and fast-food diets in the fast-paced world we live in. In reality, 
DA has much more nuanced and varied functions that include the regulation of attention, working 
memory, motivation, movement, and even endocrine functions, which largely depends upon the 
region DA is acting in the brain. Dysfunction of DA neurotransmission is implicated in conditions 
like Parkinson’s disease (PD), attention deficit/hyperactivity disorder (ADHD), drug addiction, 
and traumatic brain injury (TBI) to name just a few. As such, the DAergic system represents a 
rational pharmaceutical target that act as DA receptor agonists, antagonists, indirect agonists, and 
DA reuptake inhibitors. Understanding how region-specific DA neurotransmission is altered in 
pathological states and following both acute and chronic drug administration, requires multi-
faceted research approaches but can be significantly driven by advancements in research 
methodologies. It is for this reason that we hope readers will find the work contained herein 
particularly timely and important. Although the work contained here represents research conducted 
using fast-scan cyclic voltammetry (FSCV), an electrochemical method to monitor in vivo 
electrically stimulated DA neurotransmission that has been around since the mid 1980s, we 
describe the development of a novel quantitative interpretive framework for FSCV data that 
enhances the ability to characterize the region-specific DA neurotransmission in the context of 
drugs and diseases. To illustrate the utility of our framework, we demonstrate how our approach 
has been used to resolve the mechanistic actions of the most commonly used Parkinsonian drug, 
L-DOPA, on regiospecific DA neurotransmission. Moreover, our framework was utilized to 
characterize the regiospecific DAergic dysfunction following an experimental model of TBI and 
the robust neurorestorative effects of chronic methylphenidate treatment in this model. To this end, 
 v 
we not only describe a theoretical framework for characterizing regiospecific alterations in DA 
neurotransmission, but we also offer practical examples that may serve as a roadmap for studying 
DA neurotransmission kinetics in the context of drugs and other diseases. 
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PREFACE 
When I decided to pursue my PhD, I did it purely for idealistic reasons-to fulfill my curiosity and 
more importantly because I thought this line of research was very important for advancing the 
understanding of the dopamine system and its essential role in various human conditions. When I 
began this journey, I thought I was at the edge of making a major breakthrough in how we study 
dopamine neurotransmission. I did not know that I would have to wrestle with theories for years, 
repeatedly proving myself wrong, until I finally actualized my goal. I am very proud of the 
essential feature of my doctoral research, the development of the quantitative neurobiological 
framework to interpret stimulated DA responses, as it reflects an eclectic synthesis of various lines 
of neuroscience research. I think it’s a better outcome that I had even hoped for when I 
enthusiastically began this journey. Publishing this theory only in my final year of my PhD, I see 
this work as only the beginning of much progress that can stem from it. Now is a critical juncture 
where this line of research can take off with concerted effort, and I am excited for its future! 
 I’ve had my highest highs and my lowest lows in my PhD, and if it wasn’t for a few 
compassionate souls, I’m not sure where I would be. It was my advisor, Amy who first encouraged 
my out-of-the-box thinking about stimulated DA neurotransmission that led me to pursue my PhD. 
Through her guidance, among other things, I was able to develop the framework that became the 
foundation of my thesis. Foremost, I am most humbled by the uplifting advice she gave me to 
remind me of my calling when I forgot and inspired me more when I remembered. I am fortunate 
to have the most amazing family that has supported me from the beginning to end, being genuinely 
happy for me after all my milestones and publications. Not to belittle the chapters to follow, but I 
 xiv 
am most grateful for finding my wife Ouiam along the way. I hope that we will do great things 
together in the next chapters of our lives! 
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1.0  INTRODUCTION 
The central dopaminergic (DAergic) systems principally arise from two midbrain structures- the 
nucleus accumbens and the substantia nigra pars compacta, which densely innervate subcortical 
regions of the striatum and diffusely project throughout the cortex. As a modulatory substance, 
DA regulates various functions attributed to all these regions like abstract reasoning and working 
memory in the prefrontal cortex, and reward and reinforcement-based learning in the nucleus 
accumbens. Perhaps most obvious is the role of DA in regulating voluntary movement, which 
becomes absent following the degeneration of DAergic projections to the dorsolateral striatum in 
late-stage PD. As a neurotransmitter system that is critically involved in various conditions like 
ADHD, PD, and TBI, the DAergic system is one of the most commonly targeted systems in 
neuropsychiatric conditions.    
Techniques that can monitor in vivo DA dynamics are critical for understanding how the 
DAergic system is involved in regulating cognition/behavior and how drugs and diseases alter DA 
neurotransmission. Electrophysiology, PET imaging, and microdialysis methods offer 
complementary methods to assess neural firing, integrity of DAergic systems, and in vivo DA 
levels. In this body of work, we highlight the rich information of presynaptic DA 
neurotransmission that can be gained using fast-scan cyclic voltammetry (FSCV). 
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FSCV is a powerful technique that can monitor real-time in vivo kinetics of presynaptic 
DA neurotransmission with fine temporal and spatial resolution and unparalleled specificity. The 
development of the technique has a rich history whose origins nearly date back to the time when 
DAergic pathways were first identified in the brain (Dahlstroem & Fuxe 1964). Ralph Adams was 
the first person to insert electrodes in the brain to measure catecholamine levels (Kissinger et al. 
1973), François Gonon introduced the use of carbon fiber microelectrodes (Gonon et al. 1978) for 
voltammetric measurements, and Armstrong-James et al. introduced the application of high speed 
voltage waveforms to electrodes to detect sub-micromolar catecholamine concentrations in vitro 
(Armstrong-James et al. 1980).  It was the work of Millar, Stamford, Kruk, and Wightman who 
first demonstrated the feasibility of contemporary method of using FSCV to monitor in vivo striatal 
DA responses to electrical stimulations of ascending DAergic fibers contained within the median 
forebrain bundle (MFB) (Millar et al. 1985, Ewing et al. 1983).  
Although much contemporary FSCV research is conducted on awake freely-behaving 
animals that can be useful for correlating in vivo DA dynamics to behavior (Robinson et al. 2002, 
Saddoris et al. 2015, Cameron et al. 2014), the MFB-stimulated DA neurotransmission paradigm 
in anesthetized rats has its own set of advantages by allowing investigators to control DA neural 
firing activity to generate robust high signal-to-noise ratio DA responses that are amenable for 
quantitative analysis. The MFB-stimulated DA response paradigm is very translational in its 
approach for assessing how pharmacological agents, disease, and various experimental contexts 
can affect presynaptic DA neurotransmission primarily because it can be performed in vivo. 
Stimulated striatal DA responses reflect a complex interplay between synaptically released DA 
and DA clearance that is predominantly mediated by reuptake through DA transporters (DAT). 
The principal focus of this doctoral work has been to develop a framework to interpret FSCV data 
 3 
of stimulated DA neurotransmission and apply it to characterize drug pharmacodynamics and 
disease states as a validation for future FSCV research.  
Our framework to interpret stimulated DA responses builds off of work by Wightman et 
al. who developed the Michaelis-Menten (M-M) model of stimulated DA neurotransmission 
(Wightman et al. 1988) to estimate the contributions of release and reuptake processes that underlie 
DA response shapes. Albeit a relatively simple framework, the M-M model has been instrumental 
for research demonstrating how various drugs, genetic manipulations, disease models, and 
experimental manipulations affect presynaptic DA neurotransmission kinetics over the past 25 
years (Budygin et al. 2002, Wu et al. 2002, Wightman & Zimmerman 1990, Chadchankar et al. 
2011). However, even when the M-M model was proposed, it was duly noted that some brain 
regions like the dorsal striatum do not adhere to the kinetics of the proposed model (May & 
Wightman 1989). Moreover, this seminal publication noted “the development of valid models for 
a description of chemical neurotransmission is, thus, an ongoing process with new experimental 
data providing the necessary information to refine and adjust the models.” Although there have 
been advancements over the many years in the understanding of chemical neurotransmission, these 
contemporary principles have not been systematically incorporated to update the interpretive 
framework for stimulated DA responses. It was this void that we sought to fill in this body of work 
with our introduction of the quantitative neurobiological (QN) model of stimulated DA 
neurotransmission (Harun et al. 2015) (see Chapter 2), and it was by filling this void that allowed 
us to pave the way for future FSCV research and make important contributions in the DA research 
field.   
The QN model incorporates contemporary principles of stimulated neurotransmission and 
incorporates the effects of stimulation on release and reuptake processes during stimulated DA 
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responses. We believe the QN model not only provides more realistic estimations of underlying 
DA release and reuptake processes that contribute to DA response shapes, but also, it offers the 
flexibility to interpret responses obtained from various brain regions. In fact, it was largely out of 
necessity that we created the QN model to study regional DAergic dysfunction in the context of 
experimental brain injury, which produces more severe DAergic dysfunction in dorsal striatal 
regions that cannot adequately be described by the M-M model (see chapters 2&4). As different 
brain regions serve vastly different DA-dependent functions (Macdonald & Monchi 2011), exhibit 
differential DAergic vulnerability in disease contexts (Macdonald & Monchi 2011, Janezic et al. 
2013), and exhibit differential DA pharmacodynamics (Patel et al. 1992, Wu et al. 2001), the QN 
framework greatly extends the utility of the stimulated DA response paradigm by extending the 
regions that are amenable for characterization.  
In this body of work, we provide a detailed description of the theoretical foundations of the 
QN model, the equations developed to simulate DA responses, and examples of the application of 
the QN model in Chapter 2. By way of practical example, this work features the application of the 
QN framework to demonstrate novel findings of the dose and region-specific effects of L-DOPA 
on DA release and reuptake kinetics in Chapter 3, regiospecific dysfunction of DA 
neurotransmission after experimental brain injury and the neurorestorative effects of chronic 
methylphenidate in Chapter 4, and sex- and hormonal influences on stimulated DA 
neurotransmission in the context of experimental brain injury in Chapter 5. This body of work 
demonstrates that the combination of the stimulated DA responses paradigm and the QN 
interpretive framework can serve as a powerful tool to understand how drugs and diseases alter 
DA neurotransmission.  
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As the DAergic system plays an important role in many functions, many diseases, and 
represents a major pharmaceutical target, we hope that this work is only the very beginning of 
much more research using the methodologies described herein. We have a vested interest in seeing 
that this work serves as a catalyst for future research along these lines. Already, we are working 
on an active collaboration to apply our methods to study how DA neurotransmission is altered in 
the context of a cardiac arrest, which has been proving to be very different from what we observe 
in our TBI model. To broaden the impact of this research, we are actively working to ease the 
adoption for others by making our in-house QNsim 1.0 software freely available to others 
interested in simulating MFB stimulated DA responses according to the QN model. Moreover, we 
are pursuing the publication of an instructional video through the Journal of Visualized 
Experiments to demonstrate how to simulate DA responses with the QNsim 1.0 software.   
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2.0  A NEUROBIOLOGICAL MODEL OF STIMULATED DOPAMINE 
NEUROTRANSMISSION TO INTERPRET FAST-SCAN CYCLIC VOLTAMMETRY DATA  
Rashed Harun, BS; Christine M. Grassi; Miranda J. Munoz; 
Gonzalo E. Torres, Amy K. Wagner, MD 
2.1 SUMMARY 
Fast-scan cyclic voltammetry (FSCV) is an electrochemical method that can assess real-time in 
vivo dopamine (DA) concentration changes to study the kinetics of DA neurotransmission. 
Electrical stimulation of dopaminergic (DAergic) pathways can elicit FSCV DA responses that 
largely reflect a balance of DA release and reuptake. Interpretation of these evoked DA responses 
requires a framework to discern the contribution of DA release and reuptake. The current, widely 
implemented interpretive framework for doing so is the Michaelis-Menten (M-M) model, which 
is grounded on two assumptions- 1) DA release rate is constant during stimulation, and 2) DA 
reuptake occurs through dopamine transporters (DAT) in a manner consistent with M-M enzyme 
kinetics. Though the M-M model can simulate evoked DA responses that rise convexly, response 
types that predominate in the ventral striatum, the M-M model cannot simulate dorsal striatal 
responses that rise concavely. Based on current neurotransmission principles and experimental 
FSCV data, we developed a novel, quantitative, neurobiological framework to interpret DA 
responses that assumes DA release decreases exponentially during stimulation and continues post-
stimulation at a diminishing rate. Our model also incorporates dynamic M-M kinetics to describe 
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DA reuptake as a process of decreasing reuptake efficiency. We demonstrate that this quantitative, 
neurobiological model is an extension of the traditional M-M model that can simulate 
heterogeneous regional DA responses following manipulation of stimulation duration, frequency, 
and DA pharmacology. The proposed model can advance our interpretive framework for future in 
vivo FSCV studies examining regional DA kinetics and their alteration by disease and DA 
pharmacology. 
2.2 INTRODUCTION 
Midbrain dopaminergic neurons densely innervate the striatum, regulating motor, cognitive, and 
limbic functions. DAergic pathway dysfunction is implicated in conditions like Parkinson’s 
Disease (PD), Attention Deficit Hyperactive Disorder (ADHD), and Traumatic Brain Injury (TBI). 
Agents that affect DA neurotransmission kinetics can be effective for some in managing the 
neurobehavioral symptoms associated with these conditions; however, little is known about how 
the kinetics of DA neurotransmission are altered in these conditions. A better understanding of DA 
neurotransmission kinetics in both physiological and pathological states, and in response to 
pharmacology, could lead to better characterization of DAergic dysfunction and mechanisms of 
drug action to guide clinical treatment approaches. 
 
Fast-scan cyclic voltammetry (FSCV) is an electrochemical technique that is capable of 
measuring in vivo DA concentration changes in real time to study the kinetics of DA 
neurotransmission. Following electrical stimulation of DAergic projections, DA responses can be 
obtained using FSCV that reflect a balance of DA release and DA clearance. Interpreting DA 
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responses, therefore, requires a theoretical framework from which to delineate the contribution of 
DA release and DA clearance to the overall evoked DA responses observed.  
 
As in vivo FSCV techniques began to gain popularity as a tool to study DA 
neurotransmission, the Michaelis-Menten (M-M) model was proposed as a useful framework to 
describe stimulated DA responses in terms of DA release and reuptake (Wightman & Zimmerman 
1990). Application of the M-M model to FSCV derived data is grounded on two basic 
assumptions- 1) that each stimulation pulse releases a constant amount of DA, and 2) that DA 
clearance is primarily mediated by reuptake through DA transporters (DAT) which follow 
saturation-based Michaelis-Menten (M-M) enzyme kinetics (Figure 1A). These assumptions led 
to the formulation of Equation 1 that has been used widely used with FSCV to interpret stimulated 
DA responses (Wightman et al. 1988). Equation 1 predicts DA responses should rise linearly 
during stimulation in the absence of reuptake, but convexly when factoring in reuptake due to a 
progressively increasing contribution of DA reuptake during electrical stimulation (Figure 1B). 
 
𝑑𝑑[𝐷𝐷𝐷𝐷]
𝑑𝑑𝑑𝑑
=      𝑓𝑓 ∙ [𝐷𝐷𝐷𝐷]𝑝𝑝      −         𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝐾𝐾𝑚𝑚[𝐷𝐷𝐷𝐷] + 1 
(DA release)        (DA reuptake) 
Equation 1 
 
In this equation, [DA]p is the incremental increase in [DA] that would be evoked by one 
stimulation pulse in the absence of reuptake, Vmax is the constant for maximal DA reuptake rate, 
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and Km is the M-M constant which represents the extracellular DA concentration ([DA]EC) that 
saturates 50% of DAT. 
 
 
Figure 1: Predictions of the M-M model  
A) A reuptake efficiency curve was simulated using Vmax=5µM/s and Km=0.5µM, which shows a plausible 
relationship between DA reuptake rate and [DA]EC based on M-M enzyme kinetics. B) The M-M model always 
predicts a convex response because, in the absence of reuptake, [DA]EC would increase linearly with time due to 
constant release (gray trace). By factoring in reuptake according to M-M enzyme kinetics, the progressively greater 
reuptake rate during stimulation (progressively increasing size of black arrows) results in a convex DA stimulus 
response shape (black trace). 
 
Though the M-M model has been implemented commonly to interpret stimulated DA 
responses, several publications have demonstrated that some striatal evoked DA responses, such 
as concave DA responses, are often encountered in the dorsal striatum (May & Wightman 1989) 
and cannot be described by the M-M model (May & Wightman 1989, Moquin & Michael 2009, 
Wang et al. 2011, Taylor et al. 2012). Interestingly, these responses previously have been 
attributed to artifacts of diffusional distortion (May & Wightman 1989); however, more recent 
studies suggest that diffusion cannot explain the characteristics of these DA responses (Moquin & 
Michael 2009, Taylor et al. 2012). These findings suggest that the M-M model might not accurately 
describe the complex kinetics associated with the neurobiological mechanisms underlying 
stimulated DA neurotransmission. In their 1990 seminal publication that describes the M-M 
model, Wightman and Zimmerman acknowledged that the M-M model does not account for 
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neurobiological mechanisms that could contribute to DA stimulus response characteristics, such 
as frequency-dependent release modulation and modulation by D2 autoreceptors. Moreover, they 
asserted that “the development of valid models for a description of chemical neurotransmission is 
thus an ongoing process with new experimental data providing the necessary information to refine 
and adjust the models” (Wightman & Zimmerman 1990). 
 
Relatively recent and rapid molecular and electrophysiological advancements in 
neuroscience have made it possible to understand additional components of pre-synaptic function 
that may contribute to the heterogeneity of DA stimulus responses observed with FSCV; however, 
the information provided through these advancements have not yet been integrated or applied to 
the foundational principles offered by Wightman and Zimmerman when introducing in vivo FSCV 
as a neurotransmission assessment tool. Thus, there is a need to generate a more contemporary and 
informative model for evaluating DA kinetics using FSCV. Here, we introduce a novel 
neurobiological framework from which to interpret stimulated DA responses in a manner that 
complements and further informs current M-M approaches used in characterizing 
neurotransmission. The model is built on assumptions grounded in contemporary principles 
derived from neurotransmission research and our own experimental data. In this framework we 
describe DA release during stimulation not as a constant or increasing, as previously suggested 
from other FSCV studies (Wightman & Zimmerman 1990, Wightman et al. 1988, Moquin & 
Michael 2009), but as exponentially decreasing over the course of stimulation, a phenomenon that 
has been demonstrated with other neurotransmitter systems (Neves & Lagnado 1999, Pyott & 
Rosenmund 2002, Zucker 1999) including DA (Pan & Ryan 2012). Moreover, following 
stimulation, rather than an immediate cessation of DA release, as has previously been suggested 
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(Wightman et al. 1988), this framework accounts for a post-stimulation DA release component, 
that continues for some time after the termination of the stimulus, which occurs commonly due to 
an accumulation of [Ca2+]in as a result of stimulation (Barrett & Stevens 1972, Neves & Lagnado 
1999, Goda & Stevens 1994, Dodge et al. 1969, Delaney & Tank 1994, Borges et al. 1995, Yao 
et al. 2011).   
 
Based on observations from experimental data, we also do not describe DA clearance 
efficiency as a fixed relationship between reuptake rate and extracellular [DA] with constant Vmax 
and Km terms as the M-M model suggests. Rather, we describe clearance efficiency in the context 
of a stimulated release paradigm, and as one that decreases over the course of an evoked DA 
response due to stimulation-induced changes in transporter function. These fundamental 
assumptions provide a basis from which to mathematically model stimulated DA responses of 
various morphologies not previously possible.  
 
In experimental designs that aim to characterize alterations in striatal DA 
neurotransmission in pathological states, a neurobiological framework is necessary that can 
interpret the various response-types collected using unbiased sampling methods. The flexibility of 
the model proposed in this report is such that it can capture and characterize innate heterogeneity 
in striatal DA responses as well as perturbations in stimulus response curves due to a spectrum of 
clinically relevant pathophysiological states or drug treatment paradigms. Though this 
neurobiological framework is more complex than the basic M-M model, it uses the M-M model 
as a frame of reference to incorporate principles of neurotransmission that provide a contemporary 
and realistic perspective from which to interpret and quantify FSCV data of DA neurotransmission. 
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2.3 NEUROBIOLOGICAL PRINCIPLES OF STIMULATED DA 
NEUROTRANSMISSION 
2.3.1 Stimulated DA release 
The M-M model, as it is currently applied to DA responses, makes the assumption that each pulse 
of stimulation releases a constant amount of DA. This assertion was supported with the quality of 
fit of the M-M model to experimental DA responses collected in the ventral striatum, although it 
was noted that prolonging 60Hz stimulations to more than 5s leads to a marked diminution of DA 
release (Wightman et al. 1988). However, not all stimulated DA responses of <5s can be simulated 
using the M-M model, especially DA responses that rise concavely during stimulation, which are 
often observed in the dorsal striatum (May & Wightman 1989, Moquin & Michael 2009). The 
poor model fit in cases where concavity characterizes the rising portion of the stimulus response 
curve suggests that the presynaptic kinetics of evoked DA responses is more complex than the 
release and/or reuptake processes assumed by the M-M model. Previous FSCV studies have 
suggested that DA release rate may follow a complex pattern that may even increase for a period 
during electrical stimulation (Moquin & Michael 2009, Wang et al. 2011). However, the 
supraphysiological stimulation frequencies typically implemented for in vivo FSCV studies on 
anesthetized rats (30Hz-80Hz) (Moquin & Michael 2009, Wang et al. 2011, Wightman et al. 1988, 
Wightman & Zimmerman 1990, Wu et al. 2001, Wagner et al. 2009a, Wagner et al. 2009b) should 
result in an attenuation of DA release during the course of stimulation due to a depletion of readily-
releasable stores of synaptic vesicles, a phenomenon termed pulse train depression (PTD) that is 
widely supported in the neurotransmission literature (Dobrunz & Stevens 1997, Liley & North 
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1953, Pyott & Rosenmund 2002, Zucker 1999, Hagler & Goda 2001, Neves & Lagnado 1999, 
Hubbard 1963, Pan & Ryan 2012, Taschenberger & von Gersdorff 2000). 
 
Because the mechanisms of synaptic transmission are largely conserved across different 
synapse types, PTD associated with synaptic vesicle release has been observed in many synapses 
including hippocampal glutamatergic synapses (Pyott & Rosenmund 2002, Hagler & Goda 2001), 
retinal bipolar synapses (Neves & Lagnado 1999), and neuromuscular junctions (Hubbard 1963, 
Liley & North 1953) using membrane capacitance measurements (Neves & Lagnado 1999), live 
fluorescent synaptic vesicle imaging (Pan & Ryan 2012), and electrophysiology (Pyott & 
Rosenmund 2002). PTD has even been demonstrated in the Calyx of Held, a synapse that is known 
for its high fidelity of synaptic transmission in response to sustained high frequency stimulations 
(Taschenberger & von Gersdorff 2000). In our overview of the neurotransmission literature, PTD 
of synaptic vesicle release was a ubiquitously observed phenomenon, making it unlikely that 
DAergic synapses are a unique example that would exhibit constant or increasing release during 
the course of sustained stimulation pulse trains (Dobrunz & Stevens 1997, Liley & North 1953, 
Pyott & Rosenmund 2002, Zucker 1999, Hagler & Goda 2001, Neves & Lagnado 1999, Hubbard 
1963, Pan & Ryan 2012, Taschenberger & von Gersdorff 2000). In fact, PTD associated with DA 
release has been demonstrated recently in midbrain DAergic neuronal cultures (Pan & Ryan 2012). 
 
The discrepancy between FSCV research, which suggests constant, complex, or increasing 
neurotransmitter release with on-going stimulation pulse trains, and other lines of neurobiological 
research, which have consistently demonstrated decreasing neurotransmitter release, may be due 
to the fact that FSCV measurements represent a balance of DA release and reuptake. We assert 
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that the paradoxical findings on DA release from FSCV studies can be reconciled using a novel 
clearance kinetics paradigm that includes temporally attenuating DA reuptake efficiency that we 
describe later in this report (see DA reuptake). 
 
In our neurobiological model, we assume DA release decreases exponentially during a 
pulse train consistent with principles of neurotransmission supported in the literature noted above. 
PTD begins at the stimulation onset, and this phenomenon is often modeled as an exponential 
decay function that plateaus to a steady-state level (Taschenberger & von Gersdorff 2000, Pyott & 
Rosenmund 2002). Various studies have established a relationship between the kinetics of PTD 
and stimulation frequency, calcium influx, the size of the readily-releasable pool (RRP), and the 
kinetics of vesicle recruitment into the RRP during stimulation (Pyott & Rosenmund 2002, Zucker 
1999, Hagler & Goda 2001). Adopting a paradigm of PTD from which to model stimulated DA 
release in FSCV studies would afford the flexibility needed to model frequency-dependent 
modulation of DA release, and DA release modulation by D2 autoreceptors, both of which are 
known to affect voltage-gated calcium currents (Cardozo & Bean 1995, Jomphe et al. 2006). 
2.3.2 Post-stimulation DA release 
The M-M model assumes that DA release ceases at the end of stimulation (Wightman et al. 1988), 
because DA neurons exhibit a period of inhibited neuronal firing activity following electrical 
stimulation (Kuhr et al. 1987). However, neurotransmitter release is not directly related to neuronal 
firing activity per se, but rather, it is related to the subsequent Ca2+ influx and intracellular 
Ca2+accumulation that result from action potentials or supraphysiological electrical stimulations 
(Atluri & Regehr 1998, Fierro et al. 1998). As such, increased neurotransmitter release can persist 
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that is independent of neuronal firing, but is associated with the accumulation of intracellular Ca2+ 
([Ca2+]in) induced by pulse trains, for seconds after stimulation pulse trains cease (Barrett & 
Stevens 1972, Neves & Lagnado 1999, Goda & Stevens 1994, Dodge et al. 1969). Post-stimulation 
neurotransmitter release is a common phenomenon observed in many synapses including retinal 
amacrine cells (Borges et al. 1995), hippocampal neurons (Goda & Stevens 1994, Yao et al. 2011), 
cerebellar granule cells (Geppert et al. 1994), and DAergic/GABAergic periglomerular cells 
(Borisovska et al. 2013). 
 
The literature suggests that the post-stimulation neurotransmitter release that follows pulse 
trains has at least two distinct kinetic components, a rapid and a prolonged component, which are 
likely due to a continuation of two identified Ca2+-dependent release mechanisms that occur during 
stimulation (Atluri & Regehr 1998). Following pulse trains, intracellular calcium is rapidly 
sequestered, buffered, or extruded; however, modest elevations of [Ca2+]in can remain for many 
seconds following stimulation that are dependent on the duration of stimulation. (Fierro et al. 
1998). 
 
The rapid component post-stimulation DA release may be predominantly mediated by 
synaptotagmins. Neurons utilize the synaptotagmin family of Ca2+-sensors to precisely 
synchronize neuronal firing to synaptic vesicle release. Synaptotagmins are low-affinity Ca2+ 
sensors that form part of the SNARE complex in synaptic vesicles that are docked and primed for 
release. Synaptotagmins are ideally localized to detect large increases in [Ca2+]in by adjacent 
voltage-gated Ca2+ channels in response to action potentials. In response to Ca2+-activation, 
synaptotagmins allow for rapid synaptic vesicle extrusion. Thus, the rapid actions of the low 
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affinity synaptotagmin may be limited to a short period immediately following stimulation because 
high concentrations of [Ca2+]in are rapidly eliminated following stimulation (Fierro et al. 1998). 
 
The prolonged component of post-stimulation DA release may be mediated by members 
of the Double C2-like containing protein (DOC2) family (Yao et al. 2011). DOC2 has a much 
higher affinity for Ca2+ than synaptotagmin, but remains mainly cytosolic in the absence of Ca2+ 
(Groffen et al. 2006). The cytosolic localization of DOC2 makes these Ca2+ sensors inadequate for 
rapid neurotransmission that is induced by the membrane-bound synpatotagmins. However, DOC2 
is sensitive to generalized [Ca2+]in changes that can persist for seconds following neuronal activity 
(Fierro et al. 1998), and thus, DOC2 can increase synaptic vesicle release for a protracted period 
following stimulation (Atluri & Regehr 1998). Interestingly, members of the DOC2 family are of 
central importance to spontaneous neurotransmitter release, whose roles in regulating stimulated 
or basal DA concentrations are unexplored (Groffen et al. 2010, Pang et al. 2011).  
 
Quantifiable evidence of post-stimulation DA release may manifest itself in FSCV 
experiments by prolonging the decay phase of stimulated DA responses. Post-stimulation DA 
release may also cause DA signals to continue rising following stimulus termination if the post-
stimulation release rate is greater than the reuptake rate, a phenomenon which has been 
documented previously in the FSCV literature (Taylor et al. 2012, Kawagoe & Wightman 1994, 
Kuhr et al. 1987). Without properly accounting for post-stimulation DA release, FSCV analysis 
that uses the traditional M-M model would systematically underestimate the true reuptake kinetics 
extracted from the post-stimulation phase of DA responses. 
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2.3.3 DA reuptake 
FSCV experiments on DAT knock-out mice have demonstrated that DA reuptake via DAT is the 
predominant mechanism for striatal DA clearance (Jones et al. 1999a). To describe striatal DA 
reuptake, the M-M model assumes DA reuptake is solely dependent upon DAT saturation that can 
be described using M-M enzyme kinetics according to Equation 1. However, there are several 
potential neurobiological factors that need to be considered when modeling DA reuptake, 
including DAT trafficking to and away from presynaptic plasma membranes and the effects of 
electrically stimulated DA release and reuptake on electrochemical gradients that drive DA 
reuptake. 
 
DA reuptake through DAT is coupled to electrochemical gradients produced by Na+, Cl-, 
and DA itself. Since the electrochemical gradients for these ions are altered during electrically 
stimulated DA responses, this disruption could potentially confound the M-M model assumption 
that DA reuptake is solely dependent upon DAT saturation by [DA]EC. For instance, if Na+, Cl-, or 
DA accumulates in the intracellular space, then the driving force for further DA reuptake through 
DAT could diminish with continued stimulation (Gu et al. 1994, Jones et al. 1999b). In 
physiological conditions, ionic gradients may not be altered substantially to effect DA reuptake; 
however, with the application of supraphysiological stimulations in FSCV studies, these ionic 
gradients become more important when interpreting DA clearance associated with electrically 
evoked stimulus responses.  
 
DAergic neurons are exceptionally large unmyelinated neurons with very extensive 
terminal arborizations, making action potential propagation, the subsequent calcium influx, DA 
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release, and DA reuptake, and the restoration of electrochemical gradients energetically exhaustive 
processes (Pissadaki & Bolam 2013, Matsuda et al. 2009). Supraphysiological MFB stimulations 
in FSCV studies result in the rapid synchronous firing activity of a collection of DAergic neurons 
(Kuhr et al. 1987), which may deplete the energy required to sustain DA neurotransmission. In 
fact, in response to MFB stimulation, voltammetric responses demonstrate striatal changes in DA 
concentrations and also changes in pH, O2, and adenosine concentrations consistent with increased 
cellular activity and ATP utilization (Kennedy et al. 1992, Takmakov et al. 2010, Phillips et al. 
2003, Cechova & Venton 2008). The increased metabolic demand following MFB stimulations 
results in energy depletion, by ATP depletion and/or by depletion of energy stored in 
electrochemical gradients, which are expected to attenuate reuptake processes (Figure 2), just as 
blocking Na+-K+-ATPase with ouabain has been shown to alter stimulated DA responses, in part, 
by attenuating DA reuptake kinetics (Jones et al. 1999b). 
 
Following stimulated DA release and reuptake into the intracellular space, DA is either 
sequestered into synaptic vesicles or degraded by intracellular enzymes like monoamine oxidase 
–B (MAO-B). If the kinetics of these processes are not rapid enough, then DA would necessarily 
accumulate in the intracellular space, which could significantly diminish the electrochemical 
driving force for further DA reuptake (Figure 2).  
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Figure 2: Thermodynamic inhibition of DAT can occur during stimulated DA responses 
Thermodynamic inhibition of DAT can occur during stimulated DA responses. Following DA reuptake, DA molecules 
may get sequestered by synaptic vesicles, degraded, or transiently accumulate in the intracellular space to inhibit 
reuptake. The accumulation of intracellular DA may be predicted to increase Km. Electrical stimulation may also 
transiently diminish the electrochemical gradient of Na+ that is required for DA reuptake. The diminished Na+ 
electrochemical gradient may also decrease DA transport efficiency.   
 
 
In FSCV studies, intracellular DA accumulation during stimulated DA responses and/or 
energy depletion may manifest itself by progressively decreasing DA reuptake efficiency (i.e. the 
function of individual transporters) over the duration of a stimulated DA response (Figure 2). 
Consistent with a stimulation-induced attenuation of reuptake efficiency, Wang et al. (2011) 
recently reported that increasing stimulation duration attenuates the apparent Vmax in stimulated 
DA responses. This finding corresponds well with our empirical data demonstrating that the decay 
kinetics of stimulated DA responses are attenuated by increasing stimulation duration. Figure 3 
depicts mean DA responses collected in the dorsal (n=7) and ventral (n=6) neostriatal regions 
(Figure 3A and D, respectively) using different durations of 60Hz stimulations. Decay efficiency 
plots were generated for these responses (Figure 3B,E), graphically representing the DA decay 
rate as the dependent variable and the extracellular DA concentration load as the independent 
variable. These plots are similar to M-M plots like Figure 1A, which represent the relationship 
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between reuptake rate and [DA]EC. As DA concentration increases, reuptake rate does not increase 
ad infinitum, and reuptake rate approaches Vmax as DAT becomes saturated. Whereas, the M-M 
model predicts Vmax and Km to be constants, producing a singular relationship between reuptake 
rate vs. [DA]EC, we found that increasing the stimulation duration significantly altered the slope 
of decay efficiency curves as measured by the decay efficiency slopes at the half-maximal decay 
rate (Decay1/2mx) (repeated-measures ANOVA F(4,24)=5.330, p<0.005, F(4,20)=12.187, p<0.001, 
for dorsal and ventral responses, respectively). Pairwise comparison of 1s vs. 10s stimulations 
demonstrate that longer stimulation durations attenuate DA decay efficiency (t=2.551, p<0.05, 
t=3.738, p<0.05 for dorsal and ventral responses, respectively) (Figure 3C,E), suggesting that DA 
reuptake efficiency likely decreases with increasing stimulation duration; however, as DA decay 
rates reflect the difference between DA reuptake rate and post-stimulation DA release rate, post-
stimulation DA release may also contribute to observed changes in decay efficiency.  
 
Figure 3: Increasing stimulation duration decreases DA decay kinetics 
Mean stimulated DA responses using 1,2,3,5, and 10s stimulations were collected from the dorsal (n=6) (A) and 
ventral (n=7) (D) striatum. The circles mark the end of the stimulations stimulation.  Decay efficiency curves were 
plotted for the different stimulation durations (B,E), with circles indicating Decay Rate1/2max. The slope of the decay 
efficiency plot at Decay Rate1/2max is significantly affected by stimulation duration in the dorsal and ventral striatum 
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(repeated-measures ANOVA F(4,24)=5.330, p<0.005, F(4,20)=12.187, p<0.001, respectively). C&D) Box and 
whisker plots showing the range (vertical lines) and the interquartile range (boxes) of the decay efficiency slopes, 
demonstrate that the decay efficiency slope is significantly attenuated by longer stimulation durations (1s vs. 10s, 
t=2.551, p<0.05, t=3.738, p<0.05, respectively), suggestive of attenuating reuptake kinetics with increasing 
stimulation duration. 
 
The concept of attenuating reuptake efficiency during a stimulated DA response is also 
supported by the existence of concave DA responses that are, as aforementioned, inconsistent with 
the M-M model. In the context of an attenuating release rate described in the Stimulated Dopamine 
Release section, modeling DA responses with constant reuptake efficiency (i.e. constant Vmax 
and Km) predicts solely convex responses (Figure 4A) similar to the M-M model as demonstrated 
in Figure 1B. A constant reuptake efficiency model predicts that reuptake rate increases during 
the rising phase of DA responses; whereas, a concave stimulated DA response shape emerges only 
when the rate of reuptake decreases faster than the rate of release decreases, which can only occur 
in an attenuating reuptake efficiency model (Figure 4B). These theoretical and experimental 
results emphasize the need to account for the concept of attenuating reuptake efficiency when 
interpreting in vivo stimulated DA responses, even though the precise mechanism that causes 
reuptake rate to decrease during a stimulated DA response remains to be elucidated. In our model, 
we incorporated the concept of attenuating reuptake efficiency by allowing for an increasing Km, 
and this method can simulate DA responses that exhibit diverse concave and convex morphologies 
as demonstrated in Figure 4B- morphologies that are characteristic of experimental DA responses.  
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Figure 4: Heterogeneity of DA response patterns requires attenuating reuptake efficiency 
A) Responses simulated with constant reuptake efficiency always yields convex DA responses. B) However, responses 
simulated with an attenuating reuptake efficiency concept can yield either concave or convex DA responses depending 
on the balance between reuptake and release dynamics. Concavity of DA responses emerges when reuptake rate 
decreases faster than release rate decreases. 
2.4 MATHEMATICAL MODELING OF THE PRINCIPLES OF STIMULATED DA 
NEUROTRANSMISSION 
Above, we qualitatively described the principles of PTD associated with neurotransmitter release, 
post-stimulation neurotransmitter release, and progressively attenuating reuptake efficiency as 
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components that need to be considered when defining and interpreting kinetic parameters 
associated with stimulated DA responses. In this section, we describe how we have chosen to 
mathematically represent these components of DA neurotransmission in order to simulate DA 
responses across a range of experimental DA response types. In turn, the simulations presented 
demonstrate how these neurobiological principles map onto the characteristic behaviors of 
experimental DA responses obtained using in vivo FSCV with an evoked release paradigm, with 
the goal of providing a realistic quantitative kinetic parameterization reflective of DA release and 
reuptake processes observed with stimulated DA responses. 
 
To mathematically represent the dynamic neurobiological components of DA release and 
reuptake that contribute to variable components of stimulated DA responses, we developed 
equations to describe DA release and reuptake rates as a function of time. These rates were then 
integrated over time in Matlab to simulate DA vs. time graphs. The equations described below are 
modifiable so that they may be used to simulate a variety of DA response types observed 
experimentally.  
2.4.1 DA release (during stimulation) 
To describe DA release rate, we used a monoexponential decay function with an added constant 
(Equation 2), similar to what has previously been described for glutamatergic synapses 
(Taschenberger & von Gersdorff 2000).  
 
𝐷𝐷𝐷𝐷𝐷𝐷(𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚) = ∆𝐷𝐷𝐷𝐷𝐷𝐷 ∗ 𝑒𝑒−𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠/∆𝐷𝐷𝐷𝐷𝐷𝐷𝜏𝜏 + 𝐷𝐷𝐷𝐷𝐷𝐷𝑆𝑆𝑆𝑆 
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Equation 2 
 
In Equation 2, DAR(tstim) describes DA release rate as a function of time into the stimulation 
(tstim), with ∆DAR, ∆DARτ, and DARSS being parameters to be estimated in the simulation. ∆DAR 
represents a theoretical change in DA release rate at infinite time, ∆DARτ is the exponential decay 
constant, and DARSS is the steady-state DA release rate that maybe representative of a DA release 
rate when depletion of the RRP by the pulse-trains is offset by Ca2+-induced recruitment vesicles 
into the RRP (Neher & Sakaba 2008) (Figure 5A). 
2.4.2 Post-stimulation DA release 
Stimulated neurotransmitter release occurs through at least two kinetically distinct Ca2+-mediated 
processes, while post-stimulation DA release can be expected due to intracellular Ca2+ 
accumulation that varies based on stimulation duration (Pan & Ryan 2012, Fierro et al. 1998). We, 
thus, represented post-stimulation DA release as a function that was continuous with stimulated 
DA release (i.e. the rate of DA release at the end of stimulation (DARES) = the initial rate of post-
stimulation DA release). We implemented a function that accounts for both a rapid and prolonged 
component of post-stimulation release, similar to previous description by Atluri and Regehr 
(1998).  
 
Equation 3 describes post-stimulation DA release rate in terms of a rapid exponential 
decay phase and a prolonged linear decay phase to represent both rapid and slow components of 
post-stimulation release that are hypothesized to occur as a result of raised [Ca2+]in via 
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synaptotagmin and DOC2 relevant processes (Figure 5A).  Because of the differential kinetics of 
rapid and prolonged post-stimulation components, the relative contribution of the rapid post-
stimulation DA release component decreases over the time course of the post-stimulation period 
(Figure 5A).  
 
𝐷𝐷𝐷𝐷𝐷𝐷𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠�𝑑𝑑𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠� =    𝑋𝑋𝑟𝑟 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐸𝐸𝑆𝑆 ∗ 𝑒𝑒−𝑠𝑠𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝜏𝜏𝑟𝑟 + (1 − 𝑋𝑋𝑟𝑟)  ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐸𝐸𝑆𝑆 − 𝑚𝑚 ∗ 𝑑𝑑𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠  
 
 
Equation 3 
 
In Equation 3, XR describes the fractional component of post-stimulation DA release undergoing 
rapid decay. Neurobiologically, XR may represent the fractional component of post-stimulation 
DA release that is predominantly synaptotagmin-mediated. This fractional component may 
decrease during pulse train stimulations due to a gradual recruitment of DOC2-mediated release 
(Pyott & Rosenmund 2002). m describes the linear decay slope of the prolonged DA release 
component. Experimentally, we observe sustained elevated DA concentrations that decay with a 
time course that is related to stimulation duration (e.g. DA concentrations do not return to baseline 
even 10s post-stimulation of 60Hz, 10s responses in Figure 3A). Neurobiologically, the 
prolongations of DA release by stimulation duration, could be due to prolongations of elevated 
[Ca2+]in that are also stimulation duration-dependent (Fierro et al. 1998). 
(Rapid) (Prolonged) 
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2.4.3 DA reuptake 
Similar to the M-M model, our framework assumes that DA reuptake is determined by 
saturation of DAT, but our framework also accounts for decreasing DA reuptake efficiency as 
suggested by our experimental data (Figure 3). Therefore, to describe DA reuptake rate, we utilize 
the same equation to describe DA reuptake as the M-M model (Equation 1), except we describe 
Km as a time dependent function rather than a constant (Equation 4). 
 
𝐷𝐷𝑒𝑒𝑅𝑅𝑅𝑅𝑑𝑑𝑅𝑅𝑅𝑅𝑒𝑒𝐷𝐷𝑅𝑅𝑑𝑑𝑒𝑒(𝑑𝑑) = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
𝐾𝐾𝑚𝑚(𝑑𝑑)[𝐷𝐷𝐷𝐷] + 1 
 
Equation 4 
 
Our empirical data suggests that DAT efficiency decreases over the course of a stimulated 
DA response (Figure 3), which may be due to a rapid accumulation of [DA]in or the diminution of 
Na+ electrochemical gradients during stimulation. In our model, we assume that DAT act as pumps 
with reuptake rate not only determined by DAT saturation as M-M enzyme kinetics suggests, but 
also dependent upon the electrochemical driving force for reuptake, where the maximal rate of 
reuptake (Vmax) is a constant that can theoretically be attained when DAT is saturated and 
electrochemical gradients are large enough. However, with a diminution of electrochemical 
gradients that may occur during stimulated DA responses, the [DA]EC required to attain half-
maximal reuptake rate (Km) would progressively increase during a stimulated DA response. In this 
neurobiological context, the half-maximal reuptake rate occurs not simply when the [DA]EC 
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saturates 50% of transporters, but it can highly depend upon the thermodynamic forces mediating 
reuptake, which is different from standard definitions of Km, and so the term should be considered 
as an apparent Km. To describe the attenuation of DAT efficiency, our model assumes a variable 
Km that monotonically increases throughout the duration of a stimulated DA response, which we 
describe with a logistic function in Equation 5. 
𝐾𝐾𝑚𝑚(𝑑𝑑) =  𝐾𝐾𝑚𝑚𝑠𝑠 + Δ𝐾𝐾𝑚𝑚
⎝
⎜
⎛1 − 11 + 𝑑𝑑𝐾𝐾𝑚𝑚𝑠𝑠𝑖𝑖𝑖𝑖𝑘𝑘⎠⎟
⎞
 
Equation 5 
 
Equation 5 describes how Km increases during stimulation using Kmi, Kminf, ∆Km, and k 
parameters that can be estimated in simulations. Here, Kmi represents the initial Km value, ∆Km is 
the amplitude of the Km change, Kminf is the inflection point in the Km(t) curve, and k is the Hill-
Coefficient, representing the steepness of the function about the inflection point. These parameters 
allow for representation Km(t) and how it may increase monotonically with a single inflection point 
over the course of a DA response (Figure 5B). 
 
The time-dependent changes Km described in Equation 5 may continue to increase in the 
post-stimulation phase while DAT continues to clear [DA]EC. However, logically, Km would not 
progressively increase far after stimulation cessation. Therefore, we held Km constant after the 
rapid component of the post-stimulation DA release rate ≈ 0. Future work may help modify the 
post-stimulation Km kinetics. 
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Figure 5: Mathematical representations of DA release and reuptake kinetics utilized to perform 
simulations of experimental DA responses 
A) DA release rate during stimulation is described by Equation 3 as a mono-exponential function and an additional 
steady-state DA release rate (DARss). Post-stimulation DA release rate continues after stimulation as described by 
Equation 4, with post-stimulation DA release consisting of a rapid exponential decay and a prolonged linear decay 
component. B) A logistic function was used to describe Km as increasing during the stimulated DA responses 
according to Equation 5. This figure illustrates how the parameters ∆ Km, k, and Kmi determine how Km changes in a 
simulation. 
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Table 1. Equations and parameters utilized in simulations 
DA release rate (during stimulation): 
𝚫𝚫𝑫𝑫𝑫𝑫𝑫𝑫 ∗ 𝒆𝒆−𝒕𝒕𝒔𝒔𝒕𝒕𝒔𝒔𝒔𝒔/𝚫𝚫𝑫𝑫𝑫𝑫𝑫𝑫𝝉𝝉 + 𝑫𝑫𝑫𝑫𝑫𝑫𝑺𝑺𝑺𝑺 
 
Δ𝐷𝐷𝐷𝐷𝐷𝐷 
 
DA release rate undergoing decay 
Δ𝐷𝐷𝐷𝐷𝐷𝐷𝜏𝜏 Time constant relating to decay of 
stimulated DA release rate 
𝐷𝐷𝐷𝐷𝐷𝐷𝑠𝑠𝑠𝑠 Steady-state DA release rate 
DA release rate (post-stimulation): 
 
𝑫𝑫𝑫𝑫𝑫𝑫𝒑𝒑𝒑𝒑𝒔𝒔𝒕𝒕�𝒕𝒕𝒑𝒑𝒑𝒑𝒔𝒔𝒕𝒕� = 
    𝑿𝑿𝑫𝑫 ∗ 𝑫𝑫𝑫𝑫𝑫𝑫𝑬𝑬𝑺𝑺 ∗ 𝒆𝒆−𝒕𝒕𝒑𝒑𝒑𝒑𝒔𝒔𝒕𝒕𝝉𝝉𝒓𝒓  
 +(𝟏𝟏 − 𝑿𝑿𝑫𝑫)  ∗ 𝑫𝑫𝑫𝑫𝑫𝑫𝑬𝑬𝑺𝑺 −𝒔𝒔 ∗ 𝒕𝒕𝒑𝒑𝒑𝒑𝒔𝒔𝒕𝒕 
 
𝑋𝑋𝐷𝐷 Rapid release fractional component  𝐷𝐷𝐷𝐷𝐷𝐷𝐸𝐸𝑆𝑆 DA release rate at end of stimulation 
𝜏𝜏𝑟𝑟 Time constant of rapid release component 
𝑚𝑚 Linear decay slope of prolonged release 
component 
DA reuptake rate: 
𝑫𝑫𝒆𝒆𝑹𝑹𝒑𝒑𝒕𝒕𝑹𝑹𝑹𝑹𝒆𝒆𝑫𝑫𝑹𝑹𝒕𝒕𝒆𝒆(𝒕𝒕) = 𝑽𝑽𝒔𝒔𝑹𝑹𝒎𝒎
𝑲𝑲𝒔𝒔(𝒕𝒕)[𝑫𝑫𝑫𝑫] + 𝟏𝟏 
where, 
𝑲𝑲𝒔𝒔(𝒕𝒕) =  
𝑲𝑲𝒔𝒔𝒔𝒔 + 𝚫𝚫𝑲𝑲𝒔𝒔
⎝
⎜
⎛
𝟏𝟏 −
𝟏𝟏
𝟏𝟏 + 𝒕𝒕𝑲𝑲𝒔𝒔𝒔𝒔𝒊𝒊𝒊𝒊𝑹𝑹⎠⎟
⎞
 
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚 Maximal reuptake rate 
𝐾𝐾𝑚𝑚(𝑑𝑑) M-M constant (An inverse measure of 
efficiency) 
𝐾𝐾𝑚𝑚𝑠𝑠 Initial Km 
Δ𝐾𝐾 Magnitude of change in Km dynamics 
𝐾𝐾𝑚𝑚𝑠𝑠𝑖𝑖𝑖𝑖 Time of inflection of Km dynamics 
𝑅𝑅 Measure of the steepness of the inflection 
in Km dynamics 
 
2.5 APPLICATION OF MODELING METHODS TO EXPERIMENTAL DA RESPONSES 
Equations 2, 3 and 5 were utilized to simulate DA vs. T responses according to Equation 6 using 
MATLAB (The MathWorks Inc, Natick, MA).  
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[𝐷𝐷𝐷𝐷](𝑑𝑑) = ��𝐷𝐷𝐷𝐷𝐷𝐷(𝑑𝑑) + 𝐷𝐷𝐷𝐷𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑚𝑚𝑑𝑑�𝑑𝑑𝑝𝑝𝑠𝑠� �𝑑𝑑𝑑𝑑 − � 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝐾𝐾𝑚𝑚(𝑑𝑑)[𝐷𝐷𝐷𝐷] + 1𝑑𝑑𝑑𝑑 
Equation 6 
 
The simulations were initiated using the DA release rate at t=0 for the [DA] in the reuptake 
term. Thereafter, [DA](t) was substituted for [DA] and DA(t) was calculated iteratively for all time 
points in the simulation. We found using time increments of .005s was adequate to run simulations 
as it generated expected smooth traces of DA responses and is also shorter than the inter-scan 
intervals of DA measurements in typical FSCV studies (Wagner et al. 2009b, May & Wightman 
1989, Jones et al. 1995b). 
 
Multiple sets of parameters for Equations 2, 3, and 5, representing differential release and 
reuptake kinetics can yield a good qualitative fit of experimental data. Because stimulated DA 
responses largely represent a balance between DA release and reuptake, the less efficient reuptake 
kinetics are in a simulation, the less robust release kinetics need to be to in order to model the same 
DA response. It is informative to obtain conservative estimates of release and reuptake kinetics; 
whereas, there is no upper limit to how robust release kinetics could be- reuptake kinetics would 
have to be similarly robust to counterbalance it. In order to obtain conservative estimates of 
reuptake and release kinetics, simulations using Equation 6 were fit to experimental data by first 
minimizing Vmax and subsequently adjusting the simulation parameters to minimize the total DA 
released in the simulations. In doing so, this method yielded simulations with conservative 
estimates of reuptake, and therefore, DA release as well. 
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2.5.1 Regiospecific stimulated DA responses 
It was previously demonstrated that stimulated DA response morphology in the ventral striatum 
have a more convex rising pattern than responses collected in the dorsal striatum (May & 
Wightman 1989), and this has been a general finding in our lab as well. In order to demonstrate 
applicability of our modeling methods on the wide-ranging DA response shapes observed in the 
striatum, we obtained stimulated DA responses from the anterior dorsal (n=7) and middle ventral 
neostriatum (n=6) to collect DA responses that rise concavely and convexly during 60Hz 
stimulations, respectively, as reported previously (May & Wightman 1989) (see methods section 
for details). 
 
We demonstrate that both dorsal and ventral striatal responses can be modeled according to the 
quantitative model described in this report (Figure 6). Without accounting for post-stimulation 
DA release, the modeled DA responses (black dashed lines in Figure 6A&B) undershoot the decay 
phase of experimental DA responses, but with the addition of estimated post-stimulation DA 
release components responses could be simulated well (gray dashed lines Figure 6A&B). 
Responses from both striatal regions were modeled with similar dopamine release dynamics, but 
differences were observed with uptake kinetics (Figure 6C & D). Notably, there was a difference 
in the Kminf, where the inflection point occurs later in dorsal responses compared to ventral 
responses (5.4s vs. 2.4s, respectively) (Table 2). These differences in the Km dynamics may be 
due to regional differences in bioenergetics or DAT function, causing dorsal striatal responses to 
exhibit a more prolonged attenuation of DA reuptake efficiency compared to the ventral striatum 
(Ciliax et al. 1995). These simulations allow us to estimate the amount of DA released and cleared 
over the time course of DA responses (Table 3). These simulations suggest that a greater 
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proportion of DA released in the first 1s of stimulation is cleared by reuptake in the dorsal striatum 
compared to the ventral striatum (93.3% vs. 73.6%, respectively) (Table 3), indicative of more 
robust clearance mechanisms in the dorsal striatum compared to the ventral striatum as established 
before (Jones et al. 1995a). 
 
Figure 6: Simulations of regiospecific stimulated DA responses 
A/B) Experimental DA responses (solid black lines) were simulated using the described methods (gray dashed lines). 
Simulations of experimental data without accounting for a post-stimulation DA release component are also depicted 
(black dashed lines). C/D) Simulated DA release and reuptake rates during the response time course according to the 
neurobiological model are depicted (gray dashed lines).  Moreover, simulated release and reuptake rates without 
accounting for a post-stimulation DA release component are also depicted (black dashed lines). 
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Table 2: Simulation parameters of dorsal and ventral neostriatl DA responses 
 
Table 3: Metrics derived from simulations of regiospecific DA responses 
 
2.5.2 Varying frequency of stimulated DA responses 
To further test the validity and utility of the quantitative neurobiological model proposed, we 
simulated DA responses that were collected in the dorsal striatum (n=3), in which we varied the 
frequency of 10s stimulations between 35-60Hz (Figure 7). In simulating these DA responses, we 
held Vmax constant because the local DAT concentration should be relatively constant between 
stimulations. The model was able to simulate the different frequency responses as shown in Figure 
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7A. The frequency of the stimulation determined the initial DA release rate, wherein higher 
frequencies were associated with stronger initial release rates (Figure 7B). Moreover, with higher 
stimulation frequencies, there was a faster decay in DA release kinetics (DARτ) (Table 4). These 
simulation parameters are consistent with the demonstrated effects of stimulation frequency on 
glutamate release in glutamatergic synapses (Pyott & Rosenmund 2002). Interestingly, DA 
reuptake rate does not vary greatly across the different frequencies of stimulation (Figure 7B), but 
the Km(t) function has a strong relationship with the frequency of stimulation, such that the greater 
the stimulation frequency, the more leftward the inflection in the Km(t) function (Figure 7C and 
Table 4). Thus, these simulations suggest that the attenuation of reuptake efficiency occurs faster 
with higher frequency of stimulations, as would be expected if energy depletion and perturbations 
in electrochemical gradients by electrical stimulations underlie the major mechanism of reuptake 
efficiency attenuation during DA responses. Because the simulations suggest DA reuptake rate 
does not greatly change across different frequencies of stimulation but that the Km(t) function does, 
our data suggests that the [DA]in that accumulates during stimulated DA responses may play a 
relatively minor role compared to energy depletion in attenuating DA reuptake kinetics during a 
stimulated DA response.  
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Figure 7: Simulations of DA responses by varying frequency 
A) Experimental DA responses (solid black lines) were simulated using the quantitative neurobiological method (gray 
dashed lines). B) Simulated DA release and reuptake rates depicted for the various frequencies of stimulation. C) The 
Km(t) functions that were used to simulate each DA response reveals a left-ward shift in the Km(t) function with 
increasing stimulation frequency, suggesting faster attenuation of reuptake kinetics. 
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Table 4: Simulations of responses while varying stim frequency 
 
2.5.3 Regiospecific pharmacological response to methylphenidate 
The quantitative neurobiological framework may also be applied to study regiospecific effects of 
pharmacological agents that affect DAergic systems. We examined how mean dorsal (n=4) and 
ventral (n=4) striatal responses are altered 15min. post-administration of the competitive DAT 
inhibitor MPH (10mg/kg i.p.). Though, primarily a DAT inhibitor, MPH can have indirect effects 
on enhancing DA release (Sandoval et al. 2002, Volz et al. 2008), which may be similar to the 
effects of cocaine, a similar DAT inhibitor (Venton et al. 2006). MPH may also increase DAT 
surface expression as has been demonstrated by other DAT inhibitors (Little et al. 2002, Daws et 
al. 2002).  
 
In Figure 8A,B, we demonstrate how our simulations are capable of approximating post-
MPH changes in 60Hz, 5s stimulated DA responses from baseline. Pre- and post-MPH DA 
responses were simulated by holding constant the parameterization of post-stimulation DA release 
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kinetics (Table 5). This assumption was made because pre- and post-drug responses were recorded 
from the same site with the same duration of stimulation, which should yield similar dynamics of 
[Ca2+] accumulation and therefore post-stimulation DA release dynamics. By assuming post-
stimulation DA release kinetics are constant, MPH-induced changes could be modeled as changes 
in stimulated DA release and reuptake kinetics. Pre- and post-MPH responses were successfully 
modeled as an increase in Kmi, as expected for a DAT inhibitor, but also by increases in DA release 
rates and Vmax (Figure 8C,D, & Table 5), consistent with others’ reports (Daws et al. 2002, Little 
et al. 2002, Venton et al. 2006, Volz et al. 2008). Similar pattern of changes in Vmax, DA release 
kinetics, and Km kinetics were observed in the dorsal and ventral striatal regions.  
 
Interestingly, our simulations indicate that the % of DA released that was cleared during 
5s of stimulation did not greatly change, and even slightly increased with the MPH challenge 
(Table 6). This is because MPH enhances DA release, and although MPH inhibits DAT, this effect 
is partially masked by the stimulation-dependent attenuation of reuptake efficiency. However, 
MPH did attenuate the % of DA cleared during 1s of stimulation because the stimulation-
dependent attenuation of reuptake efficiency has a less pronounced role in the initial phase of the 
DA response, allowing for the observation of the DAT-inhibiting effect of MPH.  
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Figure 8: Regiospecific DA responses following methylphenidate administration 
Dorsal (n=4) (A) and ventral (n=4) (B) striatum before and 15 min. after administration of MPH (10mg/kg, i.p.). 
C&D) Simulated DA release rates were plotted for baseline and post-MPH responses, revealing a post-MPH increase 
in release rate. The Km(t) functions used in the simulations are also plotted, revealing the expected increase in Kmi 
post-MPH administration but similar pattern of Km increasing pre- and post-MPH. Moreover, the Vmax increases 
post-MPH administration in both the dorsal (C) and ventral (D) striatum. 
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Table 5: Simulation parameters in pre- and post-MPH responses 
 
Table 6: Metrics derived from simulations of MPH responses 
 
2.6 DISCUSSION 
FSCV DA responses obtained using electrical stimulation paradigms reflect a balance between 
DA release and reuptake. Albeit, stimulated DA responses are supra-physiological, the high signal-
to-noise ratio of stimulated DA responses is amenable for kinetic analyses that are otherwise 
difficult in physiological non-stimulated conditions.  
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This work highlights some of the dynamics of stimulated DA release and reuptake that may 
be predicted based on contemporary research and initially validated using our experimental data. 
Rather than DA reuptake following simple M-M enzyme kinetics described by constant Vmax and 
Km parameters, we suggest reuptake follows a dynamic M-M model described by a constant Vmax 
and a variable Km term associated with a decreasing efficiency of reuptake during stimulated DA 
responses.  Rather than DA release described by a constant amount of DA released-per-pulse in 
the M-M model, we suggest that release decreases exponentially during a stimulation pulse train. 
Moreover, we suggest that this release continues into the post-stimulation period following a 
biphasic decay pattern.  
 
Though the concept of release occurring in the post-stimulation phase has been 
demonstrated and studied since the late 1960s (Katz & Miledi 1968, Barrett & Stevens 1972), 
many of the specific molecular mechanisms of post-stimulation release have only recently been 
discovered and currently are being investigated (Groffen et al. 2006, Groffen et al. 2010, Pang et 
al. 2011). The elevated [Ca]in  that can result from sustained stimulations may lead to post-
stimulation DA release using the Ca2+-sensor synaptotagmin, while the prolonged phase of post-
stimulation DA release may be mediated by more sensitive Ca2+-sensors like DOC2. Since DOC2 
proteins have been demonstrated as contributors to post-stimulation release and spontaneous 
neurotransmitter release in other brain regions, (Groffen et al. 2006, Groffen et al. 2010, Pang et 
al. 2011, Yao et al. 2011) a demonstration of their expression in striatal DAergic terminals would 
be important in supporting the concept of post-stimulation DA release.  
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By taking a mathematical modeling approach, we demonstrate how the kinetics of DA 
release and reuptake may realistically contribute to the overall shape, and thus properties, of 
stimulated DA responses. A major strength of this approach is that it quantitatively describes a 
wide variety of stimulated DA response patterns exhibited throughout striatum, an exercise that 
has previously not been possible with the M-M model. In particular, dorsal striatal responses that 
predominantly rise concavely during 60Hz stimulation pulse-trains can be simulated using this 
proposed neurobiological model, without compromising the fundamental assumptions of the 
model. 
 
Stimulated DA responses that exhibit concave shapes during electrical stimulations have 
previously been attributed to diffusional delays in electrode response to nearby DA concentration 
changes (Kawagoe 1993, Wu et al. 2001) or have been attributed to possible cytoarchitectural 
diffusional barriers in the striatum (May & Wightman 1989, Taylor et al. 2012). Signal 
deconvolution methods have often been implemented to remove artifacts attributed to diffusional 
distortion on stimulated DA responses (Kawagoe & Wightman 1994, Wightman et al. 1988, Wu 
et al. 2001). These methods were originally developed to remove the signal delays caused by 
Nafion electrode coatings, but have since been applied to bare electrodes, rationalized by the 
development of a biological layer that may form around the electrode to cause signal delays (Wu 
et al. 2001). However, recent work has demonstrated that DA responses collected on bare 
electrodes do not exhibit characteristics of responses expected for signals convoluted by 
diffusional distortion (Moquin & Michael 2009, Taylor et al. 2012). Moreover, electron 
microscopy analysis revealed the existence of intact synapses less than 1µm from explanted 
electrode tracts, suggesting that the use of signal deconvolution procedures maybe unnecessary for 
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data collected on bare electrodes (Taylor et al. 2012). In this report, we attribute DA response 
morphology primarily to represent underlying neurobiological processes and, therefore, we have 
not applied signal deconvolution algorithms to our dataset. 
 
Concave responses have also been attributed to complex DA release kinetics, where release 
is initially inhibited and then gradually increases during stimulation (Moquin & Michael 2009). 
However, the theory of complex release kinetics described is at odds with the predicted exponential 
decay of release seen ubiquitously for neurotransmitter systems (Dobrunz & Stevens 1997, Liley 
& North 1953, Pyott & Rosenmund 2002, Zucker 1999, Hagler & Goda 2001, Neves & Lagnado 
1999, Hubbard 1963, Pan & Ryan 2012, Taschenberger & von Gersdorff 2000). We suggest that 
apparent complex release patterns actually be attributable to a dynamic reuptake model that we 
described in this report. Taylor (2012) et al have reported that blocking DA reuptake with 
nomifensine administration elicits robust DA responses immediately following stimulation onset, 
suggesting that DA release is not inhibited at stimulus onset, but that efficient reuptake 
mechanisms limit the observable increases in [DA]EC. The D2 antagonist raclopride, often 
considered a DA release enhancer, has similar effects to nomifensine on altering the morphology 
of concave responses (Moquin & Michael 2009). This may be due to the known effects of D2 
antagonists on reuptake inhibition, especially at higher frequencies of stimulation (>50Hz) (Wu et 
al. 2002). 
 
The concept that reuptake efficiency decreases during stimulated DA responses is a novel 
concept in the voltammetry field, but support for this finding has also been suggested by Wang et 
al. (Wang et al. 2011). Our experimental data recapitulate the previous findings by showing that 
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stimulation duration attenuated the efficiency of DA reuptake (Figure 3), but we also expound on 
how attenuating reuptake efficiency is necessary to explain the existence of the variety of 
experimental DA responses morphologies, particularly concave-shaped responses (Figure 4). We 
suggest that electrical stimulations may deplete ATP and/or the energy stored in electrochemical 
gradients- particularly, the Na+ gradients- that are necessary for DA reuptake. Though Figure 7 
suggests intracellular DA accumulation may not predominantly contribute to the attenuation of 
reuptake efficiency during a stimulated DA response, DA reuptake kinetics may be altered by 
pharmacological manipulations that increase cytosolic DA levels as with the DA precursor L-Dopa 
or vesicle depleting agents like reserpine or amphetamine.  
 
In contrast to the hypothesis that DA reuptake efficiency decreases during a stimulated DA 
response, work by Rodriguez et al. have used amperometric methods to suggest that electrical 
stimulation enhances DA reuptake (2007) and that MFB stimulation occasionally causes DA 
concentrations to transiently decrease in discrete striatal sites (2006). Our lab has never observed 
an MFB stimulated decrease in DA response voltammetrically, despite collecting stimulated 
responses in various striatal locations, using different electrode fabrication methods, and different 
frequencies and durations of stimulation presented in this report and elsewhere (Wagner et al. 
2009a). Alternatively then, we suggest that pH changes associated with MFB stimulation, which 
are known to interact with endogenous catechol molecules to yield complex shifts in 
electrochemical recordings could be misinterpreted as DA decreases in amperometric recordings 
(Takmakov et al. 2010, Phillips et al. 2003). Though pH changes can be distinguished using FSCV, 
they cannot with amperometry. This distinguishing difference with in vivo electrochemistry 
techniques then suggests that the findings by Rodriguez should consider pH change and how it 
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interacts with basal DOPAC as an apparent contributor to stimulus response patterns observed in 
amperometric recordings (Rodriguez et al. 2007a, Rodriguez et al. 2006). 
 
The neurobiological framework described in this paper suggests that stimulated DA 
responses vary greatly across striatal regions. This variation can be largely affected by local DA 
clearance mechanisms, with dorsal striatal regions having more efficient clearance kinetics leading 
to concave responses, while ventral striatum have less efficient clearance kinetics leading to 
convex responses using 60Hz stimulations. These observations are congruent with the dorso-
ventral gradient of decreasing DAT density (Ciliax et al. 1995). The striatum is known to have a 
topographical organization, and thus the regiospecific differences in DA clearance can have 
important functional implications. The efficient DA clearance kinetics in the dorsal striatum can 
serve to limit DA diffusion and the time course of signaling in order to mediate the precise neural 
communication required for cognitive and motor functions ascribed to the dorsal striatum. In 
contrast, less efficient reuptake mechanisms of the ventral striatum may prolong DA signaling and 
diffusion to mediate limbic functions that may not require such rapid and precise neural 
communication as cognitive and motor functions. This regiospecific model of DA 
neurotransmission kinetics is consistent with findings in awake freely-behaving rats which show 
that there is a relative paucity of observable spontaneous transient DA fluctuations in the dorsal 
striatum compared to the ventral striatum (Robinson et al. 2002). 
 
A caveat of the modeling approach described in this paper is that multiple sets of 
parameters can adequately model a single experimental stimulated DA response. In the 
experimental stimulated DA responses modeled in this paper, we performed the simulations by 
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minimizing the total amount of stimulated DA released. In doing so, this yielded conservative 
estimates of reuptake and post-stimulation DA release that are consistent with the equations 
incorporated into the model. Although the simulations can demonstrate how DA release and 
reuptake kinetics may contribute to the overall shape of experimental evoked DA responses, 
estimations of the true DA neurotransmission kinetics, in part, depend upon the ability to properly 
constrain parameters of the simulation. Increasing the boundary conditions for simulating the DA 
responses by collecting various durations of stimulated DA responses, particularly long 10s 
stimulations can greatly aid simulating responses that may provide a more realistic estimation of 
DA release and reuptake kinetics in a DA response. Further identification of techniques that will 
aid in realistically simulating DA responses is an on-going endeavor.  
 
Though the equations that describe the processes of DA neurotransmission here are much 
more complex than the originally proposed M-M model, they are likely still oversimplifications of 
true neurobiological processes underlying the kinetics of stimulated DA neurotransmission. For 
example, though stimulated neurotransmitter release may be adequately modeled as an exponential 
decay function, it may be more appropriately modeled as a bi-exponential decay function, with a 
rapid and prolonged decay components as shown previously (Pyott & Rosenmund 2002). 
Moreover, DA reuptake may be affected by rapid DAT phosphorylation events that could alter the 
kinetics of DA transport (Miller 2011). DAT is also known to rapidly traffic to and away from the 
membrane in response to DAT substrates like DA itself (Furman et al. 2009a), and DAT may even 
be trafficked rapidly by stimulation-induced depolarization as has been demonstrated for the 
glycine transporter-2 (Geerlings et al. 2001). However, the mechanisms of DAT trafficking and 
its kinetics are unknown in vivo. Thus, the equations described in this paper should be regarded as 
 46 
an initial set of equations and parameterization that can demonstrate how the neurobiological 
principles described in this paper may contribute to the morphology of stimulated DA responses. 
Continued advancements in the field of neurotransmission will be invaluable for further 
modification of these equations to mathematically represent DA release and reuptake kinetics and 
for developing better ways to constrain simulation parameters to reflect the true kinetics of 
stimulated DA neurotransmission. 
 
The quantitative modeling approach described here endeavors to dissect experimental DA 
responses into the realistic estimations of DA release and reuptake kinetics. Our main impetus 
behind generating this novel framework was to develop a method to characterize DAergic 
dysfunction in our experimental model of TBI, which required a framework that could first 
quantify and characterize the diverse response-types exhibited in control animals; we have 
demonstrated how this model is able to simulate DA responses in Figures 6,7, & 8. Modeling DA 
responses following administration of D2 agonists, antagonists, L-Dopa, and other agents that may 
affect DA neurotransmission could further assess the utility of this framework and its validity. We 
anticipate this quantitative method will be utilized to understand better how different experimental 
conditions like sex, aging, and chronic drug treatment paradigms, TBI, and other disease 
conditions alter presynaptic DA neurotransmission, especially in the dorsal striatum. 
2.7 METHODS 
Animal Housing 
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Young-adult Sprague Dawley rats were used for all studies (Hilltop Laboratories, PA). Rats 
were housed 2 animals per cage with standard bedding and a 12:12h light/dark cycle (on 7:00a.m. 
to 7:00pm). All housing and procedures were in compliance with the Animal Care and Use 
Committee at the University of Pittsburgh and in accordance to recommendations outlined in the 
Guide for the Care and Use of Laboratory Animals (1996). 
 
Voltammetric Electrode 
Voltammetric electrodes were assembled as previously described in our work (Wagner et 
al. 2009a, Wagner et al. 2009b). 7μm diameter carbon fiber (T-300, Union Carbide, Danbury, CT) 
were threaded through borosilicate glass capillary tubes (1.0mm outer diameter, .75mm inner 
diameter). Capillary tubes were then pulled to a tip using the micropipette puller (Narishige, East 
Meadow). The carbon fibers were secured with epoxy (Spurr Polysciences, Warrington PA) and 
cured for 12 hours in 80°C. The exposed carbon fibers were cut to approximately 400μm. Electrical 
contact was established by filling capillary tubes with mercury and inserting a ni-chrome wire and 
sealed using epoxy.  
 
Surgical Procedures for Fast-Scan Cyclic Voltammetry  
For FSCV experiments, animals were deeply anesthetized with urethane (1.3g/kg, i.p.) in 
accordance to the Institutional Animal Care and Use guidelines of the University of Pittsburgh. 
Core body temperature will be maintained at 37°C with a homeothermic blanket (Harvard 
Apparatus, Hollison MA). Midline incisions were made, and the soft tissues were reflected to 
expose the skull and relevant landmarks for stereotactic electrode placement. Small burr holes 
were drilled for the placement of stimulating, the working carbon fiber electrodes. The dura was 
 48 
removed from each area prior to electrode placement. An Ag/AgCl reference electrode was placed 
in contact with the dura mater to create a salt bridge. The voltammetric working electrode(s) were 
then lowered into the striatum using flat-skull coordinates from bregma (Anterior dorsolateral 
electrode: +1.7mm anterior-posterior (AP), -2.7mm medial-lateral (ML), and -4.6mm dorsal-
ventral (DV), Middle ventromedial electrode: +1.0 AP, 2.0 ML, and -6.6 DV) (Paxinos & Watson 
2007). Bipolar stimulating electrodes (MS301-1, Plastics One, Roanoke VA.) were placed just 
above the medial forebrain bundle (MFB) [-4.0 AP, 1.6 ML, -7.2 DV] (Paxinos & Watson 2007).   
 
Voltammetric Data Collection  
The potential applied to the carbon fiber microelectrode was controlled the LabView 
software, TarHeel CV (ESA, Chelmsford, Ma).  Just prior to use in FSCV experiments, electrodes 
were electrochemically treated to increase sensitivity by applying a 70Hz biphasic potential 
waveform to the electrodes using linear ramp from 0 to 2 to 0V for 4s. A triphasic potential 
waveform was applied to the electrodes with linear ramp from 0 to 1V, 1 to -.5V, and back to 0V 
vs. the Ag/AgCl reference electrode, where it was held for 100ms between scans. Electrodes 
equilibrated for at least another 30 minutes in vivo before collecting experimental data. Scan rates 
were set to 300V/s. Amplifier outputs were digitized during potential scans by a 12-bit analog-to-
digital converter operating at a 40KHz sampling frequency. A change in evoked [DA] 
concentration creates a signature waveform (cyclic voltammogram) with oxidation and reduction 
peaks occurring between 600-800mV and 100-300mV, respectively. The current associated with 
the DA oxidation peak was used for analysis, and the currents were converted to DA concentrations 
by ex vivo calibration of the electrode in a flow cell with different concentrations of DA in ACSF 
following the experiments.  
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Stimulation of the Medial Forebrain Bundle 
In order to evoke DA release in the striatum for measurement with FSCV, DAergic 
projections contained within the MFB were stimulated. Following stereotaxic placement of the 
bipolar stimulating electrode just above the MFB, 5s, 60Hz electrical stimulations with a bipolar 
square waveform (280µA in amplitude, with a pulse width of 2ms) were used to elicit stimulated 
DA responses recorded by the working electrode. The stimulating electrode was lowered 200μm 
every 5 minutes until a clear DA signal was observed using the TarHeel CV software. The 
stimulating electrode was then lowered 100μm every 10 minutes until the summed signal 
amplitude of the two electrodes began to decrease, at which point experimental data was collected 
for the FSCV studies.  
 
Studies of varying durations of stimulation & MPH studies: 
Because prolonged stimulation durations affect the refractory time interval necessary to 
reproduce a stimulated DA response (Justice et al. 1988), our studies utilized a conservative 
interval period between stimulations to facilitate attainment of reproducible signals.  Thus, for 
stimulations of 1s, 2s, 3s, 5s, 10s durations we waited 5, 10, 15, 15, and 20 minutes until the next 
stimulation, respectively. Following the collection of the stimulations of various durations, a subset 
of rats was used for assessing the response to a pharmacological MPH challenge. First, a 60Hz, 5s 
stimulation was collected for a baseline. 10mg/kg of MPH in .1M PBS was then administered via 
intraperitoneal injection. Another 60Hz, 5s stimulation was collected 15 min. post-MPH 
administration. 
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Studies of varying frequency of stimulation 
A similar protocol was followed for obtaining DA responses of varying frequencies as 
varying duration, except only one working electrode in the dorsal striatum was utilized. 10s 
stimulations were used to collect data with 60, 50, 40, and 35Hz frequencies, with 20, 20, 15, and 
10 min. wait intervals between stimulations, respectively, to allow for restoration of DA responses.  
 
Data analysis 
All experimental stimulated DA responses were temporally filtered using a low-pass 2-
pole Butterworth filter with a 1Hz cutoff frequency in MATLAB. 
Decay efficiency plots:  
Decay efficiency plots were generated from the post-stimulation phase of experimental DA 
vs. t data. Linear regressions were iteratively performed on 5 consecutive data points, with the 
negative of the slopes plotted vs. the corresponding ∆[DA]EC measured using FSCV. Maximal 
decay rates were determined from the decay efficiency plots. 
 
Statistical analyses were performed in SPSS 22.0 for Mac (SPSS Inc., Chicago, IL) Min, 
median, max, and 1st/3rd quartile are graphically reported for decay efficiency slopes at Decay 
Rate1/2max for each stimulation duration tested. Repeated measures ANOVA was used to assess the 
main effects of stimulation duration on decay efficiency slope at Decay Rate1/2max. Pair-wise 
comparison of 1s vs. 10s stimulations was performed using a pair-wise T-test. A p-value ≤ 0.05 
was considered significant for all analyses.  
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3.0  FAST-SCAN CYCLIC VOLTAMMTERY DEMONSTRATES THAT L-DOPA 
PRODUCES REGIONALLY-SELECTIVE, BIMODAL EFFECTS ON STRIATAL 
DOPAMINE KINETICS  
Rashed Harun, BS; Kristin M. Hare; M. Elizabeth Brough; Miranda J. Munoz; 
Christine M. Grassi; Gonzalo E. Torres; Anthony A. Grace; Amy K. Wagner, MD 
3.1 SUMMARY 
Parkinson’s disease (PD) is a debilitating condition that is caused by a relatively specific 
degeneration of dopaminergic (DAergic) neurons of the substantia nigra pars compacta. Levodopa 
(L-DOPA) was introduced as a viable treatment option for PD over 40 years ago and still remains 
the most common and effective therapy for PD. Though the effects of L-DOPA to augment striatal 
DA production are well known, little is actually known about how L-DOPA alters the kinetics of 
DA neurotransmission that contribute to its beneficial and adverse effects. In this study, we 
examined the effects of L-DOPA administration (50mg/kg carbidopa + 0, 100, and 250mg/kg L-
DOPA) on regional electrically stimulated DA response kinetics using fast-scan cyclic 
voltammetry (FSCV) in anesthetized rats. We demonstrate that L-DOPA enhances DA release in 
both the dorsal striatum (D-STR) and nucleus accumbens (NAc), but surprisingly causes a delayed 
inhibition of release in the D-STR. In both regions, L-DOPA progressively attenuated reuptake 
kinetics, predominantly through a decrease in Vmax. These findings have important implications 
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on understanding the pharmacodynamics of L-DOPA, which can be informative for understand its 
therapeutic effects and also common side effects like L-DOPA induced dyskinesias (LID). 
3.2 INTRODUCTION 
Parkinson’s Disease (PD) is the second most common neurodegenerative disease, and much 
research has been focused upon its pathophysiology and symptomology, yet there is still neither a 
cure nor an effective strategy to slow disease progression. PD associated pathology is linked to 
selective dopamine (DA) system neuronal fiber loss from projections originating in the substantia 
nigra pars compacta (SNpc) whose terminals innervate the dorsal striatum (D-STR) (McRitchie 
et al. 1997). Although several DAergic agents have been introduced (Camicioli et al. 2001, 
Guttman 1997), and have beneficial effects in PD, L-DOPA still remains the most common and 
effective therapy. Nevertheless, this drug has limitations, primarily motor complications that 
follow long-term use, which may be related to chronic dysregulation of the DA transporter (DAT) 
(Thanvi & Lo 2004, Troiano et al. 2009).  
L-DOPA is the synthetic precursor to DA, but the specifics of how L-DOPA administration 
affects presynaptic DA neurotransmission is not fully understood. Many DAergic agents like DAT 
inhibitors not only have a primary specific target (e.g. DAT) but also have secondary effects on 
DA release, DA receptor sensitivity, and DAT trafficking (Harun et al. 2014, Saunders et al. 2000, 
Volz et al. 2008, Venton et al. 2006, Wagner et al. 2009a). Due to DAT density and neurochemical 
differences across striatal regions, DAergic agents can have markedly different actions on striatal 
sub-regions (Stamford et al. 1991, Harun et al. 2014, Ciliax et al. 1995, Jones et al. 1995b).  In 
midbrain neuronal cultures, L-DOPA selectively increases intracellular DA 2-3X higher in SNc 
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vs. ventral tegmental area neurons (Mosharov et al. 2009).  Also, L-DOPA can alter the kinetics 
of vesicle fusion events in vitro (Amatore et al. 2005, Sombers et al. 2004), but how these findings 
influence regional in vivo DA kinetics is not understood. Recent work using amperometry 
demonstrated that, in addition to the known effects of L-DOPA on enhancing release, L-DOPA 
could also inhibit DA reuptake (Rodriguez et al. 2007b), which has not been demonstrated in 
previous characterizations of the effects of L-DOPA on striatal DA neurotransmission using fast-
scan cyclic voltammetry (FSCV) (Peters & Michael 2000, Wightman et al. 1988). 
 In this report, we examined how two doses of L-DOPA administration (100mg/kg 
and 250mg/kg) affects electrically stimulated DA neurotransmission kinetics using FSCV in rats, 
where FSCV DA signals represent a balance of DA release/reuptake that are amenable to kinetic 
analysis (Wightman & Zimmerman 1990).  Recently, we have incorporated neurobiological 
components of attenuating release, attenuating reuptake efficiency, and post-stimulation DA 
release into a quantitative neurobiological (QN) framework that can be used for kinetic analysis of 
stimulated DA responses. We have shown initial evidence that this analytic approach effectively 
characterizes regional differences and pharmacologically induced changes in stimulated DA 
responses (Harun et al. 2014). Using this framework, we demonstrated regiospecific and dose-
dependent effects of L-DOPA on stimulated DA release in the D-STR and NAc. As the synthetic 
precursor to DA, L-DOPA dose-dependently enhanced stimulated release, but importantly, L-
DOPA also paradoxically inhibited release, especially in the context of the high 250mg/kg L-
DOPA challenge in the D-STR. These release inhibitory effects of L-DOPA maybe due to an 
attenuation of the effective size of the readily releasable pool (RRP) of DA synaptic vesicles by 
the high dose of L-DOPA, as suggested by the faster stimulation-induced decay of DA release rate. 
Most importantly, we demonstrated that L-DOPA administration caused a progressive, dose-
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dependent attenuation of reuptake efficiency in both the NAc and D-STR, primarily by a decrease 
in the maximal reuptake rate (Vmax) and also by an increase in the Michaelis-Menten constant 
(Km) with the high-dose L-DOPA challenge. These reuptake inhibitory effects of L-DOPA may 
represent a major mechanism by which the agent enhances DA neurotransmission clinically. These 
dose and time-dependent changes in DA neurotransmission kinetics may be important to consider 
when using L-DOPA for PD treatment, for which dose titration and optimization is crucial to 
managing symptoms and side-effects effectively.  
3.3 METHODS 
Animals and surgical procedure:  
The animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh. Fifteen young-adult male Sprague-Dawley rats (Hilltop 
Laboratories, Scottsdale, PA, USA) weighing between 350-375g were used for this study. Prior to 
study procedures, all animals had access to rat chow and water ad libitum. Animals were 
transported to our surgical laboratory, anesthetized with urethane (1.3g/kg, i.p.) for consistent 
long-term anesthesia, and mounted onto a stereotactic frame. Core body temperatures were 
maintained at 37°C with a homeothermic blanket. For stereotaxic placement of electrodes in the 
brain, a midline incision was made, soft-tissues reflected, and burr holes were drilled into the right 
parietal and frontal bones, after which dura was removed. Three groups of animals were used to 
demonstrate the dose-dependent regiospecific effects of L-DOPA that differed in acute 
pharmacological manipulation. All drugs were freshly prepared in .1M phosphate buffer solution 
(pH=7.2). The control group (n=4) was administered 50mg/kg of carbidopa (Matrix Scientific, 
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Columbia, SC) intraperitoneally (i.p.) followed by PBS (3mL/kg i.p.). The two experimental 
groups received 50mg/kg administrations of carbidopa, but also were administered a 100mg/kg 
(n=5) or a 250mg/kg (n=6) dose of L-3-(3,4-dihydroxyphenyl)alanine (L-DOPA) (Acros Organics, 
NJ).  
Fast-scan cyclic voltammetry: 
Carbon fiber microelectrodes (7µm in diameter and 250µm long) were fabricated as 
previously described (Wagner et al. 2005b, Harun et al. 2014). Prior to use, electrodes were 
electrochemically pretreated by applying a 70Hz biphasic potential waveform to the electrodes for 
2s from 0 to 2 to 0 V vs. an Ag/AgCl reference electrode to enhance electrode sensitivity. Two 
recording microelectrodes were simultaneously inserted using flat skull coordinates (in mm) into 
the D-STR [anterioposterior (AP) +1.7, mediolateral (ML): 1.4, and dorsoventral (DV): -3.4] and 
into the NAc [AP: 1.0, ML: 2.1, and DV:-6.6] (Paxinos & Watson 2007). A reference electrode 
was placed in contact with proximal soft muscle tissue to create a salt bridge. A bipolar stimulating 
electrode (MS301-1, Plastics One, Roanoke, VA) was inserted over the median forebrain bundle 
(MFB) [AP: -4.0, ML: 1.6, DV: -7.2].  
Biphasic 60Hz, 5s (280µA amplitude and 2ms pulse width) electrical stimulations were 
used to evoke DA overflow in the striatum. Regional DA responses were detected using carbon 
fiber microelectrodes to which a triphasic cyclic voltage waveform (0→1→-0.5→0V) was applied 
a rate of 300V/s every 100ms using the TarHeel CV software (ESA, Chelmsford, MA). The 
stimulating electrode was lowered 200μm every 5 min until a clear DA signal was observed, and 
then lowered 100μm every 10 min, until the signal amplitudes of the two electrodes peaked. 
Experimental DA responses were then collected using alternating 60Hz, 5s and 2s stimulations, 
waiting 15 and 10 minutes after stimulations, respectively (Fig 9). Carbidopa (Matrix Scientific, 
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Columbia, SC) and L-3-(3,4-dihydroxyphenyl)alanine (L-DOPA) (Acros Organics, NJ) solutions 
in 0.1M phosphate buffered solutions were freshly prepared. Carbidopa was administered 
(50mg/kg i.p.) immediately following the first two stable baseline responses, and L-DOPA (100 
or 250mg/kg) or PBS (3mL/kg) was administered following the collection of the two post-
carbidopa responses. DA response collection resumed until 75min post-L-DOPA administration 
(Fig 1). Responses were converted from currents to DA concentrations ([DA]) following electrode 
explantation and in vitro microelectrode calibration using seven standard DA concentration 
solutions in artificial cerebrospinal fluid (pH=7.2) composed of (in mM): 1.2 CaCl2, 2.0 Na2HPO4, 
1.0 MgCl2, 2.7 KCl, 145 NaCl.  
Interpretation of DA responses 
DA response shape analysis 
DA response shape analysis was performed using two morphometric methods: decay 
behavior and response amplitudes. Response amplitude is simply the peak [DA] of a response. 
Decay behavior was examined similar to previous studies (Moquin & Michael 2009, Jones et al. 
1995b), where responses were time-shifted to match similar amplitudes in the decay phase to 
directly evaluate differences in decay behavior (see Fig 10A insert). The decay behavior was 
quantified by fitting an exponential regression to the 3s following the time point where curves 
were aligned. This approach yields a decay constant (k) that corresponds to the decay behavior, 
with larger k-values corresponding to faster decay kinetics.  
Quantitative neurobiological model 
To estimate how L-DOPA administration affected release and reuptake kinetics, 60Hz, 5s 
DA responses were modeled using our quantitative neurobiological (QN) model (Harun et al. 
2014). Traditionally, stimulated DA responses can be interpreted using the Michaelis-Menten (M-
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M) model (Wightman & Zimmerman 1990), which assumes a constant DA release rate, and DA 
reuptake rate through DAT that is modeled using M-M enzyme kinetics defined by constant Vmax 
and Km terms. The QN model is a refinement of the M-M model that accounts for stimulation 
effects on DA responses by including equations to describe stimulation-induced attenuated DA 
release, attenuated DA reuptake efficiency (increasing Km), and incorporation of a biphasic post-
stimulation DA release component. 
 
Table 7: Equations and parameters utilized in L-DOPA simulations 
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The equations and terms that the QN model utilizes to describe the release and reuptake 
components of stimulated DA responses are reproduced in Table 7. Briefly, DA release rate during 
stimulation (DARstim) is described by equation 1 as an exponential decay function with a time 
constant of ∆DARτ and a steady-state release rate (DARss). This parameterization of stimulated DA 
release rate is adopted from studies characterizing how stimulation trains exponentially decrease 
the rate of neurotransmitter release (i.e. pulse-train depression (PTD)) (Pyott & Rosenmund 2002). 
The PTD of neurotransmitter release is associated with stimulation frequency and ambient 
temperature. When these factors are held constant, they can reflect the effective size of the readily-
releasable pool (RRP) of vesicles, with faster stimulation induced decay of release associated with 
a smaller size of the RRP (Pyott & Rosenmund 2002, Dobrunz & Stevens 1997). Post-stimulation 
DA release rate (DARpost) is described in equation 2 as release rate that decreases bi-phasically 
after stimulation ends, with rapid exponential and prolonged linear decay components. The 
biphasic nature of post-stimulation DA release has been described previously (Atluri & Regehr 
1998) and is likely related to the biphasic kinetics of intracellular Ca2+ clearance after stimulation 
(Fierro et al. 1998), which mediates neurotransmitter release through different Ca2+-sensitive 
proteins (Groffen et al. 2010, Yao et al. 2011).  Lastly, reuptake kinetics was modeled similar to 
the M-M model, except Km here is defined as a dynamic term that increases during stimulation 
according to the logistic function in equation 3. We incorporated the concept of stimulation-
induced increases in Km to account for how stimulation frequency and duration attenuate the 
apparent reuptake kinetics that others and we have observed (Wang et al. 2011, Harun et al. 2014). 
How stimulation attenuates reuptake efficiency is not clearly understood, but it could be due to 
stimulation-induced depletion of energy stored in Na+-gradients that are necessary for DA reuptake 
through DAT. The effects of stimulation on energy depletion may be particularly relevant to the 
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stimulation-induced attenuation of reuptake efficiency concept because DAergic neurons are in a 
delicate energy balance state owing to their dense axonal arborizations and lack of myelination 
(Pissadaki & Bolam 2013).  
The equations in table 7 were combined into equation 4, which was used to model 
experimental DA responses in Matlab R2014a (The MathWorks, Inc, Natick, MA). Because 
multiple sets of parameterizations are able to simulate the same experimental DA response well, 
we performed simulations systematically across studies to minimize artifacts of simulation 
methods by constraining initial Km (Kmi) between 0.1-0.4µM, which is similar to the Km assumed 
in other voltammetry studies and to Km parameters extracted from in vitro studies (Wu et al. 2001, 
Povlock et al. 1996). Moreover, we included 60Hz, 2s stimulations into the experimental protocol 
for internal validation that parameterizations for 5s DA responses were consistent with DA decay 
behavior in 2s DA responses. Since our initial inception of the QN model, we have since updated 
the framework to assume the rapid post-stimulation has a time constant (τR) that increases with 
increasing stimulation duration, which may occur due to greater calcium accumulation by 
increased stimulation-duration to prolong post-stimulation DA release. Although these adaptations 
provide larger estimates of release and reuptake metrics than previously reported (Harun et al. 
2015), in our experience, they have enhanced the fit of simulations to experimental data. Moreover, 
these adaptations furthers our goal of developing systematic rational means of constraining 
parameters to enhance the accuracy of the simulations to model underlying release and reuptake 
processes.  
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Equation 4 
The simulations provide estimates of DA release and reuptake rates over the time course 
of single DA responses that are consistent with the assumptions of the model (see Fig 11B). We 
examined four metrics that are particularly relevant to characterizing the effect of L-DOPA on DA 
neurotransmission- 1) the initial DA release rate (DARi), which may be related to the physiological 
effects of L-DOPA on DA release, 2) the ∆DARτ, which, as described above, could have 
implications on changes in the effective size of the RRP, 3) Vmax, which is often related to the local 
density of DAT and also their efficiency for DA reuptake, and 4) Kmi, which is the M-M constant 
that is inversely related to DAT efficiency.   
 
Statistical analysis 
All response metrics (e.g. amplitudes, Vmax, DARi and others) were analyzed statistically 
in similar ways using SPSS 2.0 for Mac (SPSS Inc., Chicago, IL). Baseline differences between 
regions were evaluated using an independent samples Student’s T-Test. Time dependent changes 
in L-DOPA induced effects were evaluated using repeated measures analysis of variance 
(rmANOVA). Two-factor rmANOVA was used to separately probe for dose and regional 
differences in the time course of L-DOPA effects. Follow up independent samples descriptive 
comparisons were performed using Fisher’s least significant difference, while post-hoc within 
group comparisons over time were assessed using paired-T-tests. P-values ≤0.05 were considered 
to be significant in all comparisons.  
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3.4 RESULTS 
In this report, we aimed to elucidate the basic mechanisms by which L-DOPA affects presynaptic 
DA neurotransmission kinetics in the D-STR and NAc using the MFB stimulated DA response 
paradigm. As there may be differential effects of L-DOPA by dose, we assessed the effects of 
100mg/kg and 250mg/kg L-DOPA challenges. We stimulated the MFB-containing DAergic 
pathways with 60Hz, 5s stimulations to elicit robust DA responses amenable for kinetic analysis, 
which was performed using response shape analysis methods and by modeling DA responses using 
the QN method (Harun et al. 2014). Since multiple stimulation durations aid in validating the 
accuracy of the QN simulations, 60Hz, 2s stimulations were performed between 5s stimulations to 
aid with simulations, but kinetic parameters from the 60Hz, 2s responses were not directly used in 
our analyses (Fig 9). 
 
Figure 9: Timecourse of L-DOPA experiments 
Mean regional DA responses obtained in the high dose L-DOPA challenge group are represented for demonstrative 
purposes. Responses were simultaneously detected in the D-STR (black traces) and the NAc (red traces). Only the 
60Hz,5s responses (solid lines) were used for analysis, while the intermittent 60Hz, 2s responses (dashed lines) were 
used as internal validation of the accuracy of simulations performed on 60Hz,5s data. 
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3.4.1 L-DOPA-induced dose-dependent changes in stimulated DA response shapes 
Prior to L-DOPA administration, rats were administered 50mg/kg (i.p.) of carbidopa to inhibit the 
peripheral metabolism of L-DOPA. However, Jonkers et al. (2001) demonstrated that carbidopa 
itself can act centrally as well to inhibit aromatic amino acid decarboxylase activity (AADC), 
which converts L-DOPA into DA in DAergic neurons (Jonkers et al. 2001). As such, we examined 
the effects of carbidopa over the experimental time course, where in lieu of L-DOPA, PBS vehicle 
(3mL/kg) was administered 25min following 50mg/kg carbidopa. 
Both the high-dose (250mg/kg) and low dose (100mg/kg) of L-DOPA had clear effects on 
the decay phase of DA responses and response amplitudes in both regions, which were particularly 
apparent using the high dose of L-DOPA (Fig 10 A/B).  First, we examined the decay phase of 
DA responses, which primarily reflects the clearance of DA that is mediated by reuptake through 
DAT (Budygin et al. 2002), but may also be confounded by post-stimulation DA release (Harun 
et al. 2014).  We time shifted all 5s DA responses from individual recording sites to compare the 
exponential decay rates (k) of DA disappearance pre- and post-pharmacological manipulation (see 
inset in Fig 10A/B), where higher k values are indicative of faster DA clearance. 
 63 
 
Figure 10: Changes in DA response shapes in the context of carbidopa/L-DOPA administration 
Mean 5s baseline, carbidopa, and post-L-DOPA responses in the D-STR (A) and NAc (B) demonstrate effects of L-
DOPA on DA responses shapes in terms of response amplitudes and the slopes of the decay phases. The insets in 
(A,B) demonstrate how DA responses were time shifted to obtain the exponential decay constant (k). k progressively 
decreased over time in the D-STR (C) and the NAc (D), with the higher dose leading to faster decreases k (rmANOVA: 
p<0.005 and p<0.05, respectively). E) L-DOPA caused dose dependent changes in response amplitudes (p<0.005), 
with the high dose causing significant increases in amplitude at 10min (↑83.8 ±10.0%, p<0.005) and significant 
decreases at 60min(↓58.9 ±8.0%, p<0.005), which contrasted from the delayed increase observed with the low dose 
(↑103.2 ±31.6%). F) L-DOPA caused similar increases in amplitude over time between the high (p<0.005) and low 
dose (p<0.080) groups.  *p<0.05, **p<0.005 compared to baseline and #p<0.05, ##p<0.005 for denoted comparisons 
 
 64 
We noted that animals treated with carbidopa/PBS tended to decrease k over time (p=0.075) 
(Fig 10C/D); however, these effects were small, with an overall 11.2±6.4% decrease (p=0.141) by 
60min post-PBS administration (i.e. 85min post-carbidopa administration). A general progressive 
decrease in k over time was observed in all experimental groups in all regions, but k decreased 
over time differentially between groups, with significant differences apparent between the high-
dose L-DOPA group and the carbidopa/PBS group (p<0.005 in the D-STR, and p<0.05 in the 
NAc). Although, k significantly decreased over time in the low dose L-DOPA group (p<0.05 for 
both regions), this effect did not reach significance when compared to the effects of carbidopa/PBS 
itself in either region.  
L-DOPA administration caused dose-dependent decreases in k in the D-STR (p<0.05) and in 
the NAc (p<0.05), with the higher dose producing faster decreases in k. By 35min and 60min post-
L-DOPA administration, k was significantly decreased following high dose L-DOPA compared to 
low-dose L-DOPA in the D-STR (p<0.005 for both comparisons) and in the NAc at 60min 
(p<0.05). We also observed a regional difference in the effect of L-DOPA on temporal k effects, 
whereby the high dose of L-DOPA decreased k faster over time in the D-STR compared to the 
NAc (p<0.005). By 60min post-L-DOPA administration, k decreased by 81.0±2.2% in the DL-
STR vs. 52.2±4.7% in the NAc (p<0.005). As DAT is the primary mechanism of DA clearance 
after stimulated release, the dose, time, and region-dependent decreases in k strongly indicate that 
L-DOPA inhibits DAT activity.  
We next examined how response amplitudes were affected over time in the experimental 
groups. Response amplitudes represent a balance of release minus reuptake, which dynamically 
change over the course of stimulated DA responses (Harun et al. 2015). Consistent with the idea 
that carbidopa itself inhibits DA synthesis (Jonkers et al. 2001), response amplitudes significantly 
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decreased over time in the carbidopa/PBS group similarly in both the D-STR and NAc (p<0.005 
for both regions) (Fig 10 E/F). By 60min post-PBS administration, there was an overall 32.0±4.8% 
reduction in response amplitudes relative to baseline. Unpublished work in our lab suggests that a 
higher 100mg/kg dose of carbidopa produced even more marked inhibition of response amplitudes 
(>50%).   
Because L-DOPA should enhance DA synthesis, it may be predicted to enhance DA release 
and augment response amplitudes. In the NAc, there was a significant dose (p<0.05), time 
(p<0.005), and dose*time interaction (p<0.05) on how response amplitudes were affected in the 
different experimental groups. Response amplitudes in the L-DOPA groups were significantly 
different over time compared the carbidopa/PBS group (p<0.05 for the both L-DOPA doses). Both 
doses of L-DOPA resulted in significant increases in response amplitude in the NAc at all post-L-
DOPA time points compared to corresponding times in the carbidopa/PBS group (Fig 10F).  
L-DOPA produced significant time-dependent changes in response amplitudes in the D-STR 
(p<0.005) as well, which significantly differed by dose (p<0.05) (Fig 10E). The low dose of L-
DOPA enhanced response amplitudes relative to the carbidopa/PBS controls at all time points 
post-L-DOPA/PBS administration (p<0.05 for all time point comparisons). In contrast, the high 
dose of L-DOPA initially enhanced amplitude 10min post-L-DOPA administration (83.8±10.5% 
↑ relative to baseline, p<0.005), which decreased drastically over the experimental time course. 
Surprisingly, by 60min, the D-STR amplitude decreased by 58.9±8.0% (p<0.005) relative to 
baseline by 60min post-L-DOPA administration. This marked attenuation of amplitude was a 
significantly greater than the 29.3±7.5% inhibition observed 60min post-PBS in the carbidopa/PBS 
challenge group (p<0.05).  
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The delayed attenuation of response amplitude in the D-STR caused by the high dose of L-
DOPA was very paradoxical considering that L-DOPA is thought to enhance DA 
neurotransmission. The progressive impairment of DA reuptake inferred from the analysis of 
response decay behavior would be predicted to enhance response amplitude, but the concomitant 
decrease in D-STR amplitude after a delay following the high dose L-DOPA challenge suggests 
that L-DOPA causes profound impairments in D-STR DA release. 
3.4.2 QN modeling of experimental DA responses demonstrate the effects of L-DOPA on 
DA release and reuptake dynamics 
The application of the QN framework was used to generate simulations of the 60H, 5s experimental 
data as demonstrated in the representative set of D-STR responses from the 
carbidopa(50mg/kg)/L-DOPA (250mg/kg) group (Fig 11A). Overall, the fit of simulations on all 
experimental data resulted in a mean R2= 0.9956±0.0003. The simulations provided estimates of 
release and reuptake rates over the course of the stimulated DA response that fit the assumptions 
of the model, which can be visualized as in Fig 11B. Moreover, simulation parameters were 
extracted to provide estimates of initial release rate (DARi), stimulation-induced attenuation of 
release described by the time constant ∆DARτ, maximal clearance rate (Vmax), and initial Km 
(Kmi), all of which can contribute to the kinetics of presynaptic DA release and reuptake.  
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Figure 11: Representative simulations of DA responses 
A) Experimental DA responses obtained from a representative D-STR (dashed lines) and their corresponding 
simulations (solid gray lines) demonstrates that the QN model can fit experimental data remarkably well- in this case, 
R2=0.9996. B) Simulated release and reuptake rates that produced the simulations in (A) are plotted to demonstrate 
the dynamics of release and reuptake over the course of stimulations. 
3.4.3 L-DOPA has biphasic effects on DA release and inhibitory effects on apparent RRP 
size 
Using the QN model, we first examined how L-DOPA affected DA release by specifically 
examining the initial rate of DA release (DARi). DARi may be affected by various factors like the 
size of the readily releasable pool (RRP), the number of fibers being stimulated, or the local density 
of terminals. Interestingly, we found that DARi was significantly higher in the D-STR compared 
to the NAc (27.8±2.4 vs. 16.0 ±2.0, respectively, p<0.005) (Fig 12A). DARi progressively 
decreased in the carbidopa/PBS group similarly between regions (Fig 12B/C), resulting in an 
overall 27.0 ±4.6% decrease relative to baseline by 60min post-PBS administration (p<0.005). 
This finding is consistent with the idea that carbidopa inhibits DA synthesis (Jonkers et al. 2001).  
L-DOPA produced dose-dependent changes in DARi in the D-STR (p<0.005). Interestingly, 
the effects of the low dose of L-DOPA on DARi were very small and did not reach significance 
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(p=0.177) despite significant effects of the low L-DOPA dose on response amplitudes which are 
a balance of release and reuptake (see above). In contrast, the high dose of L-DOPA tended to 
increase DARi in the D-STR at 10min (29.1 ±12.0% increase relative to baseline, p=0.073), which 
was significantly different from the 13.2±4.2% decrease in DARi 10min post-PBS administration 
(p<0.05). Thereafter, the high dose L-DOPA caused a marked reduction of DARi at 35 and 60min 
by 46.1±6.8% (p<0.005) and 72.3±2.5% (p<0.005), respectively, which was significantly greater 
than the decreases observed post-PBS administration at 10 and 60min (p<0.05 and p<0.005, 
respectively). This profound inhibition of DARi in the D-STR with the high dose L-DOPA 
challenge corroborates with the expected release inhibition predicted from the basic 
characterization of response amplitudes and decay rates. 
L-DOPA had a significant effect on DARi in the NAc over time when compared to the 
carbidopa/PBS group (p<0.005) and a trend was noted between low dose and carbidopa/PBS group 
(p=0.096) (Fig 12C). Similar to the D-STR, the low dose of L-DOPA did not significantly increase 
DARi above baseline in the NAc, but DARi was significantly enhanced at 35min post L-DOPA 
administration compared to the slight decreases observed 35min post-PBS (p<0.05). The high dose 
challenge significantly enhanced DARi at both 10 and 35min post-L-DOPA (increases of 36.9 
±8.0%, p<0.05 and 30.8 ±10.1%, p<0.05, respectively). In contrast to the D-STR, DARi did not 
decrease below baseline following the high dose L-DOPA challenge in the NAc. These findings 
suggest that L-DOPA differentially affects DA release between regions, and surprisingly, the 
100mg/kg L-DOPA had very modest apparent effects on DA release rate. 
The QN framework accounts for DA release with an exponentially decreasing function with 
the time constant ∆DARτ to model the hypothesized depletion of the RRP by electrical stimulation. 
∆DARτ can provide valuable information about the size of the readily releasable pool, where a 
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longer ∆DARτ may corroborate with a larger RRP size (Pyott & Rosenmund 2002).  Interestingly, 
we found significant regional differences in ∆DARτ, where the ∆DARτ was longer in the D-STR 
compared to the NAc (21.6±1.2s vs. 11.3±1.5s, p<0.005, respectively) (Fig 12D), suggesting that 
the RRP size may be larger in the D-STR and may also contribute to the greater DARi in the D-
STR noted above.  
∆DARτ was not significantly affected by carbidopa administration in either region (Fig 
12E/F).  Both doses of L-DOPA progressively decreased ∆DARτ in the D-STR, with the higher 
dose leading to faster decreases in ∆DARτ. At 60min post-L-DOPA administration, ∆DARτ values 
were significantly different between the high dose vs. the low dose challenge (20.1±3.5% vs. 
69.2±10.3% of baseline, respectively, p<0.005) (Fig 12E). Similar changes in ∆DARτ were 
observed in the NAc, except that low dose L-DOPA did not have a significant effect on ∆DARτ 
over time (p=0.137), while the high dose did (p<0.005) (Fig 12F).  60min post-L-DOPA 
administration, ∆DARτ values were significantly different between the high dose vs. the low dose 
challenge (20.1±3.5% vs. 69.2±10.3% of baseline, respectively, p<0.005). This analysis of how 
∆DARτ changes following L-DOPA administration suggests that L-DOPA may effectively be 
reducing the amount of vesicles available for stimulated release (i.e. decreasing the size of the 
RRP), particularly in the D-STR or when using a high dose. 
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Figure 12: Effects of carbidopa and L-DOPA on DA release simulation metrics 
A) Baseline DARi was significantly higher in the D-STR compared to the NAc (27.8±2.4 vs. 16.0 ±2.0, respectively, 
p<0.005). B) L-DOPA had non-significant effects on DARi in the D-STR at the low dose, while the high dose tended 
to cause an initial enhancement at 10min but significant reductions at 35 and 60min (p<0.005 for both comparisons). 
C) L-DOPA caused a significant enhancement of DARi at 10min and 35min at the high dose in the NAc, while the 
low dose did not have a significant effect. D) ∆DARτ was significantly higher in the D-STR compared to the NAc 
(21.6±1.2s vs. 11.3±1.5s, p<0.005, respectively). E) L-DOPA caused a progressive dose-dependent decrease in 
∆DARτ in the D-STR, where the high dose produced faster decreases in ∆DARτ. F) Although ∆DARτ was not 
decreased by the low dose L-DOPA challenge, the high dose progressively decreased ∆DARτ over time. *p<0.05, 
**p<0.005 compared to baseline and #p<0.05, ##p<0.005 for denoted comparisons 
3.4.4 L-DOPA inhibits DA reuptake through changes in Vmax and Km 
Analyzing k-values above demonstrated that both doses of L-DOPA significantly prolonged the 
decay phase of stimulated DA responses in both regions, highly suggesting that L-DOPA inhibits 
DAT activity. Quantitative simulations can further clarify whether changes in reuptake could be 
attributed to changes in Km, which is inversely related to the efficiency of DAT, or to Vmax, 
which reflect both the efficiency of DAT and surface expression of functional DAT.  
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Simulations revealed that baseline Vmax was higher in the D-STR relative to the NAc (35.9 ± 
1.4 vs. 20.2 ± 0.9 µM/s, p<0.005) (Fig13 A), which is consistent with the known higher DAT 
density and faster DA reuptake kinetics in the D-STR compared to the NAc (Ciliax et al. 1995, 
Harun et al. 2014, Jones et al. 1995a). Small decreases in Vmax were noted in the carbidopa/PBS 
group over time (p<0.05). Interestingly, both doses of L-DOPA led to robust, progressive, and 
dose-dependent decreases in Vmax in both regions, with higher doses causing faster decreases in 
Vmax. All time points post-L-DOPA administration at both doses and both regions had 
significantly decreased Vmax values compared to baseline (Fig13 B/C). The reductions in Vmax 
were also significantly greater compared to carbidopa/PBS effects with both doses in both regions 
except for in the 10min time point in the D-STR. These robust changes in Vmax suggest that L-
DOPA can rapidly cause a dose-dependent inhibition of DAT activity in both regions.  
 
Figure 13: Effects of carbidopa and L-DOPA on DA reuptake simulation metrics 
A) Vmax was significantly greater in the D-STR compared to the NAc (35.9 ± 1.4 vs. 20.2 ± 0.9 µM/s, p<0.005). 
B/C) L-DOPA dose-dependently decreased Vmax in the D-STR (B) and NAc (C). D/E) Kmi increased significantly 
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in the D-STR (D) and tended to increase over time in the NAc (p=0.086) following the high dose challenge, while the 
low-dose did not have an appreciable effect on Kmi. *p<0.05, **p<0.005 compared to baseline 
 
In our QN model, we modeled Km as a variable term to model increases over the course 
of stimulation due to a stimulation-induced diminution of Na+ electrochemical gradients that are 
necessary for DA reuptake. As Km changes induced by stimulation are relatively large compared 
to estimated physiological Km values, it is difficult to extrapolate to initial Km values (Kmi) 
through the modeling approach. Nevertheless, we attempted to circumvent this problem by 
constraining baseline KmI values between Kmi=0.1 and 0.4µM as described in the methods. Using 
this approach, we examined if it was necessary to change Kmi to model subsequent DA responses 
after pharmacological manipulation. This method revealed that the Kmi increased over time in the 
D-STR following the high dose of L-DOPA (p<0.05), while Kmi tended to increase as well in 
response to the high dose L-DOPA challenge in the NAc (p=0.086). (Fig13 D/E) The L-DOPA 
induced increases in Kmi suggest that L-DOPA inhibits DAT efficiency; however, it is also 
possible that L-DOPA increases extracellular DA concentrations, which may increase the apparent 
Kmi values through competitive inhibition of DAT. When taken together, the increases in Kmi 
along with the decreases in Vmax presented above, indicate that L-DOPA inhibits DA reuptake. 
3.5 DISCUSSION 
Monitoring stimulated DA responses with FSCV is an effective means to elucidate mechanisms 
by which pharmacological agents alter DA neurotransmission. We demonstrated that L-DOPA has 
regionally selective effects on striatal DA neurotransmission, which could be related to the 
inherent regional differences in baseline DA release and reuptake kinetics demonstrated in this 
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report and elsewhere (Jones et al. 1995a, Stamford et al. 1988). Consistent with previous 
observations, both the 100 and 250mg/kg L-DOPA enhanced DA release in both the D-STR and 
NAc 10min after administration, but surprisingly, 250mg/kg L-DOPA caused a marked delayed 
inhibition of DA release in the D-STR. Moreover, L-DOPA attenuated DA reuptake kinetics in 
both regions by progressively and dose-dependently decreasing Vmax and also by increasing in 
Km with the high L-DOPA dose (250mg/kg). 
The relative impact of L-DOPA-induced release inhibition in clinically relevant doses of 
L-DOPA in the context of disease is a matter that requires further investigation, but a recent study 
demonstrated that even a modest 30mg/kg dose of L-DOPA resulted in a profound inhibition of 
DA response amplitudes using a sustained stimulated release paradigm in a transgenic mouse 
model of PD (Yavich et al. 2004). The mechanism underlying the inhibitory effects of L-DOPA 
on DA release that we demonstrated in this report are unknown, but the finding may be related to 
the physical changes in synaptic vesicles that occur after L-DOPA administration. Recent studies 
have demonstrated that L-DOPA increases the volume of synaptic vesicles, which is associated 
with alterations in vesicle fusion dynamics that are necessary for DA release (Sombers et al. 2004, 
Amatore et al. 2005). It is plausible that as synaptic vesicles accumulate DA and expand following 
L-DOPA administration, increased tensile forces oppose the full fusion of synaptic vesicles with 
the plasma membrane to inhibit DA release. Overfilled synaptic vesicles may underlie the 
observed gradual inhibition of DA release and dose-dependent changes in the effective size of the 
readily releasable pool following L-DOPA. In line with the concept that DA overfills synaptic 
vesicles to inhibit DA release, we found release inhibition was more pronounced in the D-STR, 
where we would predict greater intracellular [DA] following L-DOPA administration (Mosharov 
et al. 2009).  
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Over-filling of synaptic vesicles is one possible mechanism of L-DOPA-induced release 
inhibition, but it is conceivable that there are homeostatic mechanisms to down regulate DA release 
in response to L-DOPA administration. There are various neurochemical differences between the 
D-STR and NAc that may contribute to regional differences in DA release regulation by L-DOPA 
such as regional differences in Ca2+-coupling, cholinergic regulation, and autoregulation by D2-
like autoreceptors (Stamford et al. 1991, Wu et al. 2002, Brimblecombe et al. 2015, Zhang et al. 
2009, Maina & Mathews 2010). For instance, L-DOPA may augment extracellular DA levels to 
inhibit DA release through the activation of D2 DA autoreceptors.  Although, this form of 
homeostatic regulation of release seems to be important in physiological contexts (Benoit-Marand 
et al. 2001), our experience suggests that D2 agonists like quinpirole do not have strong release 
inhibitory effects in the context of supraphysiological stimulations used in these studies (data not 
shown). Paradoxically, we even found release to be enhanced by D2 autoreceptor activation as 
reported elsewhere (Kita et al. 2007).  Thus, if L-DOPA causes homeostatic changes to inhibit DA 
release, it likely involves other mediators besides D2 autoreceptors.  
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Figure 14: Conceptual schematic of presynaptic DA neurotransmission regulation by L-DOPA 
L-DOPA is converted to DA in DAergic neurons, which can be sequestered into synaptic vesicles to alter DA release. 
Additionally, intracellular DA may inhibit DA reuptake by a functional inhibition of DAT and by a down-regulation 
of DAT surface expression as well. 
 
In addition to the effects on DA release, we demonstrated that L-DOPA progressively 
attenuated DA reuptake kinetics (↓Vmax and ↑Km), with more marked effects in the D-STR 
compared to the NAc. Similarly, some studies demonstrated that repeated application of 
exogenous DA inhibited in vivo DA clearance more profoundly in the D-STR compared to the 
NAc (Gulley et al. 2002), and brief DA exposure inhibited 3[H]DA uptake to a greater extent in 
synaptosomes from the D-STR compared to the NAc (Richards & Zahniser 2009). The uptake 
inhibitory effect of DA may be partly caused by a down-regulation of DAT surface expression, 
which involves PKC activation (Gorentla & Vaughan 2005, Gulley et al. 2002). Notably, 
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exogenous DA application decreases DAT surface expression, even in xenopus oocytes that do not 
express DA receptors (Gulley et al. 2002), suggesting that intracellular DA may mediate DAT 
down-regulation directly as demonstrated for amphetamine (Kahlig et al. 2006).  These findings 
suggest that L-DOPA may elevate intracellular [DA], which could subsequently down-regulate 
DAT surface expression as illustrated in the conceptual figure 14.  
While in vitro studies using heterologous expression systems and striatal synaptosomes 
suggest DAT surface expression can be altered by pharmacological manipulation (Johnson et al. 
2005, Furman et al. 2009b, Saunders et al. 2000), some recent reports that suggest that DAT 
trafficking is not a prominent phenomenon observed with intact neuronal systems (Block et al. 
2015, German et al. 2012), and thus, functional changes in DAT may be a major contributor to L-
DOPA associated kinetic changes in DA clearance.  In contrast, other in vivo studies demonstrate 
that acute high doses of L-DOPA significantly decrease striatal DAT binding in rodents, 
suggesting that L-DOPA induces DAT internalization (Scheffel et al. 1996, Dresel et al. 1998). 
Moreover, these reports also demonstrated that acute administration of the DA synthesis inhibitor 
α-methyl-p-tyrosine decreases DAT binding as well, perhaps as a compensatory response to 
decreased extracellular DA levels. These latter studies suggest that in vivo DAT surface expression 
may be manipulable by certain DAergic agents, including L-DOPA, and contribute to the changes 
in Vmax noted in our study. 
Our data also suggests that DAT efficiency is impaired based on the Km increases in both 
regions following high-dose L-DOPA administration.  Functionally, DAT is regulated by multiple 
potential mechanisms including phosphorylation, post-translational modification, and protein-
protein interactions (Vaughan & Foster 2013, Garcia-Olivares et al. 2013, Lee et al. 2007, Gnegy 
2003), but how L-DOPA inhibits DAT function is also currently unknown. L-DOPA could activate 
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PKC similar to DA and amphetamine (Gorentla & Vaughan 2005, Gulley et al. 2002), a signaling 
mechanism that not only down-regulates DAT surface expression, but also inhibits DAT function 
(Foster et al. 2008). Alternatively, L-DOPA could increase intracellular [DA], causing a 
thermodynamic inhibition of DAT function (Harun et al. 2014, Metzger et al. 2002) (Figure 14). 
Intracellular DA could also form reactive oxygen species, which are known to inhibit DAT 
function (Fleckenstein et al. 1997, Berman et al. 1996). Clearly, future studies will be pivotal for 
identifying the specific molecular changes underlying the observed effects of L-DOPA on DA 
release and reuptake kinetics.  
The characterization of the effects of L-DOPA in this report utilized the use of 100mg/kg 
and 250mg/kg doses, which is similar to previous FSCV studies that examined the effects of L-
DOPA at 200-250mg/kg doses (Peters & Michael 2000, Wightman & Zimmerman 1990). 
Although these doses seem very high, doses of L-DOPA that were less than 100mg/kg have been 
shown to have insignificant effects on extracellular [DA] in naïve rats (Rodriguez et al. 2007b). 
Additional FSCV studies using 25 and 75mg/kg L-DOPA did not appreciable affect response 
amplitudes (data not shown). Moreover, our analysis suggested that even the 100mg/kg dose of L-
DOPA had very small effects on release (DARi) that did not reach significance compared to the 
carbidopa group in the D-STR. Although L-DOPA doses <100mg/kg have been reported to have 
therapeutic effects in Parkinson’s models, where L-DOPA is noted to have large effects on DA 
neurotransmission (Rodriguez et al. 2007b, Yavich et al. 2004), we needed to perform our analysis 
using doses ≥100mg/kg in the naïve rats in order to observe significant effects of L-DOPA on DA 
neurotransmission.  Thus, whether the observed results translate to the therapeutic actions of L-
DOPA remains to be determined.  
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Although we examined the acute effects of L-DOPA, these effects may relate to long-term 
changes in the DAergic system with chronic L-DOPA therapy. Several SPECT imaging studies 
reported that chronic L-DOPA treatment decreases striatal DAT binding in PD subjects (Guttman 
et al. 2001, Parkinson Study 2002, Whone et al. 2003), which we suggest could be due to the 
repeated acute effects of L-DOPA on DAT down-regulation that we suggest here. Though chronic 
DAT down-regulation can enhance presynaptic DA neurotransmission and contribute to improved 
function observed in PD patients on L-DOPA therapy (Fahn et al. 2004), DAT down-regulation is 
also associated with L-DOPA induced dyskinesias (Troiano et al. 2009). Aside from down-
regulating DAT, L-DOPA may additionally induce dyskinesia through ectopic DA release from 
serotonergic terminals in the striatum that lack DA autoreceptors to regulate DA release (Carta et 
al. 2007). The amount of ectopic DA release in the striatum after L-DOPA administration is 
expected to be limited compared to normal DA release through DAergic fibers in naïve animals 
because of the sparse serotonergic innervation of the striatum (Zhou et al. 2005); however, 
serotonergic fibers have been shown to hyper-innervate the striatum in the setting of PD and may 
significantly alter the pharmacodynamic response to L-DOPA (Gagnon et al. 2015, Gaspar et al. 
1993, Bedard et al. 2011) and contribute to the increased susceptibility to L-DOPA-induced 
dyskinesias following DAergic denervation of the striatum (Di Monte et al. 2000).  
In contrast to the chronic effects of L-DOPA on DAT regulation, very little is known about 
the chronic effects of L-DOPA on DA release, which can be elucidated in future FSCV studies. 
Moreover, both chronic and acute L-DOPA administration are known to affect DA neuronal firing 
patterns that should be considered in the context of the acute effects of L-DOPA on DA release 
and reuptake that we report here to understand the effects of L-DOPA on behavior (Harden & 
Grace 1995).  
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Using in vivo FSCV and the QN model, we demonstrated that L-DOPA has differential 
dose-dependent effects on DA release and reuptake in the D-STR vs. the NAc, which illustrates 
that the specific neurochemical environment greatly influences the effects of L-DOPA. Also, 
differences in neurochemistry may exist between individuals due to common variations in genes 
that regulate DA neurotransmission, as several reports suggest that polymorphisms in the DAT, 
DRD2, and brain-derived neurotrophic factor (BDNF) genes significantly influence the 
development of L-DOPA induced dyskinesias (Kaiser et al. 2003, Oliveri et al. 1999, Strong et al. 
2006, Wang et al. 2001, Zappia et al. 2005, Foltynie et al. 2009). Furthermore, adjuvant treatments 
with other DAergic agents like D2 agonists are common in PD subjects, and they produce long-
lasting changes in the DAergic system as well (Parkinson Study 2002, Marek et al. 2002, Ahlskog 
et al. 1999). Although L-DOPA is mostly utilized in the context of PD, it has beneficial effects in 
in other conditions like traumatic brain injury (Crownover 2012, Lal et al. 1988, Krimchansky et 
al. 2004, Haig & Ruess 1990), which has its own patterns of neurochemical alterations and genetic 
influences on DA neurotransmission (Wagner et al. 2014, Wagner et al. 2005b, Wagner et al. 
2009a, Wagner et al. 2009b, Bales et al. 2009, Massucci et al. 2004, Shin et al. 2011, Failla et al. 
In Press). The specific region, pathology, genetic influences, and drug interactions are all important 
contributors to understanding how even the same agent differentially affects DA 
neurotransmission between individuals and in different regions of the same individual. Although 
this report describes general attributes of the acute effects of L-DOPA on DA release and reuptake 
kinetics in naïve rats, future FSCV studies combined with the QN model interpretive framework 
can serve to clarify the relative impact of various factors on how they modulate baseline DA 
neurotransmission and subsequent drug-induced effects. 
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4.0  CONTROLLED-CORTICAL IMPACT PRODUCES REGIOSPECIFIC DYSFUNCTION 
OF STIMULATED DA NEUROTRANSMISSION IN THE DORSAL STRIATUM THAT CAN BE 
REVERSED WITH CHRONIC METHYLPHENIDATE TREATMMENT 
Rashed Harun, BS; Miranda J. Munoz; Kristin M. Hare; 
M. Elizabeth Brough, Amy K. Wagner, MD 
4.1 SUMMARY 
Dysfunction in the dopaminergic (DAergic) system is common following traumatic brain injury (TBI), which may underlie many aspects of cognitive and behavioral impairments following TBI. Although the DAergic system has widespread projections throughout the cortex and basal ganglia to modulate diverse functions throughout the brain, little is known about the regiosepcificity of DAergic dysfunction following brain injury. We used FSCV to examine the effects of CCI on electrically stimulated DA responses in the dorsal striatum (D-STR) and nucleus accumbens (NAc). By performing simultaneous recordings in both regions, a majority of naïve rats exhibited simultaneous responses in both regions, but only 1/9 rats exhibited non-responses in the DL-STR. In contrast, 7/8 CCI rats exhibited non-responses in the DL-STR on day 15 post-CCI, indicative of severe dysfunction with DA neurotransmission in the DL-STR after CCI. Post-CCI treatment with chronic daily MPH (5mg/kg) for 2wks exerted robust neurorestorative effects leading to the observation of stimulated DA responses in 6/7 animals with response amplitudes that tended to be 74.9±37.2% higher 
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than naïve controls. Using our recently developed quantitative neurobiological (QN) theoretical framework to discern and characterize release and reuptake components from stimulated DA responses, we demonstrated that CCI tends to impair the amount of stimulated DA released during 60Hz, 10s stimulations in the NAc, while chronic MPH tended to restore this impairment with DA release. In the D-STR, post-CCI chronic MPH treatment not only restored estimates of initial DA release rate and DA released during stimulation, but actually exceeded naïve estimates by 42.9±14.3% (p<0.05) and 45.0±13.8% (p<0.01), respectively. This work suggests that there are widespread striatal impairments of DA neurotransmission after CCI, while certain regions like the D-STR appear to be more susceptible to injury-induced deficits. Notably, this work may have important relevance to the associations between TBI and Parkinson’s disease, for which the D-STR is known to be particularly susceptible to degeneration. 
4.2 INTRODUCTION 
Traumatic brain injury (TBI) affects over 1.5 million individuals in the U.S. each year, with over 
5 million suffering from chronic disability related to TBI (Langlois et al. 2006).  TBI often 
produces cognitive and behavioral impairments that are among the most challenging symptoms to 
treat. However, indirect and direct dopamine (DA) agonists can be very effective for treating TBI-
induced cognitive impairments, which suggest the involvement of the DAergic system in TBI 
pathophysiology. Various clinical and preclinical studies have demonstrated that brain injury can 
cause chronic alterations in the DAergic system. We have previously demonstrated that there are 
chronic impairments in electrically stimulated DA neurotransmission in the dorsomedial striatum 
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using the controlled cortical impact (CCI) model of moderate TBI in rats (Wagner et al. 2005b, 
Wagner et al. 2009a, Wagner et al. 2009b), with deficits observed in DA release, clearance, and 
responsivity to an acute challenge of the DAT inhibitor/psychostimulant methylphenidate (MPH). 
Several laboratories have observed changes in tissue DA content and alterations of tyrosine 
hydroxylase expression, phosphorylation, and activity that vary by time, regional brain location, 
and injury model (McIntosh et al. 1994, Massucci et al. 2004, Kobori et al. 2006, Shin et al. 2011, 
Yan et al. 2007). In contrast, other markers of the DAergic system like striatal vesicular 
monoamine transporters (VMAT-2) remain relatively stable, suggesting that there is limited 
degeneration in brain injury (Wagner et al. 2009a). However, one of the most consistent findings 
has been the observed decrease in DA transporter (DAT) levels in both preclinical TBI models 
(Wagner et al. 2005a, Wagner et al. 2009a, Wilson et al. 2005, Yan et al. 2002) and in clinical 
cases of TBI (Wagner et al. 2014, Donnemiller et al. 2000). These decreases in DAT following 
brain injury may reflect a homeostatic down-regulation of DAT to compensate for the functional 
hypodopaminergic state caused by brain injury.  
Although brain injury often produces a hypodopaminergic state, little is known about how 
TBI differs from other conditions like Parkinson’s disease (PD), which is characterized by the loss 
of DAergic neurons in the substantia nigra pars compacta (SNpc) (Fearnley & Lees 1991, 
McRitchie et al. 1997) and the degeneration of corresponding terminals in the dorsal striatal (D-
STR) regions (Kish et al. 1988) with a relative sparing of ventral tegmental area DAergic neurons 
and ventral striatal regions like the nucleus accumbens (NAc). Some epidemiological studies 
support an association between prior head injury and PD (Bower et al. 2003, De Michele et al. 
1996, Seidler et al. 1996, Taylor et al. 1999), with one study in twins showing the relative risk of 
developing PD nearly quadruples with a prior history of head injury (Goldman et al. 2006). 
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Nevertheless, a few studies have not identified any significant association between head injury and 
PD development (Williams et al. 1991, McCann et al. 1998, Werneck & Alvarenga 1999), which 
makes this relationship still controversial even today (Wong & Hazrati 2013). Two recent 
preclinical studies have shown that mild and moderate fluid percussion injury (FPI) are both 
capable of producing progressive degeneration of DAergic neurons in the SNpc, which further 
suggests a link between TBI and the development of PD (Hutson et al. 2011, van Bregt et al. 
2012).  
It is important to identify potential therapies that may mitigate PD-like DA 
neurodegeneration following brain injury. Interestingly, several studies in preclinical PD models 
demonstrate dysfunctional DA neurotransmission precedes actual neuronal loss and terminal 
degeneration (Janezic et al. 2013, Lam et al. 2011), suggesting that restoring functional deficits 
serve as a potential avenue to halt the progression of neurodegeneration. We have previously 
shown that chronic daily MPH treatment MPH (5mg/kg) has robust neurorestorative effects 
following CCI, which enhances stimulated DA release, clearance, and restores the responsivity to 
an acute MPH challenge (Wagner et al. 2009a, Wagner et al. 2009b). In this study, we used fast-
scan cyclic voltammetry (FSCV) to demonstrate that CCI produces regional dysfunction with 
electrically stimulated DA neurotransmission the D-STR, with a relative sparing of the NAc, 
similar to the pattern of neurodegeneration in PD. Moreover, we demonstrate that chronic daily 
treatment with MPH (5mg/kg) for two weeks after CCI can restore stimulated DA 
neurotransmission in both regions. As stimulated DA responses reflect the complex interplay 
between DA release and reuptake processes that are dynamically changing over the course of a 
stimulated DA response, we recently developed a quantitative neurobiological (QN) framework, 
based on modern neurotransmission principles, to discern release from reuptake processes that 
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contribute to the overall stimulated DA response shapes observed (Harun et al. 2015). Using this 
methodology we demonstrate that the neurorestorative effects of MPH following CCI involves 
both enhancement of release and reuptake processes.  
This work not only has implications for supporting a link between brain injury and PD, but 
it also suggests that MPH therapy can not only diminish TBI related symptoms and deficits, but 
also, mitigate DA-related pathophysiology after brain injury. These findings have very strong 
translational potential for individuals with clinical TBI. Future studies are needed to examine if 
MPH therapy produces lasting neurorestorative effects, the most appropriate time window for 
introduction of MPH therapy, and the histological changes that maybe associated with the 
restorative DA transmission effects of chronic MPH therapy.  
4.3 METHODS 
Animals:  
Twenty-four (24) young-adult male Sprague Dawley rats (Hilltop Laboratories, Scottsdale, 
PA, USA) weighing between 325-350g were used for this study in accordance to the University 
of Pittsburgh’s Institutional Animal Care and Use Committee.  Rats were housed in a 12 h light-
dark cycle, with food and water provided ad libitum for at least 1 week prior any surgical 
procedures. Animals were separated into one of three groups, naïve animals that received .1M 
phosphate buffered saline (PBS) (1ml/kg) chronically for 14 days (Naïve+PBS) (n=9), or CCI 
animals that received PBS (n=7) or MPH (5mg/kg) (n=8) daily starting the day after CCI 
(CCI+PBS and CCI+MPH, respectively).  
Controlled cortical impact (CCI) injury 
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The CCI injury device (Pittsburgh Precision Instruments, Inc., Pittsburgh, PA, USA) used 
for this study has been described previously (Dixon et al. 1991). Under isoflurane anesthesia (4% 
isoflurane and a 2:1 N2/O2 initially, followed by 1–1.5% isoflurane), animals were placed in a 
stereotaxic frame. Core body temperature was maintained at 37°C during surgery using a 
homeothermic blanket (Harvard Apparatus, Edenbridge, UK). A midline scalp incision was made 
and the soft tissues reflected to perform a craniotomy over the right parietal cortex between lambda 
and bregma and approximately 2 mm lateral to the central suture. The exposed dura was struck to 
a depth of 2.8 mm with an impact velocity of 4 m/s by the CCI device as previously described 
(Wagner et al. 2005a,b, 2007a,b, 2009). The scalp was sutured, 2% lidocaine jelly was applied to 
the incision, and post-injury righting reflexes were monitored after completion of surgical 
procedures.  Animals were returned to their home cages after recovery with ad libitum access to 
food and water.  
Fast-scan cyclic voltammetry (FSCV): 
Naïve or CCI animals 15d post-injury (i.e. the day after the last PBS/MPH administration) 
were anesthetized with urethane (1.3g/kg, i.p.), and mounted onto a stereotactic frame. Core body 
temperatures were maintained at 37°C with a homeothermic blanket. For stereotaxic placement of 
electrodes in the brain, a midline incision was made, soft-tissues reflected, and burr holes were 
drilled into the right parietal and frontal bones, after which dura was removed. Carbon fiber 
microelectrodes (7µm in diameter and 250µm long) were fabricated as previously described 
(Wagner et al. 2005b, Harun et al. 2014). Prior to use, electrodes were electrochemically pretreated 
by applying a 70Hz biphasic potential waveform to the electrodes for 2s from 0 to 2 to 0 V vs. an 
Ag/AgCl reference electrode to enhance electrode sensitivity. Two recording microelectrodes were 
simultaneously inserted using flat skull coordinates (in mm) into the D-STR [anterioposterior (AP) 
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+1.7, mediolateral (ML): 1.4, and dorsoventral (DV): -3.4] and into the NAc [AP: 1.0, ML: 2.1, 
and DV:-6.6] (Paxinos & Watson 2007). A reference electrode was placed in contact with proximal 
soft muscle tissue to create a salt bridge. A bipolar stimulating electrode (MS301-1, Plastics One, 
Roanoke, VA) was inserted over the median forebrain bundle (MFB) [AP: -4.0, ML: 1.6, DV: -
7.2].  
Biphasic 60Hz, 5s or 10s (280µA amplitude and 2ms pulse width) electrical stimulations 
were used to evoke DA overflow in the right striatum. Regional DA responses were detected using 
carbon fiber microelectrodes to which a triphasic cyclic voltage waveform (0→1→-0.5→0V) was 
applied a rate of 300V/s every 100ms using the TarHeel CV software (ESA, Chelmsford, MA). 
The stimulating electrode was lowered 200μm every 5 min until a clear DA signal was observed, 
and then lowered 100μm every 10 min, until the signal amplitudes of the two electrodes peaked. 
For analysis purposes, experimental DA responses were then collected using 60Hz, 10s 
stimulations. Subsequently, a 40Hz, 10s and 60Hz, 5s stimulation was additionally collected to aid 
in performing simulations of the 60Hz, 10s DA responses. Responses were converted from 
currents to DA concentrations ([DA]) following electrode explantation and in vitro microelectrode 
calibration using seven standard DA concentration solutions in artificial cerebrospinal fluid 
(pH=7.2) composed of (in mM): 1.2 CaCl2, 2.0 Na2HPO4, 1.0 MgCl2, 2.7 KCl, 145 NaCl.  
Interpretation of DA responses 
DA response analysis 
DA response analysis was performed using two methods, by simply examining DA 
responses amplitudes, determining the frequency of measurable DA responses in the two 
simultaneously monitored regions, and by simulating stimulated DA responses to discriminate DA 
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release from reuptake components according to our recently developed QN framework (Harun et 
al. 2015).  
Quantitative neurobiological model 
To estimate how CCI and CCI + chronic MPH therapy affects regional DA release and 
reuptake kinetics, 60Hz, 10s DA responses were modeled using the QN model (Harun et al. 2014). 
Traditionally, stimulated DA responses can be interpreted using the Michaelis-Menten (M-M) 
model (Wightman & Zimmerman 1990), which assumes a constant DA release rate, and DA 
reuptake rate through DAT that is modeled using M-M enzyme kinetics defined by constant Vmax 
and Km terms. The QN model is a refinement of the M-M model that accounts for stimulation 
effects on DA responses by including equations to describe stimulation-induced attenuated DA 
release, attenuated DA reuptake efficiency (increasing Km), and incorporation of a biphasic post-
stimulation DA release component.  
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Table 8: Equations and parameters used for simulations 
 
 The equations and terms that the QN model utilizes to describe the release and reuptake 
components of stimulated DA responses are reproduced in table 8. Briefly, DA release rate 
during stimulation (DARstim) is described by equation 1 as an exponential decay function with a 
time constant of ∆DARτ and a steady-state release rate (DARss). This parameterization of 
stimulated DA release rate is adopted from studies characterizing how stimulation trains 
exponentially decrease the rate of neurotransmitter release (i.e. pulse-train depression (PTD)) 
(Pyott & Rosenmund 2002). The PTD of neurotransmitter release is associated with stimulation 
frequency and ambient temperature. When these factors are held constant, they can reflect the 
effective size of the readily-releasable pool (RRP) of vesicles, with faster stimulation induced 
decay of release associated with a smaller size of the RRP (Pyott & Rosenmund 2002, Dobrunz 
& Stevens 1997). Post-stimulation DA release rate (DARpost) is described in equation 2 as 
release rate that decreases bi-phasically after stimulation ends, with rapid exponential and 
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prolonged linear decay components. The biphasic nature of post-stimulation DA release has been 
described previously (Atluri & Regehr 1998) and is likely related to the biphasic kinetics of 
intracellular Ca2+ clearance after stimulation (Fierro et al. 1998), which mediates 
neurotransmitter release through different Ca2+-sensitive proteins (Groffen et al. 2010, Yao et al. 
2011).  Lastly, reuptake kinetics was modeled similar to the M-M model, except Km here is 
defined as a dynamic term that increases during stimulation according to the logistic function in 
equation 3. We incorporated the concept of stimulation-induced increases in Km to account for 
how stimulation frequency and duration attenuate the apparent reuptake kinetics that others and 
we have observed (Wang et al. 2011, Harun et al. 2014). How stimulation attenuates reuptake 
efficiency is not clearly understood, but it could be due to stimulation-induced depletion of 
energy stored in Na+-gradients that are necessary for DA reuptake through DAT. The effects of 
stimulation on energy depletion may be particularly relevant to the stimulation-induced 
attenuation of reuptake efficiency concept because DAergic neurons are in a delicate energy 
balance state owing to their dense axonal arborizations and lack of myelination (Pissadaki & 
Bolam 2013). 
The equations in table 8 were combined into equation 4, which was used to model 
experimental DA responses in Matlab R2014a (The MathWorks, Inc, Natick, MA). Because 
multiple sets of parameterizations are able to simulate the same experimental DA response well, 
we performed simulations systematically across studies to minimize artifacts of simulation 
methods by constraining initial Km (Kmi) between 0.1-0.4µM, which is similar to the Km assumed 
in other voltammetry studies and to Km parameters extracted from in vitro studies (Wu et al. 2001, 
Povlock et al. 1996). Moreover, we included a prior 60Hz, 10s stimulation and 60Hz, 2s 
stimulations into the experimental protocol for internal validation that for the accuracy of the fit 
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of simulations to the 5s DA responses. Since our initial inception of the QN model, we have since 
updated the framework to assume the rapid post-stimulation has a time constant (τR) that increases 
with increasing stimulation duration, which may occur due to greater calcium accumulation by 
increased stimulation-duration to prolong post-stimulation DA release. Although these adaptations 
provide larger estimates of release and reuptake metrics than previously reported (Harun et al. 
2015), in our experience, they have enhanced the fit of simulations to experimental data. Moreover, 
these adaptations furthers our goal of developing systematic rational means of constraining 
parameters to enhance the accuracy of the simulations to model underlying release and reuptake 
processes.  
[𝐷𝐷𝐷𝐷](𝑑𝑑) = ��𝐷𝐷𝐷𝐷𝐷𝐷𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚(𝑑𝑑) + 𝐷𝐷𝐷𝐷𝐷𝐷𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠�𝑑𝑑𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠� � 𝑑𝑑𝑑𝑑 − � 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝐾𝐾𝑚𝑚(𝑑𝑑)[𝐷𝐷𝐷𝐷] + 1𝑑𝑑𝑑𝑑 
Equation 4 
The simulations provide estimates of DA release and reuptake rates over the time course 
of single DA responses that are consistent with the assumptions of the model. We examined two 
metrics that are particularly relevant to characterizing the effect of CCI and MPH therapy on DA 
neurotransmission- 1) the initial DA release rate (DARi), which may be related to the physiological 
effects of CCI and MPH therapy on DA release and readily releaseable pool size, and 2) Vmax, 
which is often related to the local density of DAT and also their efficiency for DA reuptake. 
Moreover, we examined the total simulated amount of DA released during the 10s of stimulation 
(DAreleased), which may relate to amount of DA available for stimulated release in the experimental 
contexts.  
Statistical analysis 
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All response metrics (e.g. amplitudes, Vmax, and others) were analyzed statistically in 
similar ways using SPSS 2.0 for Mac (SPSS Inc., Chicago, IL). One-way ANOVAs were used to 
probe for differences in between groups, significant effects were followed up with post-hoc 
independent samples Student’s T-Test. P-values ≤0.05 were considered to be significant in all 
comparisons.  
4.4 RESULTS 
In this study, we electrically stimulated the MFB-containing ascending DAergic projections to 
monitor in vivo striatal DA responses simultaneously in the D-STR and the NAc to characterize 
CCI effects and chronic daily MPH treatment after CCI on regional stimulated DA 
neurotransmission. We used naïve rats that underwent a 2-week chronic treatment regimen with 
PBS (1mg/kg/day) (n=9), and CCI rats that underwent PBS (n=7) or chronic MPH treatment 
(5mg/kg/day) (n=8).  
4.4.1 CCI increases the frequency of non-responses in the D-STR, while post-CCI chronic 
MPH therapy restores responses in the D-STR 
Stimulated DA responses are subject to great deal of variability that may largely be due to the 
imprecision between animals with stimulating a consistent population of ascending DAergic 
projections traversing through the MFB. Albeit an infrequent occurrence in our hands, this 
imprecision may have also led to the observation of non-responses in one region while detection 
of simultaneous responses in the other region, even among naïve rats (Fig 15C/F).  Nevertheless, 
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replication of experiments circumvents some of the inherent variability in the methodology to 
allow for group-based comparisons.  
 In the NAc, DA responses were detected in all rats in all three experimental groups, with 
the exception of one Naïve+PBS rat (Fig 15C). Although the mean DA responses are different 
between the Naïve+PBS, CCI+PBS, and CCI+MPH groups, there was a large degree of variability 
as evidenced by the overlapping standard error bars between mean group DA responses (Fig 15A). 
Thus, there were no significant differences between groups in terms of response amplitudes in the 
NAc (Fig 15B). 
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Figure 15: Regional stimulated DA responses and the frequency of their observation 
A/D) Mean±SEM of 60Hz,10s stimulated DA responses of each group are represented in (A) for the NAc and (D) for 
the D-STR. The amplitudes did not significantly differ by group in the NAc (B), but tended to be higher in the 
CCI+MPH group vs. Naïve+PBS group in the D-STR (E). Responses were generally simultaneously observed in the 
NAc (C) and D-STR (F) of most rats except in the CCI+PBS group, where only 1/8 rats exhibited a DA response. 
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In contrast to the NAc, we found that were profound impairments with stimulated DA 
neurotransmission in the D-STR in CCI+PBS rats compared to the Naive+PBS rats, such that we 
only observed a response in only 1/8 CCI+PBS rats, compared to the 8/9 responses in the 
Naïve+PBS group (Fig 15E). Moreover, the 1 D-STR response in the CCI+PBS group was smaller 
in amplitude than any responses observed in the Naïve+PBS group (Fig15D/E). Because only 1 
small response was observed in the D-STR of CCI+PBS animals, it precluded the ability to 
accurately simulate the DA response or perform statistical comparisons between the D-STR of the 
CCI-PBS group with the other groups.  
 Consistent with our previous observations (Wagner et al. 2009a, Wagner et al. 2009b), 
chronic MPH therapy following CCI had robust neurorestorative effects. Not only did chronic 
MPH treatment increase the frequency of D-STR DA responses in the CCI+MPH group to 6/7 
compared to 1/8 in the CCI+PBS group, but also, response amplitudes tended to be 74.9±37.2% 
higher than the Naïve+PBS group (p=0.067) (Fig 15E). 
4.4.2 Post-CCI chronic daily MPH treatment restores stimulated DA neurotransmission 
by enhancing DA release and reuptake 
As stimulated DA responses represent a balance between DA release and reuptake processes, we 
used the QN framework to generate estimates of release and reuptake components that contribute 
to the shape of 60Hz, 10s stimulated DA responses as detailed in the methods.  
Our simulations suggested there were no significant differences between groups in terms 
of estimated initial DA release rate (DARi), maximal clearance rate (Vmax), or DA released during 
the 10s (DAreleased) (Fig 16A-C). Although the DARi and Vmax were somewhat decreased in the 
CCI+PBS group compared to the Naïve+PBS group, these observations were not statistically 
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significant (p>0.1). DAreleased tended to be 32.6±18.2% lower in the CCI+PBS group compared to 
the Naïve+PBS  (p=0.096). Moreover, the DAreleased in the CCI+MPH group tended to be 
73.4±34.2% higher compared to the CCI+PBS group (p=0.052) (Fig 16C). These findings suggest 
that there may be modest impairments in DA neurotransmission in the NAc after CCI, and chronic 
MPH treatments appear to have restorative effects in this region.  
 
Figure 16: Simulation metrics of release and reuptake derived from experimental DA responses 
Simulation metrics of release and reuptake derived from experimental 60Hz,10s stimulated DA responses. In the NAc 
(A-C), no significant differences were observed in DARi (A), Vmax (B), or DAreleased (C) between groups. However, 
DAreleased tended to be lower in the CCI+PBS group compared to both the Naïve+PBS and CCI+MPH groups. In 
the D-STR (D-F), we could not quantify the changes in the CCI+PBS group. However, DARi (D) and DAreleased (F) 
was higher in the CCI+MPH group compared to the Naïve PBS group (p<0.05 and p<0.01, respectively). Vmax also 
tended to be higher in the CCI+MPH group (p=0.0503). *p<0.05 and **p<0.01 for denoted comparisons 
In the D-STR, although we could not quantify changes occurring in the CCI+PBS group 
due to the lack of responses in this region, we found notable differences between the Naïve+PBS 
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and CCI+MPH groups. DARi was significantly higher in the CCI+MPH vs. Naïve+PBS rats 
(39.3±3.7 vs. 27.5±2.1µM/s, respectively, p<0.05) (Fig 16D). Likewise DAreleased was also greater 
in the CCI+MPH rats compared to Naïve+PBS rats (325.5 ± 29.1 vs. 224.5 ± 16.1 µ M, 
respectively, p<0.01) (Fig 16F). Moreover, we found a tendency for Vmax to be higher the 
CCI+MPH group compared to Naïve+PBS group (49.1 ± 4.6 vs. 38.0 ± 2.8, respectively, 
p=0.0503) (Fig 16E). These findings suggest that not only does the chronic MPH (5mg/kg/day) 
treatment restore DA neurotransmission, but it may also enhance DA neurotransmission beyond 
what is observed in naïve animals.  
4.5 DISCUSSION 
In this report, we demonstrated that CCI produces regional DAergic dysfunction that is similar in 
pattern to the region-specific degeneration that occurs in PD. This pattern of neurodegeneration 
adds to the body of literature that supports the possible link between brain injury and subsequent 
development of PD (Bower et al. 2003, De Michele et al. 1996, Goldman et al. 2006, Hutson et al. 
2011, Seidler et al. 1996, Taylor et al. 1999, van Bregt et al. 2012). Although, we have previously 
demonstrated DA neurotransmission deficits in our CCI model (Wagner et al. 2005a, Wagner et 
al. 2009a, Wagner et al. 2009b), this report extends previous work by demonstrating that there is 
a regiospecifity to the pattern of DAergic dysfunction with severe dysfunction in the D-STR and 
relative sparing of the NAc. As DA affects various functions like working memory, attention, 
motivation, and movement that are dependent upon specific brain regions that DA is acting on, 
regional characterization of DAergic dysfunction is important for understanding the etiology of 
the neuropsychiatric sequelae associated with TBI. The severe impairments of DA 
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neurotransmission in the D-STR may contribute to the persistent cognitive deficits, which can 
extend years after TBI (van Zomeren & van den Burg 1985, Oddy et al. 1985). 
This report features several methodological advancements we have made in characterizing 
DAergic deficits in experimental brain injury, including the simultaneous use of two electrodes for 
concurrently sampling in multiple regions. Since there is inherent experimental variability in 
stereotaxically placing the stimulating electrode into the MFB to stimulate ascending DAergic 
projections, the use of two electrodes is particularly advantageous in serving as a method to 
ascertain that the MFB is being stimulated when responses are observed in one region and not the 
other. Previously, non-responses in the dorsal striatal regions could be dismissed as being due to 
inaccurate placement of the stimulating electrode rather than the nature of DAergic dysfunction in 
our CCI model. This methodology demonstrates that non-responses in the D-STR are much more 
frequent following moderate CCI. This same methodology may be used in future FSCV studies to 
examine striatal dopamine function with different experimental injury models, and it can even be 
implemented for characterizing DAergic dysfunction in animal models of PD, including with 
recent attempts to model susceptibility to PD post-TBI (refs)(Sauerbeck et al. 2012, Hutson et al. 
2011, Zou H. 2010). Similar to the effects of MPH in CCI, this could be used to identify potential 
neurorestorative agents in PD.  
Using our recently developed QN framework (Harun et al. 2015), we have demonstrated 
that MPH treatment not only restores the frequency of response observations in the D-STR 
following CCI, but it even enhances stimulated DA release in the CCI+MPH group greater than in 
the Naïve+PBS group. Moreover, Vmax tended to be higher in the CCI+MPH group as well 
(p=0.0503). Although the traditional Michaelis-Menten model of stimulated DA 
neurotransmission has been applied widely in the FSCV field to interpret stimulated DA responses 
 98 
(May & Wightman 1989, Wightman & Zimmerman 1990), the simplicity of the model’s 
assumptions precludes its application to the study of D-STR DA responses, which significantly 
differ in response shape from the NAc (Fig 15A/D). In contrast, the QN framework incorporates 
contemporary principles of stimulated DA neurotransmission that can be used to model 
heterogeneous stimulated DA response shapes observed throughout the striatum, including the D-
STR, in order to provide estimates of DA release and reuptake rates and parameters to describe 
the heterogeneous release and reuptake processes that occur in in different striatal regions. As the 
we demonstrate here that the D-STR is particularly vulnerable to damage after brain injury and 
with PD (Kish et al. 1988), we demonstrate that the QN framework represents significant 
advancement that allows for quantitative evaluation and comparative assessment of stimulated DA 
neurotransmission in context of these pathological conditions.  
Similar to this report, we have previously demonstrated that CCI impairs striatal DA 
neurotransmission and that post-CCI chronic daily MPH treatment can have robust 
neurorestorative effects on DA neurotransmission (Wagner et al. 2009a, Wagner et al. 2009b). 
However, we did not know about the regiospecific nature of the DAergic dysfunction or the 
generalizability of the restorative effects of MPH, which this report elucidates on. The mechanisms 
underlying the effects of MPH are still unknown, but may related to its effects on altering synaptic 
vesicle distribution and properties as demonstrated previously (Sandoval et al. 2002, Volz et al. 
2008). MPH may exert its effects by altering the expression of various genes (Adriani et al. 2006). 
The simple effect of pharmacologically enhancing DA neurotransmission may itself entrain 
DAergic neurons to restore its function. In this way, the restorative effects of MPH may also extend 
to other indirect and direct DA agonists that should be explored. Along these lines, clinical reports 
have demonstrated functional restorative effects of various DAergic agents following head injury 
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such as amphetamine (Hornstein et al. 1996), amantadine (Zafonte et al. 1998, Meythaler et al. 
2002, Whyte et al. 2005, Wu & Garmel 2005, Giacino et al. 2012), bromocriptine (Passler & Riggs 
2001, Powell et al. 1996), and L-DOPA ((Haig & Ruess 1990, van Woerkom et al. 1982). 
Moreover, some DAergic agents have not only been shown to improve cognitive and behavioral 
function (Kline et al. 2004), but also restore DAergic dysfunction (Tan et al. 2015, Huang et al. 
2014), and even enhance neuronal survival (Kline et al. 2004, Wang et al. 2014) in experimental 
TBI models.  
Although we have demonstrated that MPH treatments can have neurorestorative effects on 
stimulated DA neurotransmission following CCI, we do not know if there is a particular 
therapeutic window for MPH to exert its restorative effects or whether these effects are long 
lasting. Previous groups have demonstrated that experimental brain injury can produce progressive 
degeneration of DAergic neurons (Hutson et al. 2011, van Bregt et al. 2012), suggesting that early 
intervention maybe more promising than late intervention. However, it is unclear whether chronic 
MPH therapy has an impact on DA neuronal loss, or whether the effects of chronic MPH are purely 
functional. Although this work highlights a potential neurorestorative therapy following brain 
injury that has a strong translational potential, further investigation is required to clarify the 
mechanism underlying this effect. 
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5.0  SEX AND OVARIAN HORMONES INFLUENCE STRIATAL DOPAMINERGIC 
FUNCTION FOLLOWING EXPERIMENTAL BRAIN INJURY 
Rashed Harun, BS; Kristin M. Hare;  
M. Elizabeth Brough; Amy K. Wagner, MD 
5.1 SUMMARY 
Traumatic brain injury (TBI) often produces cognitive and behavioral deficits that partly relate to 
post-traumatic dysfunction in dopaminergic (DAergic) systems that maybe secondary to the 
development of post-traumatic hypogonadism. Fast-scan cyclic voltammetry was used to 
characterize how sex and ovariectomy (OVX) affects DA neurotransmission in our controlled-
cortical impact (CCI) model of moderate TBI in Sprague Dawley rats. We found that baseline 
striatal DA responses to 60Hz, 2s electrical stimulations were similar in amplitude between naïve 
male and female rats, but were increased in naïve OVX, CCI males, and CCI females (p<0.05 for 
all comparisons).  These changes paralleled the decreased estimates of maximal clearance rate 
(Vmax), and decreased responsivity to an acute challenge of the DA transporter (DAT) inhibitor, 
methylphenidate (MPH) (10mg/kg, i.p.). We noted sex-based differences in the pharmacology of 
MPH, where the male groups had the closest association between Vmax and MPH responsivity 
and the shortest onset and duration of DA reuptake inhibitory effects of MPH. This work suggests 
that both CCI and OVX may down-regulate DAT function, which maybe a compensatory response 
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to impaired DA neurotransmission. This work supports that hypothesis that decreased circulating 
ovarian hormones could contribute to the development of post-traumatic DAergic dysfunction. 
5.2 INTRODUCTION 
Traumatic brain injury (TBI) is a leading cause of death and disability in the US (Langlois et al. 
2006). Although TBI afflicts each individual differently depending on the location, severity, and 
type of injury, various factors like age, sex, and genetic make-up affect TBI prognosis (Farace & 
Alves 2000a, Failla et al. 2013, Chiang et al. 2003, Hukkelhoven et al. 2003, Davis & Cunningham 
1984, Ono et al. 2001), some of which are sex specific (Wagner et al. 2007, Myrga (In Revision)). 
Understanding how various clinical factors affect TBI pathology can enhance individualized 
treatment strategies.  
Many studies report sex-based differences in functional outcomes after TBI, with some 
investigations demonstrating that women fare worse than men (Kraus et al. 2000, Kirkness et al. 
2004, Edna & Cappelen 1987, Farace & Alves 2000b), and this relationship varies by age (Davis 
et al. 2006). In a large study of 1425 subjects with mild TBI, women were more likely than men 
to have post-concussive symptoms three months after injury. Notably, this effect was observed 
primarily during childbearing ages (Bazarian et al. 2010). Similarly, female high school/college 
athletes were over 1.7 times more likely than men to be cognitively impaired following concussion 
(Broshek et al. 2005).  These findings suggest that female sex hormones may affect outcomes and 
cognition after TBI. Indeed, hypogonadism occurs in up to 80% of patients after significant TBI, 
which is long-lasting in many (Behan et al. 2008, Wagner et al. 2012, Barton (in revision)). 
Moreover, cortisol associated luteinizing hormone suppression (Ranganathan (in review)) also 
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amenorrhea (Ranganathan (in review)) commonly occurs following TBI, with longer durations of 
amenorrhea related to worse global outcomes, health-related quality of life, and community 
participation measures (Ripley et al. 2008). These lines of evidence suggest that the sudden decline 
of female sex hormones, like estradiol, after TBI may exacerbate the neuropsychiatric sequelae 
experienced after injury. How a sudden reduction in female sex hormones relates to specific post-
TBI impairments is unknown, but one intriguing hypothesis is that the drop in estradiol exacerbates 
dopaminergic dysfunction to a greater extent in women than men.  
The DAergic system underlies functions like attention, motivation, working memory, and 
information processing speed, which are commonly impaired following TBI (van Zomeren & van 
den Burg 1985, Oddy et al. 1985) and improved by pharmacological enhancement of DA 
neurotransmission (Powell et al. 1996, McDowell et al. 1998, Patrick et al. 2003, Speech et al. 
1993, Plenger et al. 1996, Moein et al. 2006, Gualtieri & Evans 1988). Moreover, both preclinical 
and clinical studies have demonstrated DAergic system dysfunction after TBI (Kobori et al. 2006, 
Massucci et al. 2004, Shin et al. 2011, Wagner et al. 2009a), including a consistent down-
regulation of the DA transporter (DAT) that likely reflects a compensatory response to impaired 
DA neurotransmission (Donnemiller et al. 2000, Wagner et al. 2005a, Wagner et al. 2009a, 
Wagner et al. 2014).  
There are sex-based differences in the DAergic system, notably in DAT and D2 receptor 
levels and affinity (Pohjalainen et al. 1998, Rivest et al. 1995) that may contribute to the varied 
sensitivity to dopaminergic agents between men and women. Sex hormones, of which estradiol 
has been the most studied, has a prominent role in mediating sexually dimorphic characteristics of 
the DAergic system. Estradiol has complex dose, time, target-dependent effects on pre- and post-
synaptic DA neurotransmission through rapid non-genomic and delayed genomic mechanisms, 
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that have led to various, and sometimes contradictory, conclusions about its effects on DA 
neurotransmission (Thompson & Moss 1994, Watson et al. 2006, Disshon et al. 1998, Maus et al. 
1989, Levesque & Di Paolo 1993, Mermelstein et al. 1996).  
Most studies support the assertion that physiological estradiol concentrations acutely 
enhances DA neurotransmission as evidenced by estradiol mediating greater DA turnover (Di 
Paolo et al. 1985), enhanced amphetamine-stimulated DA overflow (Becker 1990a), and DA 
reuptake inhibition (Disshon et al. 1998). Many of the estrogen effects on DA neurotransmission 
may be mediated by estrogen uncoupling the interaction between Gαi/o proteins and D2 DA 
autoreceptors (Kelly & Wagner 1999, Thompson & Certain 2005) that modulate inhibition of DA 
release and enhancement of DA reuptake (Wu et al. 2002, Benoit-Marand et al. 2011, Gubernator 
et al. 2009). As estradiol has a general pro-DAergic effect, a sudden decline in CNS estradiol 
levels following TBI-induced hypogonadism may impair DA neurotransmission to a greater extent 
in women than men. Consistent with this working hypothesis, striatal DA concentrations were 
found to be lower only in gonadectomized female rats but not males compared to their sex-based 
controls (Xiao & Becker 1994). Moreover, as estradiol mediates sex-based differences in the 
pharmacology of indirect and direct DA agonists (Becker 1990a, Becker 1990b, Becker 1999, 
Gordon 1980, Hruska et al. 1982), understanding the role of estradiol in TBI-induced DAergic 
dysfunction is critical to tailoring treatments based on age, sex, and hormonal status.  
Using the CCI model, we previously evaluated several DAergic markers and their 
relationship to presynaptic neurotransmission. Total striatal vesicular monoamine transporter type 
2 (VMAT2) and tyrosine hydroxylase protein content is not altered 2 weeks after CCI (Wagner et 
al. 2009a).  The DA transporter (DAT) is the primary structure in modulating DA transmission, 
and DAT trafficking and function are closely regulated by D2 auto-receptors. Our research 
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suggests total striatal DAT concentration is reduced post-CCI in the setting of increased membrane 
bound synaptosomal DAT (Wagner et al. 2009a). Using fast scan cyclic voltammetry (FSCV), we 
have shown that there are relative decreases with maximal evoked DA overflow 2 weeks following 
CCI proportional to striatal DAT reductions (Wagner et al. 2009a, Wagner et al. 2005b).  Also, 
daily methylphenidate (MPH) administration restored maximal evoked DA overflow (Wagner et 
al. 2009a)confirming a diminished capacity for maximal striatal outflow after CCI and stimulant 
induced plasticity evident with presynaptic DA neurotransmission after CCI. We have also shown 
reductions in striatal outflow augmentation occur with MPH challenge in our CCI model (Wagner 
et al. 2005b, Wagner et al. 2009b).  Together, these data suggest that elements of both DA release 
and reuptake are impaired by CCI. 
In this study, we examined sex and hormonal influences on electrically stimulated DA 
neurotransmission using FSCV in the context of CCI. Stimulated DA neurotransmission was 
evaluated in male, female, and ovariectomized (OVX) rats 2wks following injury and in 
corresponding naïve controls. Moreover, because we previously demonstrated that CCI alters the 
pharmacological response to the clinically relevant psychostimulant/DAT inhibitor MPH, we 
monitored how MPH alters stimulated DA responses over a 60-minute time course in all rats. 
Baseline and post-MPH DA response amplitudes and alterations in response decay behavior were 
evaluated. In addition, we implemented a modified version of the quantitative neurobiological 
(QN) model (Harun et al. 2014) to simulate baseline DA responses in order to estimate baseline 
DA release rates and maximal reuptake rates (Vmax), which we then correlated to the responsivity 
to the MPH challenge. 
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5.3 METHODS 
Animals and Surgery 
Young adult male (279–410g), female (245–323g), and ovariectomized (OVX 295–368g) 
Sprague-Dawley rats (Hilltop Laboratories, Scottsdale, PA, USA) were used in accordance with 
the regulations of the University of Pittsburgh’s Institutional Animal Care and Use Committee. 
Rats received controlled cortical impact injury (CCI) (male n=7, female n=5, OVX=5) or were 
naive (male n=7, female n=6, OVX=6) to surgery for a total of 36 animals. Rats were housed in a 
12 h light-dark cycle, with food and water provided ad libitum.  Ovariectomized rats received this 
procedure with the vendor approximately 3 weeks prior to CCI procedures. 
Controlled cortical impact (CCI) injury 
The CCI injury device (Pittsburgh Precision Instruments, Inc., Pittsburgh, PA, USA) used 
for this study has been described previously (Dixon et al. 1991). Under isoflurane anesthesia (4% 
isoflurane and a 2:1 N2/O2 initially, followed by 1–1.5% isoflurane), animals were placed in a 
stereotaxic frame. Core body temperature was maintained at 37°C during surgery using a 
homeothermic blanket (Harvard Apparatus, Edenbridge, UK). A midline scalp incision was made 
and the soft tissues reflected to perform a craniotomy over the right parietal cortex between lambda 
and bregma and approximately 2 mm lateral to the central suture. The exposed dura was struck to 
a depth of 2.8 mm with an impact velocity of 4 m/s by the CCI device as previously described 
(Wagner et al. 2005a,b, 2007a,b, 2009). The scalp was sutured, 2% lidocaine jelly was applied to 
the incision, and post-injury righting reflexes were monitored after completion of surgical 
procedures.  Animals were returned to their home cages after recovery with ad libitum access to 
food and water.  
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Fast scan cyclic voltammetry (FSCV) 
To fabricate working electrodes, 7µm diameter carbon fibers (T-300; Union Carbide, 
Danbury, CT, USA) were threaded through borosilicate glass capillaries (0.6mm o.d. and 0.4mm 
i.d. [Sutton Instruments, Novato, CA, USA]).  The glass capillary was pulled to a tip with a 
micropipette puller (Narshige, East Meadow, NY, USA), and the tip was epoxy-sealed (Spurr 
Polysciences, Warrington, PA, USA).  Electrodes were cured for at least 12 h at 70°C. The glass 
capillary was filled with mercury, and a nichrome wire was inserted to make an electrical 
connection. Exposed carbon fibers were cut to ~400µm lengths as previously described (Wagner 
et al. 2005a). Carbon fiber microelectrodes were sonicated in isopropanol/active carbon powder 
solution for 30 minutes to enhance electrode sensitivity before voltammetric experiments. 
Electrodes were post-calibrated after experiments with standard [DA] solutions (0.5µM--5µM in 
artificial cerebrospinal fluid (aCSF) buffer solution) to convert in vivo current recordings to DA 
concentrations. 
Fast scan cyclic voltammetry (FSCV) studies were performed 14 days after CCI. At this 
time, rats were re-anesthetized with 5% isoflurane and O2 initially, followed by 2.5% isoflurane 
and O2 for maintenance of anesthesia.  Once a surgical level of anesthesia was established, the 
animals were placed in a stereotaxic frame (Kopf, Tujunga, CA, USA). The skull was exposed and 
the soft tissues reflected. Portions of skull were removed using a drill to expose dura to allow for 
placement of the working, reference, and stimulating electrodes. Core body temperature was 
maintained at 37°C during surgery using a homeothermic blanket (Harvard Apparatus, 
Edenbridge, UK) 
Carbon fiber microelectrodes were lowered in the right striatal hemisphere, (ipsilateral to 
the injury site in CCI animals) using flat-skull coordinates [1.7mm AP, 2.0mm ML, and -4.5mm 
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DV] (Paxinos and Watson 1998). A bipolar stimulating electrode (MS301-1, Plastics One, 
Roanoke, VA, USA) was lowered onto the right medial forebrain bundle (MFB) at the stereotaxic 
coordinates of -4.0mm AP, 1.6mm ML, and -7.6mm DV (Paxinos and Watson 1998). A salt bridge 
was formed by placing an Ag/AgCl reference electrode in direct contact with the dura mater in the 
left hemisphere. 
DA detection using FSCV has been previously described (Wagner et al. 2005a, 2009). 
Briefly, FSCV was performed with a computer-controlled potentiostat (EI-400; Ensman 
Instruments, Bloomington, IN, U.S.A.) using TarHeel CV 1.0. A triphasic cyclic voltage 
waveform was applied to carbon fiber electrodes (0V1V-0.5V0V vs. the Ag/AgCl 
reference electrode at 400V/s). Scans were repeated every 100ms during in vivo recordings. The 
presence of DA was determined by visual inspection of background-subtracted cyclic 
voltammograms. The maximum concentration of evoked (EO) DA overflow was taken as the 
maximum change in DA signal following medial forebrain bundle stimulation.  
The MFB was stimulated at 60Hz for 2s (280 µA biphasic current pulse, 2ms pulse width) 
every 10min. The location of stimulating electrode, and also the carbon fiber microelectrode, was 
optimized to achieve a maximized and stable baseline DA response, where at least 3 consecutive 
responses had amplitudes within 10% of each other. Subsequently, 10 mg/kg MPH was 
administered intraperitoneally, and stimulated DA responses were collected every 10 minutes for 
60 minutes after drug administration. Baseline and post-MPH stimulated DA responses from each 
ratl were used for kinetic analysis.  
Data analysis: 
Basic DA response shape analysis 
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DA response shapes were analyzed using two morphometric methods: decay behavior and 
response amplitudes. Response amplitude is simply the peak [DA] of a stimulated DA response. 
Decay behavior was examined similar to previous studies (Moquin & Michael 2009, Jones et al. 
1995b), where responses were time-shifted to match similar [DA] in the decay phase to directly 
evaluate differences in decay behavior (see Figure 18H). The decay behavior was quantified by 
fitting an exponential regression to the 2s following the time point where responses were aligned. 
This approach yielded a decay constant (k) that corresponded to the decay behavior, with larger k-
values corresponding to faster decay kinetics.  
Table 9: Equations and parameters used to simulate DA responses 
 
Modeling stimulated DAergic responses  
 Baseline stimulated DA responses from each animal were modeled using a variation of 
the quantitative neurobiological (QN) framework that we recently developed (Harun et al. 2014). 
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The QN framework was used to simulate experimental DA responses to make theoretical estimates 
of DA release and reuptake components using equations to describe stimulation-induced 
attenuation of DA release, stimulation-induced attenuation of DA reuptake efficiency, and also a 
biphasic post-stimulation DA release component. Although estimates of DA release and reuptake 
can be generated from single DA responses, multiple durations of stimulation enhances the 
accuracy of simulations. Because our experimental DA responses only contained DA responses to 
2s of electrical stimulation, we modified some QN equations and assumptions of the QN model as 
summarized in Table 9. 2s stimulated DA responses cannot accurately be used to model the 
dynamics of DA release during stimulation. Thus, we simplified our assumption to include a 
constant DA release rate (Equation 1), similar to the traditional Michaelis-Menten (M-M) model 
(May & Wightman 1989). Although the constant release assumption is a simplification of 
underlying DA release processes, DA response shapes are predominantly affected by changes in 
reuptake efficiency in the dorsal striatum and not DA release; we previously demonstrated that the 
majority of the DA released by 2s of stimulation in the caudate-putamen is sequestered by reuptake 
during the 2s of electrical stimulation (Harun et al. 2014). Post-stimulation DA release was 
modeled according to the equations of the QN framework (Equation 2), except we held the time 
constant for the rapid phase of post-stimulation DA release (τR) at 0.4s-1. This assumption allowed 
us to attribute differences in the DA response decay phases to differences in reuptake dynamics 
rather than differences in post-stimulation DA release kinetics. Stimulation-induced attenuation of 
reuptake efficiency was modeled as described for the QN framework (Equation 3), where the M-
M constant, Km, is a dynamic term that increases during stimulation according to the logistic 
function in equation 4. Previous application of the QN framework demonstrated that Km is rapidly 
changing at 2s when using 60Hz stimulations, usually starting at Kmi≈0.05. To model Km 
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dynamics during the 2s of stimulation, ∆Km was held constant at 20µM, and the inflection point 
(Kminf) and the steepness of the inflection defined by the Hill coefficient, kHill, were modified to 
simulate baseline DA responses from each study. The equations in Table 9 were combined into 
equation 5, which was used to model experimental DA responses in Matlab R2014a (The 
MathWorks, Inc, Natick, MA).  
[𝐷𝐷𝐷𝐷](𝑑𝑑) = ��𝐷𝐷𝐷𝐷𝐷𝐷𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚 + 𝐷𝐷𝐷𝐷𝐷𝐷𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠�𝑑𝑑𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠� � 𝑑𝑑𝑑𝑑 − � 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝐾𝐾𝑚𝑚(𝑑𝑑)[𝐷𝐷𝐷𝐷] + 1𝑑𝑑𝑑𝑑 
Equation 5 
Because MPH alters stimulated DA release dynamics and reuptake dynamics, the 
simplified QN framework was not amenable for simulating post-MPH responses adequately in our 
dataset. Nevertheless, the modified QN framework still provided estimates of baseline DA release 
rate and Vmax. Although our modified QN framework is more complex than the traditional M-M 
model, it provides a good fit of stimulated DA responses collected from the dorsomedial striatum 
that often exhibited a concave rising phase, which is not possible using the traditional M-M model 
that can only model DA responses with convex rising phases due to its simplified assumptions of 
DA release and reuptake (May & Wightman 1989).  
Statistical analysis 
All response metrics (e.g. amplitudes, k values, Vmax, and others) were analyzed statistically using 
SPSS 2.0 for Mac (SPSS Inc., Chicago, IL). Baseline differences in metrics between groups were 
evaluated using one-way repeated measure analysis of variance (ANOVA) or an independent 
samples Student’s T-Test. Time dependent changes in MPH-induced effects between experimental 
groups were evaluated using two-way repeated measures (rm)ANOVA. Follow-up independent 
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samples descriptive comparisons were performed using Fisher’s least significant difference. P-
values ≤0.05 were considered to be significant in all comparisons. 
5.4 RESULTS 
In light of the evidence demonstrating sex-based differences in the DAergic system and the 
potential effects of female ovarian hormones in regulating DA neurotransmission, we investigated 
how sex and ovariectomy influences stimulated DA neurotransmission in the context of CCI using 
FSCV. Moreover, because of sex-based differences in the pharmacological response to 
psychostimulants, we also examined how sex, hormone status, and CCI affect stimulated DA 
responses following a pharmacological challenge to MPH (10mg/kg i.p.) over a 60min time 
course. 
5.4.1 DA response shape analysis reveals sex- and injury-based differences in baseline DA 
response amplitudes and the temporal effects of MPH 
60Hz, 2s electrical stimulations of the MFB were used to elicit DA responses in the right 
hemisphere (ipsilateral to the CCI) dorsomedial striatum as described earlier. The mean ± SEM of 
baseline, post-MPH 10min, and post-60min stimulated DA responses are depicted in Figure17A-
G to demonstrate descriptive group differences in pre- and post-MPH stimulated DA responses.  
Baseline response amplitudes were significantly different between groups (ANOVA: 
p<0.05) (Figure 17G). Although we found no difference in response amplitudes between naïve 
male and female rats (p=0.286), naïve OVX rats had significantly higher baseline amplitudes 
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compared to naïve female counterparts (p<0.05) and naïve males (p<0.005). Both CCI males and 
females had significantly higher baseline amplitudes compared to naïve males and females, 
respectively (p<0.005 for both comparisons). In contrast, CCI OVX rats had similar baseline 
response amplitudes compared to the naïve OVX group, suggesting a possible ceiling effect where 
CCI does not enhance response amplitudes beyond the effects of ovariectomy itself. Since 
response amplitudes reflect a balance between DA release and reuptake, the increased response 
amplitudes in OVX animals and in male and female CCI animals, relative to male and female 
naïve rats, may be due to enhanced release and/or reduced reuptake (examined later).  
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Figure 17: Stimulated DA response shape characteristics 
A-F) Mean ± SEM baseline, post-MPH 10min, and post-MPH 60min DA responses to 60Hz, 2s electrical stimulations 
demonstrate differential response characteristics across experimental groups pre- and post-MPH (10mg/kg) 
administration. G) Baseline amplitudes were significantly different between groups (ANOVA: p<0.005), where the 
amplitudes of the naïve OVX group was greater than naïve females (p<0.05). Additionally, CCI males and females 
had greater amplitudes than naïve counterparts (p<0.05 for both comparisons). H) MPH administration augmented 
DA response amplitudes differentially over time between groups (two-way repeated measures ANOVA: p<0.001), 
where CCI male and female groups exhibited attenuated post-MPH 10min responses compared to naïve male and 
female groups (p<0.005, and p<0.05, respectively). I) DA responses from individual studies were aligned to similar 
[DA] to examine relative changes in DA response decay behavior. An exponential regression was performed on the 
2s following the point where responses were aligned to generate an exponential decay constant (k). H) k-values were 
decreased following MPH administration in all groups, but k was differentially altered over time between groups (two-
way rmANOVA: p<0.005). The naïve male group tended to restore k faster than naïve females (two-way rmANOVA: 
p=0.054) and naïve OVX groups (two-way rmANOVA: p<0.05). Similarly, the CCI male group restored k values 
faster compared to CCI female and CCI OVX groups (2-way rmANOVA: p<0.005 for both comparisons). 
 
In response to MPH administration, DA response amplitudes were augmented relative to 
baseline at the post-MPH 10 time point in all groups (Figure 17H), consistent with MPH effects 
on reuptake inhibition reuptake and enhanced release (Harun et al. 2014, Volz et al. 2008). 
Response amplitudes subsequently decreased over the 60min assessment window in all groups. 
However, MPH had differential effects on response amplitudes between groups (p<0.005) and 
between groups across time (p<0.005). Although MPH responsivity at post-MPH 10min was 
similar between naïve groups, the naïve OVX animals had the lowest responsivity to MPH 
(197.27±28%) compared to naïve males and females (282.40±26%, 249.65±26%, respectively). 
CCI male and female rats exhibited an attenuated response to MPH in terms of amplitude 
enhancement compared to respective naïve groups (10min post-MPH amplitude relative to 
baseline for naive male: 282.40±26% vs. CCI male: 178.50±16%, p<0.05; naive female: 
249.65±26% vs. CCI female: 169.35 ±18%, p<0.05). This finding is similar to our previous study 
demonstrating male CCI rats exhibited an attenuated amplitude enhancement to an MPH (5mg/kg) 
challenge compared to naïve male rats (Wagner et al. 2009b). Interestingly, the CCI OVX rats did 
not exhibit a significantly attenuated response to MPH compared to naïve OVX rats (171.50±19% 
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vs. 197.27±28%, p=0.479, respectively). We speculate that the modest effects of CCI on the OVX 
animals in terms of attenuating MPH-responsivity can be explained by a floor effect, where CCI 
cannot robustly diminish the response to MPH more than the effect of ovariectomy itself. This 
speculation suggests that hypogonadism maybe contributing to the deficits in MPH responsivity 
observed after CCI. 
We next examined how MPH alters DA response decay behavior, which is sensitive to 
changes in DAT mediated DA reuptake. Decay behavior was examined by aligning all stimulated 
DA response from each study to similar DA concentrations and comparing the decay phase of pre- 
and post-MPH responses as illustrated in Figure 17I. Decay behavior was quantified by a mono-
exponential decay constant, k, where decreases in k correspond to prolonged DA clearance that 
can result from DA reuptake inhibition. MPH significantly attenuated k at all time points in all 
groups except at post-MPH 10min in the CCI OVX group. Notably, we found a significant 
group*time interaction for how MPH affected k values (p<0.005). Post-hoc comparisons 
demonstrated that naïve males tended to have a differential time course of MPH effects on decay 
behavior compared to naïve females (p=0.054) and naïve OVX (p<0.05) rats (Figure 17H). 
Similarly, CCI male rats had a differential time course of MPH effects on decay behavior compared 
to CCI females and CCI OVX rats (p<0.01 both comparisons) (Figure 17H). The effects of MPH 
on response decay behavior had a faster onset in male rats, with a maximal inhibition of k-values 
at 10min post-MPH in male groups, as opposed to 20-30min in the non-male groups. Moreover, 
male groups exhibited a shorter duration of MPH effects whereby k-values tended normalize more 
quickly in naïve and CCI male groups. In contrast, we noted that CCI female rats had the most 
persistent inhibition of decay with k=59.3±2.4% of baseline k-values at 60min post-MPH 
administration, which was significantly lower than male naïve and CCI groups (80.75±6.4% and 
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80.1 ±3.0%, respectively, p<0.005 for both comparisons). Taken together, the time course effects 
of MPH on DA response decay behavior suggests that MPH has more rapid onset and a shorter 
time course of effects on DA reuptake in males compared to females and OVX groups, an effect 
which persists even among CCI animals, and which may provide some insight into sex differences 
with MPH behavioral effects after CCI (Wagner et al., 2007). 
5.4.2 Data modeling demonstrates reduced Vmax in CCI and OVX animals 
DA response amplitude and decay behavior are simple methods to examine effects of 
pharmacological manipulation, but both of these quantitative parameters reflect a balance of DA 
release and DA reuptake dynamics that can only be estimated from modeling DA responses with 
a theoretical model of stimulated DA neurotransmission. As described in the methods, we applied 
a modified version of our QN model (Harun et al. 2014) to evaluate DA release and reuptake 
dynamics from baseline DA responses from each animal. We implemented the simplified 
assumption that DA release rate was constant, reuptake efficiency could be modeled by dynamic 
M-M enzyme kinetics, where the M-M constant, Km, increases over the course of stimulation, and 
post-stimulation DA release decays with a the time constant τR=0.4s-1 in all groups. Using these 
assumptions, baseline DA responses were well simulated, with a mean R2=0.983±0.005 for all 
simulations performed. Estimated baseline DA release rates were highly variable, and no 
significant differences between groups were observed (Figure 18A). The lack of significant 
differences in DA release rate may, in part, be due electrode sampling bias necessary to optimize 
electrode placement to obtain feasible 60Hz, 2s stimulated DA responses for monitoring pre- and 
post-MPH effects. In contrast, we found significant differences in Vmax between groups (p<0.05), 
where naïve OVX rats had lower Vmax values compared to naïve female rats (p<0.005), consistent 
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with a decreased DAT expression following ovariectomy reported by others (Bosse et al. 1997, 
Chavez et al. 2010). Moreover, CCI female rats tended to have lower Vmax values compared to 
naïve females (p=0.0528), and CCI males had lower Vmax values compared to naïve males 
(p<0.05). This finding is consistent with our previous characterization of stimulated DA 
neurotransmission in male rats (Wagner et al. 2009a) and the differential effects of sex on CCI-
induced DAT down-regulation (Wagner et al. 2005a). In contrast, Vmax was not significantly 
different between CCI OVX and naïve OVX groups. 
 
Figure 18: Estimates of DA release rate and Vmax from modeling baseline experimental DA responses 
A) DA release rates were highly variable and no significant differences were found between groups. B) Estimated 
Vmax differed between groups (one-way ANOVA: p<0.05), where naïve OVX animals had lower Vmax compared to 
naïve females. Vmax was lower in CCI male animals compared to naïve males (p<0.05), and tended to be lower in CCI 
females compared to naïve counterparts (p=0.058). 
5.4.3 MPH responsivity is partly explained by baseline Vmax and sex-differences 
Because Vmax is an estimate of the functional capacity of DAT, and MPH primarily acts by 
competitively inhibiting DAT, we postulated that the MPH-induced DA responses amplitude 
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augmentation would be directly related to Vmax. To test this hypothesis, we examined the 
relationship between the relative enhancements of stimulated DA response amplitudes by MPH 
10min post-injection vs. baseline Vmax values from each individual study (Figure 19).  Overall, 
there was a significant association between MPH-induced response amplitude augmentation and 
Vmax (p<0.005) (Figure 19A), with a particularly marked association in the male naïve and CCI 
groups (R2=0.559, p<0.005) (Figure 19B). Although there was a modest association among female 
groups (R2=0.153, p=0.054) (Figure 19C), this association was even less apparent in the OVX 
groups (R2=0.127, p=0.156) (Figure 19D). The association between MPH responsivity and Vmax 
that we demonstrate here suggests that decreases in DAT density in male and female rats after CCI 
may, in part, underlie the reduced responsivity to MPH that we demonstrate here and previously 
(Wagner et al. 2009b).  
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Figure 19: Sex-based associations between MPH-induced response enhancement at 10min post-MPH 
(10mg/kg) and baseline Vmax 
A) A plot of post-MPH (10min) amplitude enhancement vs. baseline Vmax values demonstrates an overall positive 
relationship when examining individual studies in all groups (R2=0.192, p<0.005). B) The amplitude enhancement vs. 
baseline Vmax correlation was strongest in the male groups (R2=0.559, p<0.005). In contrast, the female (C) and OVX 
(D) groups had non-significant positive relationships between post-MPH (10min) amplitude enhancement and Vmax 
(p=0.054 and p=0.127, respectively). 
 
The positive correlation between MPH responsivity and Vmax is consistent with the 
expected relationship between baseline Vmax and MPH responsivity. However, the smaller 
associations between Vmax and MPH responsivity among female and OVX groups suggests sex 
and hormone-dependent variation in DAT functional states may mediate differential MPH 
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pharmacodynamics. Contributors to variation could perhaps be due to estrous cycle variation 
(Czoty et al. 2009, Morissette & Di Paolo 1993) or non-DAT dependent mechanisms of MPH 
action (Volz et al. 2008, Sandoval et al. 2002). 
5.5 DISCUSSION 
In this study, we explored how sex and hormone status affects DA neurotransmission in the context 
of experimental brain injury. Unlike previous electrochemical DA monitoring studies (Walker et 
al. 2000, Walker et al. 2006), we did not find significant sex-based differences in baseline DA 
response amplitudes, Vmax, nor did we see a differential effect of a DAT inhibitor on DA response 
amplitude augmentation. Although this was somewhat surprising, there is a large degree of 
variability in DAT function over the rat estrous cycle that may contribute to non-significant sex-
based differences (Morissette & Di Paolo 1993, Thompson & Moss 1997). We found that male 
and female CCI animals had similar alterations in DA neurotransmission compared to their naïve 
counterparts, such that male/female CCI animals had increased response amplitude, decreased 
Vmax, and decreased the responsivity to an acute MPH challenge, consistent with our previous 
reports (Wagner et al. 2009a, Wagner et al. 2009b). While our current study does not fully support 
a “double hit hypothesis” for further increasing DA transmission deficits for OVX rats and females 
after TBI relative to males, the findings do suggest novel alterations in DA transmission with 
hormone status that are similar in nature to those observed with CCI.  In addition, DA clearance 
patterns, and their relationship to DAT concentration with MPH challenge, appear to be both sex 
and hormone specific. 
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In this report, male/female CCI animals had increased DA response amplitudes to 60Hz,2s 
stimulation compared to naïve counterparts, which contrasts from a previous study demonstrating 
attenuated response amplitudes to maximal 60Hz, 10s stimulations in male CCI animals (Wagner 
et al. 2009a). This discrepancy may be explained by the use of a submaximal stimulation paradigm 
used in this report, while utilizing a maximal stimulation paradigm previously. It is likely that if 
we prolonged the stimulation duration, male/female CCI animals would have exhibited attenuated 
response amplitudes compared to their naïve counterparts, as both release and reuptake dynamics 
vary over time. Moreover, the optimization of the working electrode placement in this report to 
obtain robust 60Hz, 2s responses to compare pre- and post-MPH pharmacodynamics may have 
introduced a bias towards sampling more intact responses from injured animals in this report. Our 
previous study using unbiased stereotaxic methods demonstrated profound deficits in stimulated 
DA neurotransmission in the dorsomedial striatum that implicated deficits in DA release and 
reuptake (Wagner et al. 2009a). 
As response amplitudes reflect a balance between DA release and reuptake, and we saw no 
significant changes in DA release between groups (Figure 18A), the decreases in Vmax in 
male/female CCI animals may, in part, explain the increased amplitudes in male/female CCI 
animals. The decreases in Vmax following CCI may reflect a compensatory down-regulation of 
DAT to a functional hypodopaminergic state after brain injury, similar to the findings of down-
regulated DAT expression following a prolonged DA synthesis inhibition with α-methyl-p-
tyrosine (Han et al. 1999). Interestingly, injury-induced down-regulation of DAT is a consistent 
finding in the clinical and preclinical TBI literature (Donnemiller et al. 2000, Wagner et al. 2009a, 
Wagner et al. 2005a, Wagner et al. 2014). Although we did not observe significant sex-based 
differences in injury-induced effects on baseline DA neurotransmission in this report, it is possible 
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that differences may be observed in a mild injury paradigm where it may be possible to model the 
clinically observed sex-based differences in functional outcome after mild TBI (Bazarian et al. 
2010, Broshek et al. 2005). 
We observed significant differences in baseline DA responses in ovariectomized rats 
compared to naïve female rats, such that OVX rats had increased response amplitudes and 
decreased Vmax, similar to the effects of CCI itself. Although, the naïve OVX group had an 
attenuated response to MPH compared to the naïve female group, this effect was not significant 
(10min. post-MPH amplitude as a % of baseline: 249.6±26% vs. 197.3±28%, respectively, 
p=0.204) (Figure 17H). Others have demonstrated that ovariectomy decreases striatal DAT 
expression in rats (Bosse et al. 1997, Chavez et al. 2010), which is consistent with the reduction in 
Vmax that we demonstrate in this study. The decreases in Vmax may be due to a compensatory 
response to impaired DA neurotransmission following ovariectomy. Interestingly, Vmax was not 
further down-regulated in the CCI OVX group compared to the naïve OVX group, as we observed 
in male/female groups. This finding suggests that ovariectomy either produces a floor effect, where 
CCI cannot further down-regulate DAT function or that CCI precipitates hypogonadism that partly 
mediates decreases in DAT function after CCI according to our working model. The link between 
hypogonadism and DA dysfunction after brain injury requires further study. Because ovariectomy 
was performed by our vendor approximately 3 weeks prior to CCI, our injured OVX animals did 
not precisely model post-traumatic hypogonadism. Nevertheless, it is interesting to note that 
ovariectomy mimics some of the effects of CCI on stimulated DA neurotransmission, which may 
underlie the clinical finding that post-injury functional outcomes are exacerbated in females of 
childbearing ages that would be expected to be particularly affected by the effects of post-traumatic 
hypogonadism (Bazarian et al. 2010, Broshek et al. 2005).  
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Clinically, post-traumatic hypogonadism occurs in both males and females (Behan et al. 
2008, Barton (in revision), Wagner et al. 2012, Ranganathan (in review)), but little is known about 
how a lack of testosterone itself affects DA neurotransmission in males. Although androgen 
receptors exist on midbrain DAergic neurons (Purves-Tyson et al. 2012), castration of male rats 
has no apparent effect on nigral mRNA levels for DAergic markers like tyrosine hydroxylase, 
DAT, vesicular monoamine transporter, and various DA receptors (Purves-Tyson et al. 2012, 
Purves-Tyson et al. 2014), nor does castration affect striatal DA levels like the decreases in DA 
levels observed after ovariectomy (Xiao & Becker 1994). Thus, although both sexes frequently 
exhibit post-traumatic hypogonadism, females are more likely to have DAergic impairments 
resulting from it.  
Clinical and experimental data show efficacy with DA enhancing agents in reducing 
cognitive dysfunction after CCI (Bales et al. 2009).  Our experimental work evaluating sex 
differences with daily MPH treatment suggests that females are more sensitive than males to 
stimulant treatment (Wagner et al. 2007). The findings in our current study are consistent with this 
behavioral study and suggest sex-specific pharmacodynamics and mechanisms of action where 
DAT inhibition is longer lasting in female rats compared to male rats.  Although, this post-hoc 
contrast should be validated and further understood in order to further inform if/how treatment 
with stimulants like MPH might be tailored based on sex. 
Clinically, DA dysfunction post-injury, and its effects on cognition, clinically can be 
mediated by genetic variants that influence DA levels.  In addition, studies indicate a sex-based 
dimorphism, or a difference in outcomes or phenotype related to biological differences between 
the sexes, within the DA system (Munro et al. 2006, Becker 1999). Recent clinical work suggests 
that interactions with DA genetics and sex could affect cognitive performance (Gurvich & Rossell 
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2015, Jacobs & D'Esposito 2011, Glatt et al. 2006, Harrison & Tunbridge 2008, Soeiro-De-Souza 
et al. 2013). Our own clinical work demonstrates significant interactions between sex and DA 
genotype in moderating DA neurotransmission effects on cognition after severe TBI (Myrga (In 
Revision)), findings that may be due to post-injury hypogonadotropic hypogonadism and 
sensitivity of DA systems to sex hormone dysfunction as well as injury specific effects.  
While this animal study did not fully illustrate a double hit hypothesis for DA transmission, 
our investigation suggests that hypogonadism may produce similar alterations in stimulated DA 
neurotransmission as CCI such as increased response amplitude and decreased Vmax as we 
observed among ovariectomized rats. These findings are consistent with the idea that post-
traumatic hypogonadism can contribute to post-traumatic DAergic alterations. However, a detailed 
investigation of how CCI influences female gonadal hormone and gonadotropin levels and how 
hormone replacement strategies affects DAergic alterations would be important next steps to test 
this causal relationship. In addition, these data show distinct DA stimulant response patterns that 
are sex specific.  These animal data, taken together with our findings of sex-specific DA gene 
effects on cognition after TBI, support further study into the mechanisms underlying possible sex-
specific differences in DA neurotransmission and neurostimulant response after TBI.  In particular, 
future work should focus on the timing of ovariectomy in relationship to TBI.  Also, future work 
could further characterize mechanisms underlying possible enhanced vulnerability to cognitive 
and behavioral dysfunction for women after TBI. 
With our recent advancements in FSCV interpretative framework and methodology (Harun et al. 
2014), future studies using multiple stimulation durations and unbiased carbon fiber electrode 
placement would be expected to enhance our ability to extract multiple parameters relating to DA 
release and reuptake dynamics that we might expect to show significant group-based differences 
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in DA release that we failed to observe in this report. Although we demonstrated that CCI and 
OVX induce decreases in Vmax that imply DAergic impairments in these contexts, Vmax is an 
indirect measure of impaired DA neurotransmission that could be corroborated with future in vivo 
microdialysis measurements of basal DA levels and electrophysiology to monitor DA neuron 
firing activity.   
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6.0  DISCUSSION 
As the (neuro)science fiction author William Gibson said, “the future is here, it’s just not evenly 
distributed yet.” Our work on developing the QN model does not reflect so much on 
groundbreaking observations on the kinetics of neurotransmission that have been made, but rather, 
it reflects a synthesis of wide-ranging principles of neurotransmission that is supported by the 
research of others in various neuroscience sub-fields. Although the QN model incorporates 
concepts gleaned from electrochemical investigations of DA neurotransmission (Wang et al. 2011, 
May & Wightman 1989), it is largely supplemented by neurotransmission research on GABAergic, 
glutamatergic, and cholinergic neurotransmission using electrophysiology, false-fluorescent 
neurotransmitters, calcium imaging, and various molecular and genetic techniques (Atluri & 
Regehr 1998, Fierro et al. 1998, Goda & Stevens 1994, Liley & North 1953, Pan & Ryan 2012, 
Pyott & Rosenmund 2002). These principles have largely guided the development of the QN model 
that defines the expected patterns of release and reuptake during the course a stimulated DA 
response. As we ourselves have experienced, without this theoretical framework, it is quite 
challenging to estimate effectively how DA release and reuptake are balanced to produce a 
stimulated DA response.  
Although the MFB-stimulated DA response paradigm has been around since the mid-
1980s, there is still intense current interest in understanding how to properly interpret MFB 
stimulated DA responses. Recent studies have demonstrated again that stimulated DA responses 
do not follow simple M-M model kinetics (Moquin & Michael 2009, Taylor et al. 2012, Wang et 
al. 2011, Taylor et al. 2013). To explain observed DA response patterns, a recent model was even 
published this year shortly after the publication of our QN model (Taylor et al. 2015). The 
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assumptions of the QN model are grounded and supported by what is known about contemporary 
principles of neurotransmission as discussed in chapter 2. Briefly, we introduce the concept that 
stimulated DA release rate monotonically decreases over the course of stimulation to the FSCV 
field, which is similar to the concept of pulse train depression that electrophysiologists have known 
and studied for years (Pyott & Rosenmund 2002, Hagler & Goda 2001). This contrasts from the 
constant or region-dependent increasing/decreasing DA release patterns suggested by the other 
available quantitative models of stimulated DA neurotransmission (Taylor et al. 2015, May & 
Wightman 1989). We also introduced the concept of post-stimulation DA release that is supported 
by research on in various neurotransmitter systems (Goda & Stevens 1994, Medrihan et al. 2013, 
Barrett & Stevens 1972, Dodge et al. 1969, Neves & Lagnado 1999), and attenuation of reuptake 
efficiency during stimulation that has been vetted through our own investigations and supported 
by the observations made by others in the voltammetry field (Harun et al. 2015, Wang et al. 2011). 
The QN model has been tested using various stimulation frequencies, stimulation durations, 
examining DA responses in different regions, and in the context of various pharmacological 
manipulations. All of this testing has led to findings that might be expected in these various 
contexts from what is known about the effects of stimulation on neurotransmitter release patterns, 
the known neurochemical differences between regions, and the known pharmacology of the agents 
we tested.  
6.1.1 Limitations of the QN model and the stimulated DA neurotransmission paradigm 
The QN model has been vetted through various experimental manipulations, which has 
demonstrated that it can be a very powerful tool to study DA neurotransmission. However, the 
model is only slightly less than a year old. Already, we have five publications that have either been 
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accepted, submitted, or in progress using the QN model. However, what our experimental work 
has suggested thus far is that the model is still a work in progress, with more experimentation 
leading to modest adaptions of the model, resulting in improved consistency with our approach to 
simulating FSCV data.  
The application of the QN model to interpret FSCV data of stimulated DA 
neurotransmission is admittedly complex, but reflects the fact that DA response signals are a 
complex interplay of DA release and reuptake. As we developed the QN model, we took the 
principle that a good model should be as simple as possible, but just simple enough to generally 
capture the complexity of release and reuptake processes that we hypothesize underlie stimulated 
DA responses. Nevertheless, systematically applying the equations of the QN model to simulate 
DA responses is a process that can involve a long learning curve when done without appropriate 
bearings in mathematics and computer programing in Matlab, and this, in and of itself is likely a 
barrier for those interested in utilizing these methods. To address this issue, we are actively 
working on freely disseminating software and publishing an instructional video that may make 
using these techniques more practical and accessible for interested parties through a software 
program we have developed.  
Although the QN model has advanced our quantitative analysis of MFB-stimulated DA 
neurotransmission data, like all quantitative models, it is limited by the conditions in which the 
assumptions are valid. For instance, one of the assumptions of the model is that DA clearance is 
mediated by DAT. This assumption is supported by work in DAT knockout mice that demonstrates 
DAT is by and large, the predominant mechanism of DA clearance in the striatum (Budygin et al. 
2002); however, clearance by diffusion and neighboring norepinephrine transporters are likely 
more prominent factors in other regions like the amygdala or prefrontal cortex (Garris & 
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Wightman 1994b, Jones et al. 1995a, Garris & Wightman 1994a). Although the current version of 
the QN model does not incorporate other clearance components that may be more relevant in extra-
striatal regions, the modular nature of the QN model is such that other quantifiable assumptions 
can be incorporated and modified as necessary for other regions or as more is learned about the 
processes underlying stimulated DA neurotransmission. 
6.1.2 QN model to characterize DAergic pharmacology 
The benefits of a quantitative framework that suitably disentangles release from reuptake 
components to study DAergic pharmacology cannot be emphasized fully. FSCV generates data of 
in vivo DA concentration fluctuations at sub-second resolution that contains within it rich 
information about the kinetics of DA release and reuptake, but this information is largely lost 
without a biologically applicable framework. For example, in chapter 3, it was possible to 
demonstrate the effects of L-DOPA on response amplitudes and the decay phase of DA responses 
without the use of the QN model. This finding highly suggested that L-DOPA produces changes 
in DA release and reuptake kinetics. However, QN model introduced additional quantitative 
analysis that demonstrated L-DOPA decreased Vmax, increased Km, enhanced initial DA release 
rate, but also showed how DA release rate decays over the course of stimulation. Moreover, the 
QN model allowed us to quantify to what extent all of these parameters changed over time, 
between different regions, and by different doses. As such, this body of work demonstrates that 
this QN model can perform flexibility, and with a high degree of accuracy, to characterize how 
pharmacological agents affect the kinetics of DA neurotransmission; thus, our work has perhaps 
the greatest implications for those interested in DA pharmacology. 
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6.1.3 QN model to characterize regiospecific DAergic dysfunction in disease-states 
The use of FSCV to study in vivo stimulated neurotransmission is a very remarkable technique. It 
allows us to monitor neurotransmission with the temporal and spatial resolution that cannot be 
achieved with any other method. Moreover, this technique is best for detecting DA, which has 
implications for many functions, diseases, and drugs. Although the M-M model had been 
developed over 25 years ago to interpret FSCV data of stimulated DA neurotransmission, it was 
known that DA response patterns can be very heterogeneous and not all DA responses appear to 
follow the M-M model. This has been the focus of FSCV research early on (May & Wightman 
1989), but there has also been a resurgence of this topic lately (Wang et al. 2011, Taylor et al. 
2013, Moquin & Michael 2009). Groups have differed in their hypotheses and suppositions about 
the underlying reasons for the DA response heterogeneity, citing cytoarchitectural differences 
between regions that may produce diffusional mass-transport barriers for DA (May & Wightman 
1989), differences in the size of synaptic vesicle pools (Wang et al. 2011), or nuance 
conceptualizations similar to the original assertion that there are regional differences in DA 
diffusion (Taylor et al. 2013, Taylor et al. 2015). As I saw the value in the type of information that 
FSCV research could provide us with for so many research questions, understanding and properly 
explaining the underlying neurobiological processes of stimulated DA responses was the impetus 
for me to continue my graduate studies under the mentorship of Dr. Amy Wagner. We toiled with 
many theories over the years, and we have repeatedly proven ourselves wrong until we developed 
the QN model. This theory is supported by contemporary neurotransmission principles, and it can 
quantifiably explain the regional heterogeneity of the stimulated DA response shapes remarkably 
well. For us, this body of work represents an extensive endeavor immersed in theory and 
experimentation that ultimately led to a fruitful outcome where we are now better able to interpret 
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stimulated DA responses to answer many research questions, including our original questions that 
focused on determining how DA neurotransmission is altered in the context of traumatic brain 
injury and how can these dysfunctional neurotransmission patterns be manipulated by drug 
treatment paradigms. 
In the chapter 3, we demonstrated that CCI produced DAergic deficits that were much more 
pronounced in the D-STR compared to the NAc. In the end, the QN model served simply to 
corroborate data generated using conventional response shape analysis that demonstrate this effect; 
importantly, this work benefited from the use of our simultaneous recording electrodes so that we 
could better demonstrate this effect. Nevertheless, the QN model was helpful in demonstrating that 
post-CCI chronic MPH treatment enhanced both release and reuptake in the D-STR relative to 
naïve animals.  
 Because this experimental paradigm was able to demonstrate the striking regiospecific 
dysfunction in DA neurotransmission after CCI, we became interested in other neuropathological 
conditions. To our surprise, very little has been published on the use of the MFB-stimulated DA 
neurotransmission in contemporary Parkinson’s disease models that are known to produce 
regiospecific degeneration of DAergic neurons and terminals (Cannon et al. 2009). Similarly, little 
research using FSCV has been published characterizing and comparatively assessing DA 
transmission in other disease states including attention deficit hyperactivity disorder, 
schizophrenia or Huntington’s Disease. In our own research center, there are on-going 
investigations using various disease models that produce neurodegeneration. One such model that 
we have begun to examine was a 5-minute asphyxial cardiac arrest (CA) model in rats. At similar 
a 2-week time point post-injury to what we have studied with experimental TBI (CCI), we found 
the CA model produced a very different pattern of regiospecific DAergic alterations, where 
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stimulated DA responses are greatly augmented after CA as opposed to decreased in CCI (Figure 
20).  
 
Figure 20: Comparison of stimulated DA responses in CCI and cardiac arrest models 
One working hypothesis we have is that the spontaneous spiking of DAergic neurons is 
impaired after TBI and results in hypotonic DA state that contributes to the alterations, but other 
points of dysfunction (e.g. with vesicular release and docking proteins) may also exist.  However, 
our early evidence suggests that other clinical conditions like CA alter DA status in ways that are 
vastly different than anything we have observed with TBI; if corroborated, the findings will have 
significant impact in guiding specific treatment approaches for an emerging CA survivor 
population that only exists through other advancements in acute care and resuscitation research 
forged by some of my colleagues and mentors at the Safar Center for Resuscitation Research, the 
research center which I have embraced as my dissertation home here at the University of 
Pittsburgh. Although we evaluated the 2-week time point in both conditions, future work will 
extend investigations to earlier and later time points, and examine relevant behavioral correlates 
to these changes.   
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6.2 CONCLUSION 
Our body of work has focused on how to maximize our understanding and use of data generated 
by the MFB-stimulated DA neurotransmission experimental paradigm primarily through the 
development of the QN model. There are, however, clear limitations on what kind of DA 
neurotransmission-relevant information this methodology can provide us with- problems that have 
always been present with the use of the MFB-stimulated DA neurotransmission paradigm. The 
experimental paradigm uses artificial electrical stimulations, but we cannot say what changes are 
occurring in spontaneous DA neural firing; that line of inquiry falls in the realm of 
electrophysiology research. We can probe for alterations in DA release and reuptake machinery, 
but we cannot say what changes are actually occurring to spontaneous DA neurotransmission per 
se; that line of inquiry falls in the realm of more recent advancements being made in the FSCV 
field to monitor spontaneous DA neurotransmission in awake freely-moving animals. Although 
we may gain insight into the presynaptic mechanisms that alter basal DA levels, measurements of 
basal DA levels are best performed by microdialysis or informed by clinical PET imaging. Moving 
forward, the comprehensive understanding of how drugs and disease affect DA neurotransmission 
will clearly require the use of complementary research methodologies. This body of work 
demonstrates the advancements we have made to just one methodology that can be used to extract 
a unique and information-rich perspective on presynaptic DA neuronal function in the context of 
drugs and disease.   
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